[
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT05552157",
    "title": "A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation",
    "phase": "PHASE3",
    "imp": "Remternetug (SC), Matching Placebo (Remternetug)",
    "indications": "Alzheimers Disease, Dementia, Alzheimers Disease, Familial",
    "sample_size": "280",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2034-03-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-08-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07153471",
    "title": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Osteoarthritis",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06672939",
    "title": "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Obesity, Overweight",
    "sample_size": "125",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06921759",
    "title": "A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis",
    "phase": "PHASE3",
    "imp": "Lebrikizumab, Placebo",
    "indications": "Atopic Hand and Foot Dermatitis",
    "sample_size": "206",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06339008",
    "title": "A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)",
    "phase": "PHASE3",
    "imp": "LY3650150, Placebo, Standard therapy for INCS",
    "indications": "Perennial Allergic Rhinitis (PAR)",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06653153",
    "title": "A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)",
    "phase": "PHASE3",
    "imp": "Remternetug, Placebo",
    "indications": "Alzheimer's Disease",
    "sample_size": "1400",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06662383",
    "title": "A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity",
    "phase": "PHASE3",
    "imp": "Retatrutide, Tirzepatide",
    "indications": "Obesity",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05026866",
    "title": "A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)",
    "phase": "PHASE3",
    "imp": "Donanemab, Placebo",
    "indications": "Alzheimer Disease",
    "sample_size": "2996",
    "enrollment_type": "E",
    "start_date_iso": "2021-08-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05803421",
    "title": "A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk",
    "phase": "PHASE3",
    "imp": "Orforglipron, Insulin Glargine",
    "indications": "Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease",
    "sample_size": "2749",
    "enrollment_type": "A",
    "start_date_iso": "2023-04-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT02763566",
    "title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer",
    "phase": "PHASE3",
    "imp": "Abemaciclib, Anastrozole, Letrozole, Placebo, Fulvestrant",
    "indications": "Breast Cancer",
    "sample_size": "463",
    "enrollment_type": "A",
    "start_date_iso": "2016-12-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2019-03-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07213804",
    "title": "A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer",
    "phase": "PHASE3",
    "imp": "Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin",
    "indications": "Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis",
    "sample_size": "1080",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT04965493",
    "title": "A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",
    "phase": "PHASE3",
    "imp": "Pirtobrutinib, Venetoclax, Rituximab",
    "indications": "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2021-09-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05169567",
    "title": "Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer",
    "phase": "PHASE3",
    "imp": "Abemaciclib, Fulvestrant, Placebo",
    "indications": "Breast Neoplasm, Neoplasm Metastasis",
    "sample_size": "368",
    "enrollment_type": "A",
    "start_date_iso": "2022-03-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-02-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04396236",
    "title": "A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine",
    "phase": "PHASE3",
    "imp": "Lasmiditan, Placebo",
    "indications": "Migraine",
    "sample_size": "1633",
    "enrollment_type": "E",
    "start_date_iso": "2020-06-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07218380",
    "title": "A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract",
    "phase": "PHASE3",
    "imp": "Vepugratinib, Placebo, EV, Pembrolizumab",
    "indications": "Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05882045",
    "title": "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease",
    "phase": "PHASE3",
    "imp": "Retatrutide, Placebo",
    "indications": "Obesity, Cardiovascular Diseases",
    "sample_size": "1800",
    "enrollment_type": "E",
    "start_date_iso": "2023-05-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT03155997",
    "title": "Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer",
    "phase": "PHASE3",
    "imp": "Abemaciclib, Standard Adjuvant Endocrine Therapy",
    "indications": "Breast Cancer",
    "sample_size": "5637",
    "enrollment_type": "A",
    "start_date_iso": "2017-07-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-03-16",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05723198",
    "title": "A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata",
    "phase": "PHASE3",
    "imp": "Baricitinib, Placebo",
    "indications": "Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical",
    "sample_size": "595",
    "enrollment_type": "E",
    "start_date_iso": "2023-02-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07174336",
    "title": "A Study of LY4064809 (Tersolisib) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)",
    "phase": "PHASE3",
    "imp": "LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant",
    "indications": "Breast Neoplasms, Neoplasm Metastasis",
    "sample_size": "920",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04844606",
    "title": "A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)",
    "phase": "PHASE3",
    "imp": "Mirikizumab, Mirikizumab",
    "indications": "Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease",
    "sample_size": "150",
    "enrollment_type": "E",
    "start_date_iso": "2021-05-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT04967521",
    "title": "SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma",
    "phase": "PHASE3",
    "imp": "Abemaciclib, Placebo",
    "indications": "Advanced Dedifferentiated Liposarcoma",
    "sample_size": "108",
    "enrollment_type": "E",
    "start_date_iso": "2021-11-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07202884",
    "title": "A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Urinary Incontinence,Stress",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT03432286",
    "title": "A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine",
    "phase": "PHASE3",
    "imp": "Galcanezumab, Placebo",
    "indications": "Episodic Migraine",
    "sample_size": "533",
    "enrollment_type": "A",
    "start_date_iso": "2018-03-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-14",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06119581",
    "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed",
    "indications": "Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis",
    "sample_size": "1016",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT06647498",
    "title": "A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation",
    "phase": "PHASE3",
    "imp": "Remternetug, Matching Placebo (Remternetug)",
    "indications": "Alzheimers Disease, Dementia, Alzheimers Disease, Familial",
    "sample_size": "280",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2034-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07222332",
    "title": "A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)",
    "phase": "PHASE3",
    "imp": "Baricitinib, Placebo",
    "indications": "Diabetes Mellitus, Type 1",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2026-03",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-07",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05559359",
    "title": "A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis",
    "phase": "PHASE3",
    "imp": "Lebrikizumab, Placebo, Topical Corticosteroid (TCS)",
    "indications": "Atopic Dermatitis, Eczema",
    "sample_size": "367",
    "enrollment_type": "A",
    "start_date_iso": "2022-10-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-14",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07157774",
    "title": "Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)",
    "phase": "PHASE3",
    "imp": "Muvalaplin, Placebo",
    "indications": "Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)",
    "sample_size": "10450",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06588283",
    "title": "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Ixekizumab, Tirzepatide",
    "indications": "Psoriasis, Obesity",
    "sample_size": "250",
    "enrollment_type": "E",
    "start_date_iso": "2024-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07353931",
    "title": "Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Eloralintide, Placebo",
    "indications": "Osteoarthritis, Overweight or Obesity",
    "sample_size": "900",
    "enrollment_type": "E",
    "start_date_iso": "2026-02",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT04565054",
    "title": "Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC",
    "phase": "PHASE3",
    "imp": "Abemaciclib 50 MG; 150mg 1-0-1 per os",
    "indications": "Breast Cancer Female",
    "sample_size": "1260",
    "enrollment_type": "E",
    "start_date_iso": "2020-09-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06292013",
    "title": "A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)",
    "phase": "PHASE3",
    "imp": "Lepodisiran Sodium, Placebo",
    "indications": "Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)",
    "sample_size": "17300",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06948435",
    "title": "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Hypertension, Overweight or Obesity",
    "sample_size": "487",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06890598",
    "title": "Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Olomorasib, Pembrolizumab, Durvalumab, Placebo",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04616326",
    "title": "A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine",
    "phase": "PHASE3",
    "imp": "Galcanezumab, Placebo",
    "indications": "Chronic Migraine",
    "sample_size": "312",
    "enrollment_type": "A",
    "start_date_iso": "2020-11-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-10",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04527380",
    "title": "A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis",
    "phase": "PHASE3",
    "imp": "Ixekizumab, Adalimumab",
    "indications": "Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis",
    "sample_size": "101",
    "enrollment_type": "A",
    "start_date_iso": "2021-04-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-02-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07282600",
    "title": "A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes",
    "phase": "PHASE3",
    "imp": "Eloralintide, Placebo",
    "indications": "Overweight, Obesity",
    "sample_size": "1035",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05869903",
    "title": "A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Obesity, Overweight, Overweight or Obesity",
    "sample_size": "3127",
    "enrollment_type": "A",
    "start_date_iso": "2023-06-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-25",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT05633602",
    "title": "Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study",
    "phase": "PHASE3",
    "imp": "Chemotherapy, Pembrolizumab, Ramucirumab",
    "indications": "Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8",
    "sample_size": "838",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06914895",
    "title": "A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Tirzepatide, Placebo",
    "indications": "Type 1 Diabetes, Obesity, Overweight",
    "sample_size": "905",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT03773965",
    "title": "A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis",
    "phase": "PHASE3",
    "imp": "Baricitinib",
    "indications": "Juvenile Idiopathic Arthritis",
    "sample_size": "190",
    "enrollment_type": "E",
    "start_date_iso": "2019-04-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT03519945",
    "title": "A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)",
    "phase": "PHASE3",
    "imp": "Mirikizumab",
    "indications": "Ulcerative Colitis",
    "sample_size": "1063",
    "enrollment_type": "E",
    "start_date_iso": "2018-07-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT05002127",
    "title": "A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)",
    "phase": "PHASE3",
    "imp": "Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel",
    "indications": "Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma",
    "sample_size": "127",
    "enrollment_type": "A",
    "start_date_iso": "2022-01-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-24",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT04607421",
    "title": "A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer",
    "phase": "PHASE3",
    "imp": "Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab",
    "indications": "Neoplasms",
    "sample_size": "831",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04819100",
    "title": "A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)",
    "phase": "PHASE3",
    "imp": "Selpercatinib, Placebo",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "152",
    "enrollment_type": "E",
    "start_date_iso": "2021-12-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04437511",
    "title": "A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)",
    "phase": "PHASE3",
    "imp": "Donanemab, Placebo",
    "indications": "Alzheimer Disease",
    "sample_size": "1736",
    "enrollment_type": "A",
    "start_date_iso": "2020-06-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-04-14",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07369011",
    "title": "A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Eloralintide, Placebo",
    "indications": "Sleep Apnea, Obstructive, Obesity, Overweight",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2026-03",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06588296",
    "title": "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Ixekizumab, Tirzepatide",
    "indications": "Psoriatic Arthritis, Obesity",
    "sample_size": "279",
    "enrollment_type": "A",
    "start_date_iso": "2024-09-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-18",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05288166",
    "title": "A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)",
    "phase": "PHASE3",
    "imp": "Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib",
    "indications": "Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6",
    "sample_size": "925",
    "enrollment_type": "A",
    "start_date_iso": "2022-04-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-02-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05738486",
    "title": "A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)",
    "phase": "PHASE3",
    "imp": "Donanemab, Placebo, Dexamethasone",
    "indications": "Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders",
    "sample_size": "1175",
    "enrollment_type": "A",
    "start_date_iso": "2023-02-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-16",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04396574",
    "title": "A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine",
    "phase": "PHASE3",
    "imp": "Lasmiditan",
    "indications": "Migraine",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2020-06-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06962280",
    "title": "A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Tirzepatide, Placebo",
    "indications": "Type 1 Diabetes, Obesity, Overweight",
    "sample_size": "465",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07142954",
    "title": "Epidemiology and Biomarker Study in Alzheimer's Disease",
    "phase": "PHASE3",
    "imp": "P-tau217 Test",
    "indications": "Alzheimer Disease",
    "sample_size": "3400",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04647526",
    "title": "Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment",
    "phase": "PHASE3",
    "imp": "[Lu-177]-PNT2002, Abiraterone, Enzalutamide",
    "indications": "Metastatic Castration-Resistant Prostate Cancer",
    "sample_size": "455",
    "enrollment_type": "A",
    "start_date_iso": "2021-02-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-11-01",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT04662255",
    "title": "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)",
    "phase": "PHASE3",
    "imp": "Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib",
    "indications": "Lymphoma, Mantle-Cell",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2021-04-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04975308",
    "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer",
    "phase": "PHASE3",
    "imp": "Imlunestrant, Exemestane, Fulvestrant, Abemaciclib",
    "indications": "Breast Neoplasms, Neoplasm Metastasis",
    "sample_size": "874",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-06-24",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06280716",
    "title": "A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis",
    "phase": "PHASE3",
    "imp": "Placebo, Lebrikizumab, Topical Corticosteroid",
    "indications": "Atopic Dermatitis",
    "sample_size": "301",
    "enrollment_type": "A",
    "start_date_iso": "2024-04-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-25",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06672549",
    "title": "A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Obesity, Overweight",
    "sample_size": "125",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06383390",
    "title": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)",
    "phase": "PHASE3",
    "imp": "Retatrutide, Placebo",
    "indications": "Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)",
    "sample_size": "10000",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07357415",
    "title": "A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Retatrutide",
    "indications": "Obesity, Overweight",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06972459",
    "title": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Obesity, Overweight",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT01760005",
    "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001",
    "phase": "PHASE3",
    "imp": "Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), Gantenerumab, E2814, Lecanemab, Matching Placebo (E2814)",
    "indications": "Alzheimers Disease, Dementia, Alzheimers Disease, Familial",
    "sample_size": "490",
    "enrollment_type": "E",
    "start_date_iso": "2012-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05514054",
    "title": "A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer",
    "phase": "PHASE3",
    "imp": "Imlunestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane",
    "indications": "Breast Neoplasms",
    "sample_size": "8000",
    "enrollment_type": "E",
    "start_date_iso": "2022-10-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06649045",
    "title": "A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "OSA, Overweight or Obesity",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06972472",
    "title": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Obesity, Overweight, Type 2 Diabetes",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06047548",
    "title": "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",
    "phase": "PHASE3",
    "imp": "Tirzepatide, Placebo",
    "indications": "Overweight, Obesity",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2023-09-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07219953",
    "title": "A Study of Brenipatide in Participants With Alcohol Use Disorder",
    "phase": "PHASE3",
    "imp": "LY3537031, Placebo",
    "indications": "Alcohol Use Disorder",
    "sample_size": "1100",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06260722",
    "title": "Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)",
    "phase": "PHASE3",
    "imp": "Retatrutide, Semaglutide",
    "indications": "Diabetes Mellitus, Type 2",
    "sample_size": "1250",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06338995",
    "title": "A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)",
    "phase": "PHASE3",
    "imp": "LY3650150, Placebo, Standard therapy for INCS",
    "indications": "Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)",
    "sample_size": "510",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05508789",
    "title": "A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)",
    "phase": "PHASE3",
    "imp": "Donanemab, Placebo",
    "indications": "Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders",
    "sample_size": "1500",
    "enrollment_type": "E",
    "start_date_iso": "2022-10-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT03952559",
    "title": "A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis",
    "phase": "PHASE3",
    "imp": "Baricitinib, Placebo, Topical corticosteroid",
    "indications": "Atopic Dermatitis",
    "sample_size": "516",
    "enrollment_type": "A",
    "start_date_iso": "2019-05-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-04-24",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT05023980",
    "title": "A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
    "phase": "PHASE3",
    "imp": "Pirtobrutinib, Bendamustine, Rituximab",
    "indications": "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",
    "sample_size": "309",
    "enrollment_type": "A",
    "start_date_iso": "2021-09-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06937086",
    "title": "Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study",
    "phase": "PHASE3",
    "imp": "Mirikizumab, Mirikizumab, Tirzepatide, Placebo",
    "indications": "Ulcerative Colitis, Obesity or Overweight",
    "sample_size": "350",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06952530",
    "title": "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Hypertension",
    "sample_size": "487",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07165028",
    "title": "A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)",
    "phase": "PHASE3",
    "imp": "Tirzepatide, Retatrutide, Placebo",
    "indications": "Metabolic Dysfunction-Associated Steatotic Liver Disease",
    "sample_size": "4500",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04194944",
    "title": "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "261",
    "enrollment_type": "A",
    "start_date_iso": "2020-02-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-05-01",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2030-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT04666038",
    "title": "Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
    "phase": "PHASE3",
    "imp": "Pirtobrutinib, Idelalisib, Bendamustine, Rituximab",
    "indications": "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",
    "sample_size": "238",
    "enrollment_type": "A",
    "start_date_iso": "2021-03-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-08-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07219966",
    "title": "A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder",
    "phase": "PHASE3",
    "imp": "LY3537031, Placebo",
    "indications": "Alcohol Use Disorder",
    "sample_size": "1100",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT04870203",
    "title": "Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis",
    "phase": "PHASE3",
    "imp": "baricitinib treatment, anti-TNF therapy, Placebo",
    "indications": "Rheumatoid Arthritis",
    "sample_size": "178",
    "enrollment_type": "E",
    "start_date_iso": "2021-07-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06297603",
    "title": "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)",
    "phase": "PHASE3",
    "imp": "Retatrutide, Placebo",
    "indications": "Type 2 Diabetes",
    "sample_size": "320",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06439277",
    "title": "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)",
    "phase": "PHASE3",
    "imp": "Tirzepatide, Placebo",
    "indications": "Obesity, Weight Gain",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07241390",
    "title": "A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease",
    "sample_size": "7140",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05767021",
    "title": "A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Mirikizumab, Mirikizumab",
    "indications": "Ulcerative Colitis, Ulcerative Colitis Chronic",
    "sample_size": "172",
    "enrollment_type": "A",
    "start_date_iso": "2023-05-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-08-09",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06859268",
    "title": "A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity",
    "phase": "PHASE3",
    "imp": "Retatrutide, Placebo",
    "indications": "Obesity",
    "sample_size": "643",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05556512",
    "title": "A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity",
    "phase": "PHASE3",
    "imp": "Tirzepatide, Placebo",
    "indications": "Obesity, Overweight",
    "sample_size": "15374",
    "enrollment_type": "A",
    "start_date_iso": "2022-10-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT04232553",
    "title": "A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Mirikizumab",
    "indications": "Crohn's Disease",
    "sample_size": "996",
    "enrollment_type": "A",
    "start_date_iso": "2020-06-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-11-28",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": true,
    "nct_id": "NCT07279688",
    "title": "Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica",
    "phase": "PHASE3",
    "imp": "Baricitinib 4 MG Oral Tablet, Baricitinib 2 MG Oral Tablet, Placebo 4 mg, Placebo 2 mg",
    "indications": "Polymyalgia Rheumatica (PMR)",
    "sample_size": "140",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-12",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-11-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-12",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05463731",
    "title": "A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)",
    "phase": "PHASE3",
    "imp": "Remternetug (IV), Remternetug (SC), Placebo",
    "indications": "Alzheimer's Disease",
    "sample_size": "1667",
    "enrollment_type": "A",
    "start_date_iso": "2022-08-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-04-24",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06993792",
    "title": "A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Obesity, Overweight, Type 2 Diabetes",
    "sample_size": "1200",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT03706365",
    "title": "A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer",
    "phase": "PHASE3",
    "imp": "Abemaciclib, Placebo, Abiraterone acetate, Prednisone",
    "indications": "Prostate Cancer",
    "sample_size": "393",
    "enrollment_type": "A",
    "start_date_iso": "2018-11-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-02",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT02411448",
    "title": "A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)",
    "phase": "PHASE3",
    "imp": "Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib",
    "indications": "Metastatic Non-Small Cell Lung Cancer",
    "sample_size": "545",
    "enrollment_type": "A",
    "start_date_iso": "2015-05-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2019-01-23",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07232719",
    "title": "A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Retatrutide, Placebo",
    "indications": "Obesity, Overweight",
    "sample_size": "250",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07321886",
    "title": "A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes",
    "phase": "PHASE3",
    "imp": "Eloralintide, Placebo",
    "indications": "Obesity, Overweight",
    "sample_size": "1980",
    "enrollment_type": "E",
    "start_date_iso": "2026-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-07",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06948422",
    "title": "A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Hypertension",
    "sample_size": "974",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05929079",
    "title": "A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Retatrutide, Placebo",
    "indications": "Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2023-07-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07222137",
    "title": "A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults",
    "phase": "PHASE3",
    "imp": "Baricitinib, Placebo",
    "indications": "Diabetes Mellitus, Type 1",
    "sample_size": "150",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05929066",
    "title": "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Retatrutide, Placebo",
    "indications": "Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea",
    "sample_size": "2300",
    "enrollment_type": "E",
    "start_date_iso": "2023-07-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06937099",
    "title": "Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight",
    "phase": "PHASE3",
    "imp": "Mirikizumab, Mirikizumab, Tirzepatide, Placebo",
    "indications": "Crohn's Disease, Obesity or Overweight",
    "sample_size": "290",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07223593",
    "title": "Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease",
    "phase": "PHASE3",
    "imp": "Orforglipron, Placebo",
    "indications": "Peripheral Arterial Disease",
    "sample_size": "1205",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT05735483",
    "title": "A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis",
    "phase": "PHASE3",
    "imp": "Lebrikizumab, Placebo",
    "indications": "Atopic Dermatitis, Eczema",
    "sample_size": "310",
    "enrollment_type": "E",
    "start_date_iso": "2023-03-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT02107703",
    "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer",
    "phase": "PHASE3",
    "imp": "Abemaciclib, Fulvestrant, Placebo",
    "indications": "Breast Neoplasms",
    "sample_size": "669",
    "enrollment_type": "A",
    "start_date_iso": "2014-07-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2017-02-14",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT07035093",
    "title": "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain",
    "phase": "PHASE3",
    "imp": "Retatrutide, Placebo",
    "indications": "Obesity, Overweight, Chronic Low Back Pain (CLBP)",
    "sample_size": "586",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Eli Lilly",
    "is_collaborator": false,
    "nct_id": "NCT06075667",
    "title": "A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",
    "phase": "PHASE3",
    "imp": "Tirzepatide, Placebo",
    "indications": "Obesity, Overweight",
    "sample_size": "150",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT05546242",
    "title": "Improving HIV-1 Control in Africa with Long Acting Antiretrovirals",
    "phase": "PHASE3",
    "imp": "Cabotegravir/Rilpivirine, Antiretroviral",
    "indications": "HIV-1-infection",
    "sample_size": "540",
    "enrollment_type": "A",
    "start_date_iso": "2022-12-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05912517",
    "title": "A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)",
    "phase": "PHASE3",
    "imp": "Nipocalimab, Placebo",
    "indications": "Hemolytic Disease of the Fetus and Newborn",
    "sample_size": "120",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT07196748",
    "title": "A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Icotrokinra, Placebo",
    "indications": "Colitis, Ulcerative",
    "sample_size": "882",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-01-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05884398",
    "title": "A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC",
    "phase": "PHASE3",
    "imp": "Apalutamide, Androgen-deprivation Therapy (ADT)",
    "indications": "Metastatic Castrate-sensitive Prostate Cancer",
    "sample_size": "420",
    "enrollment_type": "A",
    "start_date_iso": "2023-08-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT05299931",
    "title": "An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study",
    "phase": "PHASE3",
    "imp": "Ustekinumab",
    "indications": "Crohn Disease",
    "sample_size": "108",
    "enrollment_type": "E",
    "start_date_iso": "2021-09-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06919965",
    "title": "A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer",
    "phase": "PHASE3",
    "imp": "TAR-210, Mitomycin C, Gemcitabine",
    "indications": "Non-Muscle Invasive Bladder Neoplasms",
    "sample_size": "220",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-03-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04119050",
    "title": "Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia",
    "phase": "PHASE3",
    "imp": "M281, Placebo",
    "indications": "Warm Autoimmune Hemolytic Anemia",
    "sample_size": "111",
    "enrollment_type": "E",
    "start_date_iso": "2019-08-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-02-02",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-04-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT03299049",
    "title": "Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults",
    "phase": "PHASE3",
    "imp": "Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension",
    "indications": "HIV Infections",
    "sample_size": "1049",
    "enrollment_type": "A",
    "start_date_iso": "2017-10-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2019-06-06",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05438043",
    "title": "A Study of Daratumumab",
    "phase": "PHASE3",
    "imp": "Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide",
    "indications": "Multiple Myeloma",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-01-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05714202",
    "title": "A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) in Participants With BCG-na\u00efve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)",
    "phase": "PHASE3",
    "imp": "TAR-200, Cetrelimab, BCG Vesiculture",
    "indications": "Bladder Cancer",
    "sample_size": "1135",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-09-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-09-18",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05754957",
    "title": "A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome",
    "phase": "PHASE3",
    "imp": "Milvexian, Placebo",
    "indications": "Acute Coronary Syndrome",
    "sample_size": "14194",
    "enrollment_type": "A",
    "start_date_iso": "2023-04-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05757869",
    "title": "A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation",
    "phase": "PHASE3",
    "imp": "Milvexian, Apixaban, Placebo, Apixaban Placebo",
    "indications": "Atrial Fibrillation",
    "sample_size": "20283",
    "enrollment_type": "A",
    "start_date_iso": "2023-04-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT03390504",
    "title": "A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations",
    "phase": "PHASE3",
    "imp": "Erdafitinib, Vinflunine, Docetaxel, Pembrolizumab, Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)",
    "indications": "Urothelial Cancer",
    "sample_size": "629",
    "enrollment_type": "A",
    "start_date_iso": "2018-03-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-04-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06934226",
    "title": "A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis",
    "phase": "PHASE3",
    "imp": "JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab, Matching Placebo to Ustekinumab",
    "indications": "Plaque Psoriasis",
    "sample_size": "752",
    "enrollment_type": "A",
    "start_date_iso": "2025-04-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-20",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT03462719",
    "title": "A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
    "phase": "PHASE3",
    "imp": "Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)",
    "indications": "Leukemia, Lymphocytic, Chronic, B-Cell",
    "sample_size": "211",
    "enrollment_type": "A",
    "start_date_iso": "2018-04-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-02-26",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-04-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06220604",
    "title": "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)",
    "phase": "PHASE3",
    "imp": "JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo",
    "indications": "Plaque Psoriasis",
    "sample_size": "731",
    "enrollment_type": "A",
    "start_date_iso": "2024-03-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-11-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-09-20",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT04071457",
    "title": "S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration",
    "phase": "PHASE3",
    "imp": "Lenalidomide, Daratumumab/rHuPH20",
    "indications": "Multiple Myeloma",
    "sample_size": "1100",
    "enrollment_type": "E",
    "start_date_iso": "2019-08-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-07-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2040-07-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT03767244",
    "title": "A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",
    "phase": "PHASE3",
    "imp": "Apalutamide, Androgen Deprivation Therapy (ADT), Placebo",
    "indications": "Prostatic Neoplasms",
    "sample_size": "2517",
    "enrollment_type": "A",
    "start_date_iso": "2019-06-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT03652064",
    "title": "A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy",
    "phase": "PHASE3",
    "imp": "Daratumumab, Bortezomib, Lenalidomide, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "395",
    "enrollment_type": "A",
    "start_date_iso": "2018-11-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-07",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04538664",
    "title": "A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions",
    "phase": "PHASE3",
    "imp": "Amivantamab, Pemetrexed, Carboplatin, Pemetrexed",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "308",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-05-03",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06559306",
    "title": "Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms",
    "phase": "PHASE3",
    "imp": "Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)",
    "indications": "Depressive Disorder, Major",
    "sample_size": "752",
    "enrollment_type": "E",
    "start_date_iso": "2024-07-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05455320",
    "title": "A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment",
    "phase": "PHASE3",
    "imp": "Talquetamab, Daratumumab, Pomalidomide, Dexamethasone",
    "indications": "Relapsed or Refractory Multiple Myeloma",
    "sample_size": "864",
    "enrollment_type": "A",
    "start_date_iso": "2022-10-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04936308",
    "title": "Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent",
    "phase": "PHASE3",
    "imp": "Guselkumab, Placebo",
    "indications": "Arthritis, Psoriatic",
    "sample_size": "453",
    "enrollment_type": "A",
    "start_date_iso": "2021-09-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-10-28",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-07-16",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT07164443",
    "title": "A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)",
    "phase": "PHASE3",
    "imp": "Pasritamig, Placebo, Best Supportive Care (BSC)",
    "indications": "Metastatic Castration-resistant Prostate Neoplasms",
    "sample_size": "663",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT05154747",
    "title": "Long-Acting Treatment in Adolescents (LATA)",
    "phase": "PHASE3",
    "imp": "Cabotegravir, Rilpivirine Drug Combination, TLD",
    "indications": "Hiv, HIV Infections, HIV-1-infection, Paediatric Human Immunodeficiency Virus Infection",
    "sample_size": "476",
    "enrollment_type": "A",
    "start_date_iso": "2023-06-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT04608318",
    "title": "Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)",
    "phase": "PHASE3",
    "imp": "Ibrutinib, Venetoclax, Obinutuzumab",
    "indications": "Chronic Lymphoid Leukemia",
    "sample_size": "897",
    "enrollment_type": "E",
    "start_date_iso": "2021-03-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT05257083",
    "title": "A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, Cyclophosphamide, Fludarabine",
    "indications": "Multiple Myeloma",
    "sample_size": "759",
    "enrollment_type": "A",
    "start_date_iso": "2023-10-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2040-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06750094",
    "title": "A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy",
    "phase": "PHASE3",
    "imp": "Amivantamab, Cetuximab, Bevacizumab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Irinotecan",
    "indications": "Colorectal Neoplasms",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04892173",
    "title": "JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC",
    "phase": "PHASE3",
    "imp": "JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy",
    "indications": "Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2021-12-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05388669",
    "title": "A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous",
    "indications": "Advanced or Metastatic Non-small Cell Lung Cancer",
    "sample_size": "418",
    "enrollment_type": "A",
    "start_date_iso": "2022-08-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-03",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06741969",
    "title": "Nipocalimab in Moderate to Severe Sjogren's Disease",
    "phase": "PHASE3",
    "imp": "Nipocalimab, Placebo, Standard of care treatment",
    "indications": "Sjogrens Syndrome",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06211764",
    "title": "A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Gu\u00e9rin (BCG)",
    "phase": "PHASE3",
    "imp": "TAR-200, Mitomycin C, Gemcitabine",
    "indications": "Non-Muscle Invasive Bladder Neoplasms",
    "sample_size": "272",
    "enrollment_type": "A",
    "start_date_iso": "2024-04-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-11-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-04-14",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06852222",
    "title": "A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)",
    "phase": "PHASE3",
    "imp": "Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Placebo",
    "indications": "Leukemia, Myeloid, Acute",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-06-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06408935",
    "title": "Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients",
    "phase": "PHASE3",
    "imp": "Guselkumab",
    "indications": "Crohn's Disease",
    "sample_size": "112",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT07276399",
    "title": "A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer",
    "phase": "PHASE3",
    "imp": "Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin",
    "indications": "Squamous Cell Carcinoma of Head and Neck",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-06-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05572515",
    "title": "A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Teclistamab, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib",
    "indications": "Relapsed or Refractory Multiple Myeloma",
    "sample_size": "614",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT07196722",
    "title": "A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Icotrokinra, Placebo",
    "indications": "Crohn Disease",
    "sample_size": "1092",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-10-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04951622",
    "title": "A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis",
    "phase": "PHASE3",
    "imp": "Nipocalimab, Placebo, Nipocalimab SC-LIV",
    "indications": "Myasthenia Gravis",
    "sample_size": "219",
    "enrollment_type": "A",
    "start_date_iso": "2021-07-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-11-17",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-04-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04487080",
    "title": "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Amivantamab, Osimertinib, Lazertinib, Placebo",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "1074",
    "enrollment_type": "A",
    "start_date_iso": "2020-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-08-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-06-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05552222",
    "title": "A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab",
    "indications": "Multiple Myeloma",
    "sample_size": "1590",
    "enrollment_type": "E",
    "start_date_iso": "2022-10-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-04-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-10-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT01804686",
    "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)",
    "phase": "PHASE3",
    "imp": "Ibrutinib",
    "indications": "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2013-09-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT02951052",
    "title": "Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults",
    "phase": "PHASE3",
    "imp": "Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI",
    "indications": "Infection, Human Immunodeficiency Virus, HIV Infections",
    "sample_size": "618",
    "enrollment_type": "A",
    "start_date_iso": "2016-10-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2018-05-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05197049",
    "title": "A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo",
    "indications": "Crohn Disease",
    "sample_size": "350",
    "enrollment_type": "A",
    "start_date_iso": "2022-01-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-07-04",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-10-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT05047172",
    "title": "Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis",
    "phase": "PHASE3",
    "imp": "Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management",
    "indications": "Intracranial Arteriosclerosis, Stroke",
    "sample_size": "1683",
    "enrollment_type": "E",
    "start_date_iso": "2022-08-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT03901963",
    "title": "A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant",
    "phase": "PHASE3",
    "imp": "Daratumumab, Lenalidomide",
    "indications": "Multiple Myeloma",
    "sample_size": "200",
    "enrollment_type": "A",
    "start_date_iso": "2019-04-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-04-04",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-05-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06663332",
    "title": "A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants",
    "phase": "PHASE3",
    "imp": "Guselkumab",
    "indications": "Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile",
    "sample_size": "196",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-12-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-12-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06095102",
    "title": "A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)",
    "phase": "PHASE3",
    "imp": "JNJ-77242113, Placebo",
    "indications": "Plaque Psoriasis",
    "sample_size": "311",
    "enrollment_type": "A",
    "start_date_iso": "2023-10-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-06-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-02-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04033445",
    "title": "A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Placebo, Guselkumab",
    "indications": "Ulcerative Colitis",
    "sample_size": "1064",
    "enrollment_type": "A",
    "start_date_iso": "2019-09-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-09-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-10-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT01957436",
    "title": "A Phase III Study for Patients With Metastatic Hormone-na\u00efve Prostate Cancer",
    "phase": "PHASE3",
    "imp": "abiraterone acetate, radiotherapy, Androgen Deprivation Therapy, Docetaxel",
    "indications": "Metastatic Prostate Cancer",
    "sample_size": "1173",
    "enrollment_type": "A",
    "start_date_iso": "2013-11-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-08-18",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2032-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT03748641",
    "title": "A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer",
    "phase": "PHASE3",
    "imp": "Niraparib, Abiraterone Acetate, Prednisone, Placebo, New Formulation of Niraparib and Abiraterone Acetate (AA)",
    "indications": "Castration-Resistant Prostatic Cancer",
    "sample_size": "765",
    "enrollment_type": "A",
    "start_date_iso": "2019-01-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-10-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-02-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT00980538",
    "title": "TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants",
    "phase": "PHASE3",
    "imp": "Etravirine",
    "indications": "HIV Infections, HIV-1",
    "sample_size": "180",
    "enrollment_type": "A",
    "start_date_iso": "2009-12-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-11-25",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2032-01-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT05660746",
    "title": "Precise Infliximab Exposure and Pharmacodynamic Control",
    "phase": "PHASE3",
    "imp": "RoadMAB, Infliximab",
    "indications": "Crohn Disease",
    "sample_size": "180",
    "enrollment_type": "E",
    "start_date_iso": "2023-07-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT07217587",
    "title": "Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis",
    "phase": "PHASE3",
    "imp": "Nipocalimab, Efgartigimod",
    "indications": "Myasthenia Gravis",
    "sample_size": "115",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06143878",
    "title": "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis",
    "phase": "PHASE3",
    "imp": "JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo",
    "indications": "Plaque Psoriasis",
    "sample_size": "774",
    "enrollment_type": "A",
    "start_date_iso": "2024-02-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-09-17",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-06-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05083169",
    "title": "A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab",
    "indications": "Multiple Myeloma",
    "sample_size": "587",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05327114",
    "title": "Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
    "phase": "PHASE3",
    "imp": "Nipocalimab, Placebo",
    "indications": "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",
    "sample_size": "201",
    "enrollment_type": "E",
    "start_date_iso": "2022-09-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06662786",
    "title": "A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer",
    "phase": "PHASE3",
    "imp": "Amivantamab, Cetuximab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin, Irinotecan Hydrochloride",
    "indications": "Colorectal Neoplasms",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-12-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT03451851",
    "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants",
    "phase": "PHASE3",
    "imp": "Guselkumab, Placebo for guselkumab, Etanercept",
    "indications": "Psoriasis",
    "sample_size": "120",
    "enrollment_type": "A",
    "start_date_iso": "2018-07-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-07-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12-18",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT04181203",
    "title": "Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy",
    "phase": "PHASE3",
    "imp": "Apalutamide, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa)",
    "indications": "Prostate Cancer",
    "sample_size": "490",
    "enrollment_type": "E",
    "start_date_iso": "2020-01-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-12-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT03301220",
    "title": "A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Daratumumab SC: daratumumab + rHuPH20",
    "indications": "Smoldering Multiple Myeloma",
    "sample_size": "390",
    "enrollment_type": "A",
    "start_date_iso": "2017-11-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-01",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT07225946",
    "title": "A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer",
    "phase": "PHASE3",
    "imp": "Pasritamig, Docetaxel, Prednisone",
    "indications": "Prostatic Neoplasms, Castration-Resistant",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06208150",
    "title": "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide",
    "phase": "PHASE3",
    "imp": "Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib",
    "indications": "Multiple Myeloma",
    "sample_size": "795",
    "enrollment_type": "E",
    "start_date_iso": "2024-01-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04557059",
    "title": "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer",
    "phase": "PHASE3",
    "imp": "Radiotherapy, LHRHa, Apalutamide",
    "indications": "Prostatic Neoplasms",
    "sample_size": "694",
    "enrollment_type": "A",
    "start_date_iso": "2020-11-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-08-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05923073",
    "title": "A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Guselkumab, Guselkumab",
    "indications": "Crohn's Disease",
    "sample_size": "120",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-07-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05347095",
    "title": "A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Guselkumab, Placebo",
    "indications": "Fistulizing Crohns Disease, Perianal Crohns Disease",
    "sample_size": "288",
    "enrollment_type": "A",
    "start_date_iso": "2022-09-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-25",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT01760005",
    "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001",
    "phase": "PHASE3",
    "imp": "Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), Gantenerumab, E2814, Lecanemab, Matching Placebo (E2814)",
    "indications": "Alzheimers Disease, Dementia, Alzheimers Disease, Familial",
    "sample_size": "490",
    "enrollment_type": "E",
    "start_date_iso": "2012-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05092269",
    "title": "A Long-term Extension Study of Ustekinumab in Pediatric Participants",
    "phase": "PHASE3",
    "imp": "Ustekinumab",
    "indications": "Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic",
    "sample_size": "151",
    "enrollment_type": "E",
    "start_date_iso": "2021-10-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT03466411",
    "title": "A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo",
    "indications": "Crohn's Disease",
    "sample_size": "1409",
    "enrollment_type": "A",
    "start_date_iso": "2018-04-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-10-20",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-01-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT03710603",
    "title": "Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Daratumumab, Velcade, Lenalidomide, dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "709",
    "enrollment_type": "A",
    "start_date_iso": "2018-12-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-08-01",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06319820",
    "title": "A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer",
    "phase": "PHASE3",
    "imp": "TAR-210, Gemcitabine, MMC",
    "indications": "Non-Muscle Invasive Bladder Neoplasms",
    "sample_size": "561",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04497844",
    "title": "A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)",
    "phase": "PHASE3",
    "imp": "Niraparib, Abiraterone acetate (AA), Prednisone, Placebo for Niraparib",
    "indications": "Metastatic Castration-sensitive Prostate Cancer",
    "sample_size": "696",
    "enrollment_type": "A",
    "start_date_iso": "2020-09-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-01-07",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-11-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04988295",
    "title": "A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure",
    "phase": "PHASE3",
    "imp": "Lazertinib, Amivantamab, Pemetrexed, Carboplatin",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "776",
    "enrollment_type": "A",
    "start_date_iso": "2021-11-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-07-10",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT06274047",
    "title": "PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.",
    "phase": "PHASE3",
    "imp": "Apalutamide, Androgen Deprivation Therapy",
    "indications": "Androgen Axis Suppression, Prostatectomy, Prostate Cancer",
    "sample_size": "120",
    "enrollment_type": "E",
    "start_date_iso": "2024-09-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT03903835",
    "title": "ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer",
    "phase": "PHASE3",
    "imp": "Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin, Cabazitaxel 60 mg Solution for Injection, Docetaxel Injectable Solution, Radium Chloride Ra-223, Niraparib plus Abiraterone acetate plus Prednisone, Capivasertib plus Docetaxel, Apalutamide, Darolutamide",
    "indications": "Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2019-02-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04882098",
    "title": "A Study of Guselkumab in Participants With Active Psoriatic Arthritis",
    "phase": "PHASE3",
    "imp": "Guselkumab, Placebo",
    "indications": "Arthritis, Psoriatic",
    "sample_size": "1054",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-12-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-05-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05528510",
    "title": "A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo",
    "indications": "Colitis, Ulcerative",
    "sample_size": "418",
    "enrollment_type": "A",
    "start_date_iso": "2022-09-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-04-02",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-10-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06095115",
    "title": "A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis",
    "phase": "PHASE3",
    "imp": "JNJ-77242113, Placebo",
    "indications": "Plaque Psoriasis",
    "sample_size": "684",
    "enrollment_type": "A",
    "start_date_iso": "2023-10-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-07-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-04-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT04061512",
    "title": "Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenstr\u00f6m's Macroglobulinaemia",
    "phase": "PHASE3",
    "imp": "Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib",
    "indications": "Waldenstrom Macroglobulinemia",
    "sample_size": "148",
    "enrollment_type": "E",
    "start_date_iso": "2020-02-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT07227454",
    "title": "A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder",
    "phase": "PHASE3",
    "imp": "Esketamine, Midazolam, Oral Placebo, Intranasal Placebo",
    "indications": "Depressive Disorder, Major",
    "sample_size": "258",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-04-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-09-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04658862",
    "title": "A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder",
    "phase": "PHASE3",
    "imp": "Cetrelimab, TAR-200, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy",
    "indications": "Urinary Bladder Neoplasms",
    "sample_size": "518",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06878404",
    "title": "A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-na\u00efve Participants With Active Psoriatic Arthritis",
    "phase": "PHASE3",
    "imp": "Icotrokinra, Placebo, Active reference comparator",
    "indications": "Arthritis, Psoriatic",
    "sample_size": "540",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11-21",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06260163",
    "title": "A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Guselkumab Subcutaneous, Guselkumab Intravenous",
    "indications": "Colitis, Ulcerative",
    "sample_size": "120",
    "enrollment_type": "E",
    "start_date_iso": "2024-01-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04923893",
    "title": "A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy",
    "phase": "PHASE3",
    "imp": "Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine",
    "indications": "Multiple Myeloma",
    "sample_size": "743",
    "enrollment_type": "A",
    "start_date_iso": "2021-08-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2036-09-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT04181827",
    "title": "A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab",
    "indications": "Multiple Myeloma",
    "sample_size": "419",
    "enrollment_type": "A",
    "start_date_iso": "2020-06-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-01",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-04-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT07258511",
    "title": "A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "JNJ-79635322, Teclistamab",
    "indications": "Multiple Myeloma",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2026-02-20",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-12-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-09-30",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT05702034",
    "title": "A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE",
    "phase": "PHASE3",
    "imp": "Milvexian, Placebo",
    "indications": "Ischemic Stroke; Ischemic Attack, Transient",
    "sample_size": "15000",
    "enrollment_type": "E",
    "start_date_iso": "2023-02-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": false,
    "nct_id": "NCT06807424",
    "title": "A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis",
    "phase": "PHASE3",
    "imp": "Icotrokinra, Placebo",
    "indications": "Arthritis, Psoriatic",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Johnson & Johnson",
    "is_collaborator": true,
    "nct_id": "NCT05243797",
    "title": "Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation",
    "phase": "PHASE3",
    "imp": "Teclistamab, Lenalidomide",
    "indications": "Multiple Myeloma",
    "sample_size": "1594",
    "enrollment_type": "E",
    "start_date_iso": "2022-09-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT05685238",
    "title": "A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)",
    "phase": "PHASE3",
    "imp": "Mim8",
    "indications": "Haemophilia A, Haemophilia A With Inhibitors",
    "sample_size": "451",
    "enrollment_type": "E",
    "start_date_iso": "2023-02-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT07220642",
    "title": "Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide",
    "phase": "PHASE3",
    "imp": "Cagrilintide, Placebo",
    "indications": "Obesity, Overweight",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT03811561",
    "title": "A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes",
    "phase": "PHASE3",
    "imp": "Semaglutide, Placebo (semaglutide)",
    "indications": "Diabetes Mellitus, Type 2",
    "sample_size": "1500",
    "enrollment_type": "E",
    "start_date_iso": "2019-05-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT07271251",
    "title": "A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes",
    "phase": "PHASE3",
    "imp": "Oral semaglutide",
    "indications": "Type 2 Diabetes",
    "sample_size": "264",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08-21",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT07207811",
    "title": "CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis",
    "phase": "PHASE3",
    "imp": "NNC6019-0001, Placebo (NNC6019-0001)",
    "indications": "Transthyretin Amyloid Cardiomyopathy (ATTR CM)",
    "sample_size": "1280",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-06-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": true,
    "nct_id": "NCT04624659",
    "title": "A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)",
    "phase": "PHASE3",
    "imp": "Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets",
    "indications": "Sickle Cell Disease",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2021-01-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT05021835",
    "title": "ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation",
    "phase": "PHASE3",
    "imp": "Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C)",
    "indications": "Cardiovascular Risk, Chronic Kidney Disease, Inflammation",
    "sample_size": "6200",
    "enrollment_type": "E",
    "start_date_iso": "2021-08-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-06-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT06221969",
    "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor",
    "phase": "PHASE3",
    "imp": "Cagrilintide, Semaglutide, Tirzepatide",
    "indications": "Type 2 Diabetes",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2024-01-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-04-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": true,
    "nct_id": "NCT07227246",
    "title": "Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2",
    "phase": "PHASE3",
    "imp": "Recombinant Factor VIIa, Biological/Vaccine: Placebo",
    "indications": "Intracerebral Hemorrhage",
    "sample_size": "350",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT07076199",
    "title": "A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes",
    "phase": "PHASE3",
    "imp": "Insulin icodec, Insulin glargine, Insulin aspart",
    "indications": "Diabetes Mellitus, Type 1",
    "sample_size": "877",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": true,
    "nct_id": "NCT03496883",
    "title": "Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial",
    "phase": "PHASE3",
    "imp": "Recombinant Activated Factor VII (rFVIIa), Placebo",
    "indications": "Intracerebral Hemorrhage",
    "sample_size": "860",
    "enrollment_type": "E",
    "start_date_iso": "2021-12-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT04082429",
    "title": "Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors",
    "phase": "PHASE3",
    "imp": "Concizumab",
    "indications": "Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors",
    "sample_size": "156",
    "enrollment_type": "A",
    "start_date_iso": "2019-11-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-07-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-02-21",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT07220759",
    "title": "Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide",
    "phase": "PHASE3",
    "imp": "Cagrilintide, Placebo (matched to Cagrilintide)",
    "indications": "Overweight, Obesity, Type 2 Diabetes",
    "sample_size": "330",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT07011667",
    "title": "A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term",
    "phase": "PHASE3",
    "imp": "CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)",
    "indications": "Obesity",
    "sample_size": "609",
    "enrollment_type": "A",
    "start_date_iso": "2025-06-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT05726227",
    "title": "A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight",
    "phase": "PHASE3",
    "imp": "Semaglutide, Placebo",
    "indications": "Obesity",
    "sample_size": "210",
    "enrollment_type": "E",
    "start_date_iso": "2023-07-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-10-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT04083781",
    "title": "Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors",
    "phase": "PHASE3",
    "imp": "Concizumab",
    "indications": "Haemophilia A With Inhibitors, Haemophilia B With Inhibitors",
    "sample_size": "134",
    "enrollment_type": "A",
    "start_date_iso": "2019-10-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-12-27",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-02-21",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT06780449",
    "title": "A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity",
    "phase": "PHASE3",
    "imp": "Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide",
    "indications": "Obesity",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-08-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT06388187",
    "title": "A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight",
    "phase": "PHASE3",
    "imp": "Cagrilintide, Semaglutide, Placebo",
    "indications": "Obesity",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-04-21",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": true,
    "nct_id": "NCT07276282",
    "title": "Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction",
    "phase": "PHASE3",
    "imp": "Ziltivekimab, Placebo",
    "indications": "Coronary Artery Disease, Acute Myocardial Infarction (AMI), Coronary Atherosclerosis of Native Coronary Artery",
    "sample_size": "332",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-11",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-09-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-01",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT05636176",
    "title": "A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation",
    "phase": "PHASE3",
    "imp": "Ziltivekimab, Placebo",
    "indications": "Heart Failure",
    "sample_size": "5600",
    "enrollment_type": "E",
    "start_date_iso": "2023-05-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT06118281",
    "title": "ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack",
    "phase": "PHASE3",
    "imp": "Ziltivekimab, Placebo",
    "indications": "Cardiovascular Risk, Acute Myocardial Infarction (AMI)",
    "sample_size": "10000",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT04822181",
    "title": "Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)",
    "phase": "PHASE3",
    "imp": "Semaglutide, Placebo",
    "indications": "Non-alcoholic Steatohepatitis",
    "sample_size": "1205",
    "enrollment_type": "A",
    "start_date_iso": "2021-04-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-04-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-25",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT07357766",
    "title": "A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight",
    "phase": "PHASE3",
    "imp": "Cagrisema, Placebo CagriSema",
    "indications": "Overweight, Obesity",
    "sample_size": "1400",
    "enrollment_type": "E",
    "start_date_iso": "2026-06-09",
    "start_date_type": "E",
    "primary_completion_date_iso": "2027-11-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01-04",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT05669755",
    "title": "REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels",
    "phase": "PHASE3",
    "imp": "Cagrilintide, Semaglutide, Placebo",
    "indications": "Cardiovascular Disease",
    "sample_size": "7101",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT07253285",
    "title": "A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight",
    "phase": "PHASE3",
    "imp": "Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide",
    "indications": "Overweight, Obesity",
    "sample_size": "460",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-09-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT05330325",
    "title": "A Research Study to Compare Somapacitan Once a Week With Norditropin\u00ae Once a Day in Children Who Need Help to Grow",
    "phase": "PHASE3",
    "imp": "Somapacitan, Norditropin\u00ae",
    "indications": "SGA, Turner Syndrome, Noonan Syndrome, ISS",
    "sample_size": "399",
    "enrollment_type": "E",
    "start_date_iso": "2022-08-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-08-05",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-10-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT05567796",
    "title": "A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight",
    "phase": "PHASE3",
    "imp": "Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide",
    "indications": "Obesity",
    "sample_size": "3400",
    "enrollment_type": "E",
    "start_date_iso": "2022-11-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-10-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-10-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT06609226",
    "title": "A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia",
    "phase": "PHASE3",
    "imp": "Etavopivat A, Etavopivat B, Etavopivat C",
    "indications": "Sickle Cell Disease, Thalassemia",
    "sample_size": "480",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-12-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT07339423",
    "title": "AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight",
    "phase": "PHASE3",
    "imp": "NNC0487-0111, Placebo (matched to NNC0487-0111)",
    "indications": "Obesity",
    "sample_size": "1150",
    "enrollment_type": "E",
    "start_date_iso": "2026-02-24",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-06-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-21",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT07301034",
    "title": "A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack",
    "phase": "PHASE3",
    "imp": "Ziltivekimab, Ziltivekimab Placebo",
    "indications": "Myocardial Infarction",
    "sample_size": "332",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT04596631",
    "title": "A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes",
    "phase": "PHASE3",
    "imp": "Oral semaglutide, Placebo (semaglutide)",
    "indications": "Diabetes Mellitus, Type 2",
    "sample_size": "132",
    "enrollment_type": "E",
    "start_date_iso": "2020-11-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-04-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-02-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT06200207",
    "title": "A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation",
    "phase": "PHASE3",
    "imp": "Ziltivekimab, Placebo",
    "indications": "Heart Failure, Systemic Inflammation",
    "sample_size": "680",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT06612268",
    "title": "A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease",
    "phase": "PHASE3",
    "imp": "Etavopivat, Placebo",
    "indications": "Sickle Cell Disease",
    "sample_size": "408",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT05135559",
    "title": "A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors",
    "phase": "PHASE3",
    "imp": "Concizumab",
    "indications": "Haemophilia A and B With and Without Inhibitors",
    "sample_size": "153",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-11-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novo Nordisk",
    "is_collaborator": false,
    "nct_id": "NCT06534411",
    "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both",
    "phase": "PHASE3",
    "imp": "Cagrilintide, Semaglutide, Tirzepatide",
    "indications": "Diabetes Mellitus, Type 2",
    "sample_size": "1023",
    "enrollment_type": "A",
    "start_date_iso": "2024-11-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07-14",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06012240",
    "title": "A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata",
    "phase": "PHASE3",
    "imp": "Upadacitinib, Placebo",
    "indications": "Alopecia Areata",
    "sample_size": "1500",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT07155187",
    "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Telisotuzumab Adizutecan, Standard of Care",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "430",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT03345823",
    "title": "A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433",
    "phase": "PHASE3",
    "imp": "Upadacitinib, Placebo for Upadacitinib",
    "indications": "Crohn's Disease",
    "sample_size": "747",
    "enrollment_type": "E",
    "start_date_iso": "2018-03-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05995353",
    "title": "A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Risankizumab, Risankizumab",
    "indications": "Crohn's Disease",
    "sample_size": "118",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT07023302",
    "title": "A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata",
    "phase": "PHASE3",
    "imp": "Upadacitinib, Upadacitinib Placebo",
    "indications": "Alopecia Areata",
    "sample_size": "123",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05407636",
    "title": "Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD",
    "phase": "PHASE3",
    "imp": "ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA\u00ae)",
    "indications": "AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV",
    "sample_size": "660",
    "enrollment_type": "E",
    "start_date_iso": "2022-01-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT03398135",
    "title": "A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "risankizumab, placebo for risankizumab",
    "indications": "Ulcerative Colitis (UC)",
    "sample_size": "1242",
    "enrollment_type": "A",
    "start_date_iso": "2018-08-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT03006068",
    "title": "A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)",
    "phase": "PHASE3",
    "imp": "Upadacitinib (ABT-494), Placebo",
    "indications": "Ulcerative Colitis (UC)",
    "sample_size": "950",
    "enrollment_type": "E",
    "start_date_iso": "2017-01-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06063967",
    "title": "A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.",
    "phase": "PHASE3",
    "imp": "Risankizumab SC, Placebo for risankizumab",
    "indications": "Crohn's Disease",
    "sample_size": "289",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT07095452",
    "title": "A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant",
    "phase": "PHASE3",
    "imp": "Etentamig, Lenalidomide, Daratumumab, Dexamethasone, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "660",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2042-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2042-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05707949",
    "title": "Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine",
    "phase": "PHASE3",
    "imp": "Atogepant",
    "indications": "Migraine Prophylaxis",
    "sample_size": "650",
    "enrollment_type": "E",
    "start_date_iso": "2023-06-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-04",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06236438",
    "title": "Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",
    "phase": "PHASE3",
    "imp": "Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin, Carboplatin",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "167",
    "enrollment_type": "A",
    "start_date_iso": "2024-04-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04468984",
    "title": "Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis",
    "phase": "PHASE3",
    "imp": "Navitoclax, Ruxolitinib, Best Available Therapy (BAT)",
    "indications": "Myelofibrosis (MF)",
    "sample_size": "330",
    "enrollment_type": "E",
    "start_date_iso": "2020-08-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-01-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06109272",
    "title": "A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)",
    "phase": "PHASE3",
    "imp": "Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab",
    "indications": "Hepatocellular Carcinoma",
    "sample_size": "660",
    "enrollment_type": "E",
    "start_date_iso": "2024-01-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05843643",
    "title": "Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus",
    "phase": "PHASE3",
    "imp": "Upadacitinib, Placebo",
    "indications": "Systemic Lupus Erythematosus",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2023-07-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": true,
    "nct_id": "NCT04608318",
    "title": "Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)",
    "phase": "PHASE3",
    "imp": "Ibrutinib, Venetoclax, Obinutuzumab",
    "indications": "Chronic Lymphoid Leukemia",
    "sample_size": "897",
    "enrollment_type": "E",
    "start_date_iso": "2021-03-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06794866",
    "title": "A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants",
    "phase": "PHASE3",
    "imp": "OnabotulinumtoxinA, Placebo",
    "indications": "Forehead Lines",
    "sample_size": "150",
    "enrollment_type": "A",
    "start_date_iso": "2025-01-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06810505",
    "title": "A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years",
    "phase": "PHASE3",
    "imp": "Atogepant, Placebo for Atogepant",
    "indications": "Chronic Migraine",
    "sample_size": "420",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05748483",
    "title": "Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine",
    "phase": "PHASE3",
    "imp": "Atogepant, Placebo for Atogepant, Topiramate, Placebo for Topiramate",
    "indications": "Migraine",
    "sample_size": "545",
    "enrollment_type": "A",
    "start_date_iso": "2023-10-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-04-28",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT03671148",
    "title": "A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)",
    "phase": "PHASE3",
    "imp": "Placebo, Risankizumab",
    "indications": "Psoriatic Arthritis (PsA)",
    "sample_size": "444",
    "enrollment_type": "A",
    "start_date_iso": "2019-03-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-06-22",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04880876",
    "title": "A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)",
    "phase": "PHASE3",
    "imp": "25mg Eluxadoline, 100mg Eluxadoline",
    "indications": "Irritable Bowel Syndrome",
    "sample_size": "124",
    "enrollment_type": "E",
    "start_date_iso": "2021-08-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-12",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04401748",
    "title": "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome",
    "phase": "PHASE3",
    "imp": "Venetoclax, Azacitidine, Placebo",
    "indications": "Myelodysplastic Syndrome (MDS)",
    "sample_size": "531",
    "enrollment_type": "A",
    "start_date_iso": "2020-09-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06468228",
    "title": "A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa",
    "phase": "PHASE3",
    "imp": "Lutikizumab, Placebo",
    "indications": "Hidradenitis Suppurativa",
    "sample_size": "1280",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT07284381",
    "title": "A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease",
    "phase": "PHASE3",
    "imp": "ABBV-444, REFRESH OPTIVE UD",
    "indications": "Dry Eye Disease",
    "sample_size": "250",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04333576",
    "title": "Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain",
    "phase": "PHASE3",
    "imp": "Elagolix, Placebo, Combined Oral Contraceptive",
    "indications": "Endometriosis",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2020-08-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05445778",
    "title": "Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer",
    "phase": "PHASE3",
    "imp": "Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab",
    "indications": "Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer",
    "sample_size": "520",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06428019",
    "title": "A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)",
    "phase": "PHASE3",
    "imp": "Venetoclax, Acalabrutinib, Obinutuzumab",
    "indications": "Chronic Lymphocytic Leukemia",
    "sample_size": "170",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06389136",
    "title": "A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab",
    "phase": "PHASE3",
    "imp": "Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose",
    "indications": "Atopic Dermatitis",
    "sample_size": "200",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT03105102",
    "title": "A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI)",
    "indications": "Crohn's Disease",
    "sample_size": "1336",
    "enrollment_type": "A",
    "start_date_iso": "2018-04-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05711394",
    "title": "A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine",
    "phase": "PHASE3",
    "imp": "Atogepant, Placebo-Matching Atogepant",
    "indications": "Episodic Migraine",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2023-05-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT03675308",
    "title": "A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy",
    "phase": "PHASE3",
    "imp": "Placebo, Risankizumab",
    "indications": "Psoriatic Arthritis",
    "sample_size": "964",
    "enrollment_type": "A",
    "start_date_iso": "2019-03-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-10-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-09-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05814627",
    "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis",
    "phase": "PHASE3",
    "imp": "Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo",
    "indications": "Rheumatoid Arthritis",
    "sample_size": "487",
    "enrollment_type": "A",
    "start_date_iso": "2023-06-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06158841",
    "title": "Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "380",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04928846",
    "title": "A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",
    "phase": "PHASE3",
    "imp": "Telisotuzumab Vedotin, Docetaxel",
    "indications": "Non Small Cell Lung Cancer",
    "sample_size": "698",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": true,
    "nct_id": "NCT06508658",
    "title": "A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
    "phase": "PHASE3",
    "imp": "Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine",
    "indications": "Diffuse Large B-Cell Lymphoma",
    "sample_size": "360",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04750226",
    "title": "Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease",
    "phase": "PHASE3",
    "imp": "ABBV-951",
    "indications": "Parkinson's Disease (PD)",
    "sample_size": "118",
    "enrollment_type": "A",
    "start_date_iso": "2021-02-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04379050",
    "title": "Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease",
    "phase": "PHASE3",
    "imp": "ABBV-951",
    "indications": "Parkinson's Disease (PD)",
    "sample_size": "130",
    "enrollment_type": "E",
    "start_date_iso": "2020-06-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT07365241",
    "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "ABBV-706, Topotecan, Topotecan, Lurbinectedin, Amrubicin",
    "indications": "Small Cell Lung Cancer",
    "sample_size": "531",
    "enrollment_type": "E",
    "start_date_iso": "2026-04-14",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05125302",
    "title": "Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)",
    "phase": "PHASE3",
    "imp": "Ubrogepant, Placebo-Matching Ubrogepant",
    "indications": "Migraine",
    "sample_size": "1059",
    "enrollment_type": "E",
    "start_date_iso": "2022-01-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06345339",
    "title": "A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants",
    "phase": "PHASE3",
    "imp": "Armour Thyroid, Levothyroxine",
    "indications": "Hypothyroidism",
    "sample_size": "2800",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04862286",
    "title": "Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977",
    "phase": "PHASE3",
    "imp": "Risankizumab",
    "indications": "Psoriasis",
    "sample_size": "132",
    "enrollment_type": "E",
    "start_date_iso": "2021-07-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT07032597",
    "title": "A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants",
    "phase": "PHASE3",
    "imp": "HArmonyCa Lidocaine Injectable Gel, Restylane\u00ae Perlane\u00ae Lidocaine",
    "indications": "Mid Face Volume Deficit",
    "sample_size": "252",
    "enrollment_type": "A",
    "start_date_iso": "2025-05-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT03568318",
    "title": "A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis",
    "phase": "PHASE3",
    "imp": "Placebo, Upadacitinib, Topical corticosteroids (TCS)",
    "indications": "Atopic Dermatitis",
    "sample_size": "1533",
    "enrollment_type": "A",
    "start_date_iso": "2018-08-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-02-16",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2030-10-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06461897",
    "title": "A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis",
    "phase": "PHASE3",
    "imp": "Upadacitinib, Dupilumab",
    "indications": "Atopic Dermatitis",
    "sample_size": "675",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT07207369",
    "title": "A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars",
    "phase": "PHASE3",
    "imp": "ELAPR002f Injectable Gel, Saline Control",
    "indications": "Acne Scars",
    "sample_size": "395",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05127954",
    "title": "Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)",
    "phase": "PHASE3",
    "imp": "Ubrogepant",
    "indications": "Migraine",
    "sample_size": "1200",
    "enrollment_type": "E",
    "start_date_iso": "2022-01-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04102020",
    "title": "A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy",
    "phase": "PHASE3",
    "imp": "Venetoclax, Azacitidine, Azacitidine",
    "indications": "Acute Myeloid Leukemia (AML)",
    "sample_size": "112",
    "enrollment_type": "A",
    "start_date_iso": "2020-03-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-09-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06614192",
    "title": "A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer",
    "phase": "PHASE3",
    "imp": "Telisotuzumab Adizutecan, Trifluridine/Tipiracil, Bevacizumab",
    "indications": "Metastatic Colorectal Cancer",
    "sample_size": "460",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06241313",
    "title": "Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine",
    "phase": "PHASE3",
    "imp": "Atogepant, Placebo for Atogepant",
    "indications": "Migraine",
    "sample_size": "1300",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-07",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06332534",
    "title": "Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Upadacitinib",
    "indications": "Crohn's Disease",
    "sample_size": "110",
    "enrollment_type": "E",
    "start_date_iso": "2024-07-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06880744",
    "title": "A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab",
    "phase": "PHASE3",
    "imp": "Risankizumab, Risankizumab, Vedolizumab",
    "indications": "Ulcerative Colitis",
    "sample_size": "530",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05889182",
    "title": "A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy",
    "phase": "PHASE3",
    "imp": "Upadacitinib, Placebo",
    "indications": "Hidradenitis Suppurativa",
    "sample_size": "1328",
    "enrollment_type": "E",
    "start_date_iso": "2023-06-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06417775",
    "title": "Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine",
    "phase": "PHASE3",
    "imp": "Ubrogepant, Placebo for Ubrogepant",
    "indications": "Migraine",
    "sample_size": "496",
    "enrollment_type": "E",
    "start_date_iso": "2024-09-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT07005102",
    "title": "A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi)",
    "indications": "Non-Squamous Non-Small Cell Lung Cancer",
    "sample_size": "694",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06118411",
    "title": "A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo",
    "phase": "PHASE3",
    "imp": "Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy",
    "indications": "Vitiligo",
    "sample_size": "614",
    "enrollment_type": "A",
    "start_date_iso": "2023-12-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-23",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": true,
    "nct_id": "NCT04628494",
    "title": "A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)",
    "phase": "PHASE3",
    "imp": "Epcoritamab, Investigator's Choice Chemotherapy",
    "indications": "Diffuse Large B-cell Lymphoma",
    "sample_size": "484",
    "enrollment_type": "A",
    "start_date_iso": "2021-01-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-10-13",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": true,
    "nct_id": "NCT05409066",
    "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma",
    "phase": "PHASE3",
    "imp": "Epcoritamab, Rituximab, Lenalidomide",
    "indications": "Follicular Lymphoma (FL)",
    "sample_size": "549",
    "enrollment_type": "A",
    "start_date_iso": "2022-09-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT03891446",
    "title": "Long-term Safety and Efficacy Extension Trial of Bimatoprost SR",
    "phase": "PHASE3",
    "imp": "Bimatoprost SR, Standard of Care",
    "indications": "Open-Angle Glaucoma, Ocular Hypertension",
    "sample_size": "455",
    "enrollment_type": "A",
    "start_date_iso": "2019-03-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT03539744",
    "title": "A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.",
    "phase": "PHASE3",
    "imp": "Pomalidomide, Dexamethasone, Venetoclax",
    "indications": "Multiple Myeloma",
    "sample_size": "265",
    "enrollment_type": "A",
    "start_date_iso": "2018-10-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04524611",
    "title": "Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)",
    "phase": "PHASE3",
    "imp": "Risankizumab, Risankizumab, Ustekinumab, Ustekinumab",
    "indications": "Crohn's Disease (CD)",
    "sample_size": "527",
    "enrollment_type": "A",
    "start_date_iso": "2020-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": true,
    "nct_id": "NCT06191744",
    "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma",
    "phase": "PHASE3",
    "imp": "Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine",
    "indications": "Follicular Lymphoma (FL)",
    "sample_size": "1095",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2037-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2037-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04704921",
    "title": "Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD",
    "phase": "PHASE3",
    "imp": "ABBV-RGX-314, ABBV-RGX-314, Ranibizumab (LUCENTIS\u00ae)",
    "indications": "AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization",
    "sample_size": "630",
    "enrollment_type": "E",
    "start_date_iso": "2020-12-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06575192",
    "title": "Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants",
    "phase": "PHASE3",
    "imp": "ARTIA Reconstructive Tissue Matrix, No Intervention",
    "indications": "Breast Reconstruction",
    "sample_size": "783",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06806293",
    "title": "Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine",
    "phase": "PHASE3",
    "imp": "Atogepant, Placebo for Atogepant",
    "indications": "Menstrual Migraine (MM)",
    "sample_size": "430",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT07007065",
    "title": "Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)",
    "phase": "PHASE3",
    "imp": "Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control",
    "indications": "Neovascular Age-related Macular Degeneration",
    "sample_size": "561",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05995340",
    "title": "ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars",
    "phase": "PHASE3",
    "imp": "ELAPR002f Injectable Gel, Saline Active Control",
    "indications": "Atrophic Acne Scars",
    "sample_size": "157",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06734351",
    "title": "A Study to Assess Safety and Effectiveness of Injections of NOA VOLUME Injectable Gel in Adult Participants Compared to JUV\u00c9DERM VOLUMA XC for Change of Mid-Face Volume",
    "phase": "PHASE3",
    "imp": "NOA VOLUME, VOLUMA XC",
    "indications": "Mid Face Volume Deficit",
    "sample_size": "231",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": true,
    "nct_id": "NCT06660693",
    "title": "Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Upadacitinib Oral Product",
    "indications": "Colitis, Ulcerative",
    "sample_size": "134",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT06822738",
    "title": "A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma",
    "phase": "PHASE3",
    "imp": "XEN63 Glaucoma Treatment System",
    "indications": "Primary Open Angle Glaucoma",
    "sample_size": "130",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT07071519",
    "title": "A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Risankizumab, Risankizumab",
    "indications": "Ulcerative Colitis",
    "sample_size": "120",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2034-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT04777357",
    "title": "A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.",
    "phase": "PHASE3",
    "imp": "Cariprazine, Placebo",
    "indications": "Depression, Bipolar I Disorder",
    "sample_size": "380",
    "enrollment_type": "E",
    "start_date_iso": "2021-04-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT05782907",
    "title": "Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.",
    "phase": "PHASE3",
    "imp": "Upadacitinib",
    "indications": "Ulcerative Colitis",
    "sample_size": "122",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AbbVie",
    "is_collaborator": false,
    "nct_id": "NCT02629159",
    "title": "A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate",
    "phase": "PHASE3",
    "imp": "Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib",
    "indications": "Rheumatoid Arthritis",
    "sample_size": "1629",
    "enrollment_type": "A",
    "start_date_iso": "2015-12-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2017-10-27",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT05722886",
    "title": "DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol",
    "phase": "PHASE3",
    "imp": "Alectinib, Atezolizumab, Entrectinib, Trastuzumab in combination with pertuzumab, Vemurafenib in combination with cobimetinib, Capmatinib",
    "indications": "Haematological Malignancy, Solid Tumour",
    "sample_size": "825",
    "enrollment_type": "E",
    "start_date_iso": "2023-03-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT04446117",
    "title": "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC",
    "phase": "PHASE3",
    "imp": "Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone",
    "indications": "Metastatic Prostate Cancer, Prostate Adenocarcinoma",
    "sample_size": "575",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-04-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-10-16",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05269004",
    "title": "A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Ocrelizumab",
    "indications": "Multiple Sclerosis",
    "sample_size": "1300",
    "enrollment_type": "E",
    "start_date_iso": "2022-05-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT05881408",
    "title": "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)",
    "phase": "PHASE3",
    "imp": "delandistrogene moxeparvovec, placebo",
    "indications": "Duchenne Muscular Dystrophy",
    "sample_size": "148",
    "enrollment_type": "E",
    "start_date_iso": "2023-05-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05646862",
    "title": "A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy",
    "phase": "PHASE3",
    "imp": "Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam",
    "indications": "Breast Cancer",
    "sample_size": "420",
    "enrollment_type": "E",
    "start_date_iso": "2023-06-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04586010",
    "title": "A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)",
    "phase": "PHASE3",
    "imp": "Fenebrutinib, Teriflunomide, Placebo",
    "indications": "Relapsing Multiple Sclerosis",
    "sample_size": "746",
    "enrollment_type": "A",
    "start_date_iso": "2021-03-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT07174310",
    "title": "A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease",
    "phase": "PHASE3",
    "imp": "Prasinezumab, Placebo",
    "indications": "Parkinson's Disease",
    "sample_size": "900",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-06-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06094010",
    "title": "A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts",
    "phase": "PHASE3",
    "imp": "Baloxavir Marboxil",
    "indications": "Influenza",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06790693",
    "title": "A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer",
    "phase": "PHASE3",
    "imp": "Inavolisib, Placebo, CDK4/6i, Letrozole",
    "indications": "Breast Cancer",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-05-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-05-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT03683251",
    "title": "Extension Study for the Port Delivery System With Ranibizumab (Portal)",
    "phase": "PHASE3",
    "imp": "PDS Implant with Ranibizumab 100 mg/mL",
    "indications": "Neovascular Age-Related Macular Degeneration",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2018-09-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT03595592",
    "title": "Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab, Pertuzumab, Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide, Atezolizumab, Surgery",
    "indications": "Invasive Breast Cancer",
    "sample_size": "650",
    "enrollment_type": "E",
    "start_date_iso": "2018-09-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05115110",
    "title": "A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy",
    "phase": "PHASE3",
    "imp": "RO7204239, Placebo, Risdiplam",
    "indications": "Spinal Muscular Atrophy (SMA)",
    "sample_size": "259",
    "enrollment_type": "E",
    "start_date_iso": "2022-06-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT03523858",
    "title": "A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Ocrelizumab",
    "indications": "Progressive Multiple Sclerosis (PMS)",
    "sample_size": "927",
    "enrollment_type": "A",
    "start_date_iso": "2018-05-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-11-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT07170150",
    "title": "A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease",
    "phase": "PHASE3",
    "imp": "Trontinemab, Placebo",
    "indications": "Alzheimers Disease",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05271409",
    "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease",
    "phase": "PHASE3",
    "imp": "Satralizumab, Placebo",
    "indications": "Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)",
    "sample_size": "152",
    "enrollment_type": "E",
    "start_date_iso": "2022-08-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-20",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-12-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT07169578",
    "title": "A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease",
    "phase": "PHASE3",
    "imp": "Trontinemab, Placebo",
    "indications": "Alzheimers Disease",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06819878",
    "title": "A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Afimkibart, Placebo",
    "indications": "Moderately to Severely Active Crohns Disease",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-12-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04963296",
    "title": "A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus",
    "phase": "PHASE3",
    "imp": "Obinutuzumab, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone",
    "indications": "Systemic Lupus Erythematosus",
    "sample_size": "303",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-03-14",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06588855",
    "title": "A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Afimkibart, Placebo",
    "indications": "Moderately to Severely Active Ulcerative Colitis",
    "sample_size": "350",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04660344",
    "title": "A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Placebo, Signatera",
    "indications": "Muscle-invasive Bladder Cancer",
    "sample_size": "761",
    "enrollment_type": "A",
    "start_date_iso": "2021-05-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-09-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06106828",
    "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease",
    "phase": "PHASE3",
    "imp": "Satralizumab, Placebo",
    "indications": "Thyroid Eye Disease",
    "sample_size": "127",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-24",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-07-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04544436",
    "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",
    "phase": "PHASE3",
    "imp": "Ocrelizumab, Ocrelizumab, Antihistamine, Methylprednisolone",
    "indications": "Multiple Sclerosis",
    "sample_size": "864",
    "enrollment_type": "A",
    "start_date_iso": "2020-11-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-12-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04035005",
    "title": "A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Ocrelizumab, Placebo",
    "indications": "Multiple Sclerosis, Primary Progressive",
    "sample_size": "1013",
    "enrollment_type": "A",
    "start_date_iso": "2019-08-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-01-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-01-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT04608318",
    "title": "Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)",
    "phase": "PHASE3",
    "imp": "Ibrutinib, Venetoclax, Obinutuzumab",
    "indications": "Chronic Lymphoid Leukemia",
    "sample_size": "897",
    "enrollment_type": "E",
    "start_date_iso": "2021-03-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04873362",
    "title": "A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab",
    "indications": "Breast Cancer",
    "sample_size": "1188",
    "enrollment_type": "A",
    "start_date_iso": "2021-05-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-08-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-10-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT04332822",
    "title": "A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma",
    "phase": "PHASE3",
    "imp": "R-pola-mini-CHP, R-mini-CHOP",
    "indications": "DLBCL, Diffuse Large B Cell Lymphoma",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2020-08-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT06680258",
    "title": "A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy",
    "phase": "PHASE3",
    "imp": "TPST-1120, Atezolizumab, Bevacizumab",
    "indications": "Hepatocellular Carcinoma (HCC)",
    "sample_size": "740",
    "enrollment_type": "E",
    "start_date_iso": "2025-12",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-07",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05862285",
    "title": "A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study",
    "phase": "PHASE3",
    "imp": "Ipatasertib, Tiragolumab, Atezolizumab, Tiragolumab and Atezolizumab, Bevacizumab, Entrectinib, Inavolisib, Divarasib",
    "indications": "Cancer",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2023-06-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-03-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-03-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT06790784",
    "title": "Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR",
    "phase": "PHASE3",
    "imp": "Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP)",
    "indications": "Proliferative Diabetic Retinopathy (PDR)",
    "sample_size": "426",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05503264",
    "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis",
    "phase": "PHASE3",
    "imp": "Satralizumab, Placebo",
    "indications": "NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis",
    "sample_size": "152",
    "enrollment_type": "E",
    "start_date_iso": "2022-09-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06176352",
    "title": "A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia",
    "phase": "PHASE3",
    "imp": "Faricimab, Ranibizumab, Sham Procedure",
    "indications": "Choroidal Neovascularization Secondary to Pathologic Myopia",
    "sample_size": "280",
    "enrollment_type": "A",
    "start_date_iso": "2024-03-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-05-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04586023",
    "title": "Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)",
    "phase": "PHASE3",
    "imp": "Fenebrutinib, Teriflunomide, Placebo",
    "indications": "Relapsing Multiple Sclerosis",
    "sample_size": "751",
    "enrollment_type": "A",
    "start_date_iso": "2021-03-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-05",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-07-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT03178552",
    "title": "A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)",
    "phase": "PHASE3",
    "imp": "Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2017-09-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT04111978",
    "title": "MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)",
    "phase": "PHASE3",
    "imp": "Letrozole 2.5mg, Placebo",
    "indications": "Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma",
    "sample_size": "540",
    "enrollment_type": "E",
    "start_date_iso": "2020-11-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-07-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT04401748",
    "title": "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome",
    "phase": "PHASE3",
    "imp": "Venetoclax, Azacitidine, Placebo",
    "indications": "Myelodysplastic Syndrome (MDS)",
    "sample_size": "531",
    "enrollment_type": "A",
    "start_date_iso": "2020-09-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT03456076",
    "title": "A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Alectnib, Cisplatin, Vinorelbine, Gemcitabine, Pemetrexed, Carboplatin",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "257",
    "enrollment_type": "A",
    "start_date_iso": "2018-08-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-06-26",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-11-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05987423",
    "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease",
    "phase": "PHASE3",
    "imp": "Satralizumab, Placebo",
    "indications": "Thyroid Eye Disease, TED",
    "sample_size": "131",
    "enrollment_type": "A",
    "start_date_iso": "2023-10-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-07-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06084936",
    "title": "A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma",
    "phase": "PHASE3",
    "imp": "Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab",
    "indications": "Lymphoma",
    "sample_size": "182",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04191499",
    "title": "A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",
    "phase": "PHASE3",
    "imp": "Inavolisib, Placebo, Palbociclib, Fulvestrant",
    "indications": "Breast Cancer",
    "sample_size": "325",
    "enrollment_type": "A",
    "start_date_iso": "2020-01-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-09-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-11-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06819891",
    "title": "A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Afimkibart, Placebo",
    "indications": "Moderately to Severely Active Crohns Disease",
    "sample_size": "425",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05296798",
    "title": "A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)",
    "phase": "PHASE3",
    "imp": "Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice",
    "indications": "Locally Advanced or Metastatic Breast Cancer",
    "sample_size": "922",
    "enrollment_type": "E",
    "start_date_iso": "2022-07-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05595642",
    "title": "A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease",
    "phase": "PHASE3",
    "imp": "Astegolimab, Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease (COPD)",
    "sample_size": "1290",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-24",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-03-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04221477",
    "title": "A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis",
    "phase": "PHASE3",
    "imp": "Obinutuzumab, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine",
    "indications": "Lupus Nephritis",
    "sample_size": "271",
    "enrollment_type": "A",
    "start_date_iso": "2020-08-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-08-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2031-02-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT03281954",
    "title": "Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo",
    "phase": "PHASE3",
    "imp": "Placebo, Atezolizumab",
    "indications": "Triple Negative Breast Cancer",
    "sample_size": "1550",
    "enrollment_type": "A",
    "start_date_iso": "2017-12-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05123703",
    "title": "A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)",
    "phase": "PHASE3",
    "imp": "Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo",
    "indications": "Relapsing-Remitting Multiple Sclerosis",
    "sample_size": "188",
    "enrollment_type": "A",
    "start_date_iso": "2022-05-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-09",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-09-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04770896",
    "title": "A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Lenvatinib, Sorafenib",
    "indications": "Unresectable Hepatocellular Carcinoma",
    "sample_size": "557",
    "enrollment_type": "A",
    "start_date_iso": "2021-04-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06047080",
    "title": "An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma",
    "phase": "PHASE3",
    "imp": "Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone",
    "indications": "Large B-Cell Lymphoma",
    "sample_size": "1130",
    "enrollment_type": "A",
    "start_date_iso": "2023-09-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04543617",
    "title": "A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy",
    "phase": "PHASE3",
    "imp": "Tiragolumab, Atezolizumab, Tiragolumab Matching Placebo, Atezolizumab Matching Placebo",
    "indications": "Esophageal Squamous Cell Carcinoma",
    "sample_size": "760",
    "enrollment_type": "A",
    "start_date_iso": "2020-09-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT02486718",
    "title": "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "1280",
    "enrollment_type": "A",
    "start_date_iso": "2015-10-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-26",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-12-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT04650581",
    "title": "Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor",
    "phase": "PHASE3",
    "imp": "Ipatasertib, Fulvestrant, Placebo",
    "indications": "Breast Cancer",
    "sample_size": "250",
    "enrollment_type": "A",
    "start_date_iso": "2021-01-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-05-23",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04434092",
    "title": "A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors",
    "phase": "PHASE3",
    "imp": "Crovalimab, Eculizumab",
    "indications": "Paroxysmal Nocturnal Hemoglobinuria",
    "sample_size": "210",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-11-16",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04629248",
    "title": "A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy",
    "phase": "PHASE3",
    "imp": "Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine",
    "indications": "Primary Membranous Nephropathy",
    "sample_size": "142",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-22",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-12-21",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04546009",
    "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)",
    "phase": "PHASE3",
    "imp": "Giredestrant, Giredestrant-matched Placebo, Letrozole, Letrozole-matched Placebo, Palbociclib, LHRH Agonist",
    "indications": "Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",
    "sample_size": "992",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-25",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04657289",
    "title": "A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)",
    "phase": "PHASE3",
    "imp": "Ranibizumab, Port Delivery System with Ranibizumab",
    "indications": "Neovascular Age-related Macular Degeneration (nAMD)",
    "sample_size": "451",
    "enrollment_type": "A",
    "start_date_iso": "2021-07-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04548999",
    "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",
    "phase": "PHASE3",
    "imp": "Ocrelizumab, Ocrelizumab, Antihistamine, Methylprednisolone",
    "indications": "Multiple Sclerosis",
    "sample_size": "769",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-09-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04102098",
    "title": "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Bevacizumab",
    "indications": "Carcinoma, Hepatocellular",
    "sample_size": "668",
    "enrollment_type": "A",
    "start_date_iso": "2019-12-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-10-21",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-07-16",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT05967351",
    "title": "A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study",
    "phase": "PHASE3",
    "imp": "delandistrogene moxeparvovec",
    "indications": "Duchenne Muscular Dystrophy",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2023-09-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-11-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-11-30",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05171647",
    "title": "A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma",
    "phase": "PHASE3",
    "imp": "Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin",
    "indications": "Non-Hodgkin Lymphoma",
    "sample_size": "242",
    "enrollment_type": "A",
    "start_date_iso": "2022-04-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-02-17",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-02-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT03148418",
    "title": "A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Bevacizumab",
    "indications": "Cancer",
    "sample_size": "382",
    "enrollment_type": "A",
    "start_date_iso": "2017-09-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05797610",
    "title": "A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression",
    "phase": "PHASE3",
    "imp": "Sefaxersen (RO7434656), Placebo",
    "indications": "Primary IgA Nephropathy",
    "sample_size": "428",
    "enrollment_type": "E",
    "start_date_iso": "2023-08-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04961996",
    "title": "A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",
    "phase": "PHASE3",
    "imp": "Giredestrant, Endocrine Therapy of Physician's Choice, LHRH Agonist, Abemaciclib",
    "indications": "Early Breast Cancer",
    "sample_size": "4200",
    "enrollment_type": "E",
    "start_date_iso": "2021-08-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2035-01-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04712097",
    "title": "A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma",
    "phase": "PHASE3",
    "imp": "Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab",
    "indications": "Relapsed or Refractory Follicular Lymphoma",
    "sample_size": "478",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT01760005",
    "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001",
    "phase": "PHASE3",
    "imp": "Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), Gantenerumab, E2814, Lecanemab, Matching Placebo (E2814)",
    "indications": "Alzheimers Disease, Dementia, Alzheimers Disease, Familial",
    "sample_size": "490",
    "enrollment_type": "E",
    "start_date_iso": "2012-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04108156",
    "title": "A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME",
    "phase": "PHASE3",
    "imp": "PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange",
    "indications": "Diabetic Macular Edema",
    "sample_size": "634",
    "enrollment_type": "E",
    "start_date_iso": "2019-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT04102020",
    "title": "A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy",
    "phase": "PHASE3",
    "imp": "Venetoclax, Azacitidine, Azacitidine",
    "indications": "Acute Myeloid Leukemia (AML)",
    "sample_size": "112",
    "enrollment_type": "A",
    "start_date_iso": "2020-03-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-09-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT07298421",
    "title": "A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Afimkibart",
    "indications": "Moderately to Severely Active Crohns Disease",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2026-05-29",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-05-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-05-29",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04712643",
    "title": "A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE)",
    "indications": "Hepatocellular Carcinoma",
    "sample_size": "342",
    "enrollment_type": "A",
    "start_date_iso": "2021-03-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04544449",
    "title": "A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib",
    "indications": "Multiple Sclerosis, Primary Progressive",
    "sample_size": "985",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-17",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-07-21",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT07351058",
    "title": "A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes",
    "phase": "PHASE3",
    "imp": "Placebo, RO7795068",
    "indications": "Obesity or Overweight, Type 2 Diabetes Mellitus",
    "sample_size": "1600",
    "enrollment_type": "E",
    "start_date_iso": "2026-02-27",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-08-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-07",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06675955",
    "title": "An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment",
    "phase": "PHASE3",
    "imp": "Ocrelizumab",
    "indications": "Multiple Sclerosis",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT07351045",
    "title": "A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes",
    "phase": "PHASE3",
    "imp": "Placebo, RO7795068",
    "indications": "Obesity or Overweight",
    "sample_size": "2000",
    "enrollment_type": "E",
    "start_date_iso": "2026-02-27",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-08-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-28",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06589986",
    "title": "A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Afimkibart, Placebo",
    "indications": "Moderately to Severely Active Ulcerative Colitis",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2024-09-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06847542",
    "title": "A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD",
    "phase": "PHASE3",
    "imp": "Susvimo PDS Implant, Ranibizumab",
    "indications": "Neovascular Age-related Macular Degeneration",
    "sample_size": "250",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06065748",
    "title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",
    "phase": "PHASE3",
    "imp": "Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx)",
    "indications": "Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",
    "sample_size": "1050",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT02758951",
    "title": "Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases",
    "phase": "PHASE3",
    "imp": "Perioperative systemic therapy, Perioperative CAPOX-bevacizumab, Perioperative FOLFOX-bevacizumab, Perioperative FOLFIRI-bevacizumab, CRS-HIPEC, experimental arm, CRS-HIPEC, control arm",
    "indications": "Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant, Colorectal Carcinoma, Colorectal Adenocarcinoma, Peritoneal Neoplasms, Peritoneal Carcinomatosis, Peritoneal Cancer, Peritoneal Metastases, Peritoneal Neoplasm Malignant Secondary Carcinomatosis, Peritoneal Neoplasm Malignant Secondary",
    "sample_size": "358",
    "enrollment_type": "A",
    "start_date_iso": "2017-06-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-10-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-06-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT06733038",
    "title": "FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Bevacizumab, Irinotecan (CPT-11), Oxaliplatin, Leucovorin, Fluorouracil (5-FU)",
    "indications": "Colorectal Cancer",
    "sample_size": "238",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT02320435",
    "title": "A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial",
    "phase": "PHASE3",
    "imp": "Pertuzumab, Trastuzumab, Other Combination Anti-Cancer Therapies",
    "indications": "Solid Tumors",
    "sample_size": "154",
    "enrollment_type": "A",
    "start_date_iso": "2015-02-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT03539744",
    "title": "A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.",
    "phase": "PHASE3",
    "imp": "Pomalidomide, Dexamethasone, Venetoclax",
    "indications": "Multiple Myeloma",
    "sample_size": "265",
    "enrollment_type": "A",
    "start_date_iso": "2018-10-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06793215",
    "title": "A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Divarasib, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin",
    "indications": "Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-10-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT07181109",
    "title": "Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease",
    "phase": "PHASE3",
    "imp": "Zilebesiran, Placebo",
    "indications": "High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk",
    "sample_size": "11000",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-10-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-10-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT04702256",
    "title": "Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF",
    "phase": "PHASE3",
    "imp": "Obinutuzumab administration, Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil, Administration of methylprednisolone, paracetamol and dexchlorpheniramine",
    "indications": "Lupus Nephritis, Systemic Lupus Erythematosus (SLE)",
    "sample_size": "196",
    "enrollment_type": "E",
    "start_date_iso": "2021-12-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04665856",
    "title": "Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Tiragolumab, Atezolizumab, Carboplatin, Etoposide, Tiragolumab Matching Placebo",
    "indications": "Small Cell Lung Carcinoma",
    "sample_size": "123",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-08-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT03194893",
    "title": "A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer",
    "phase": "PHASE3",
    "imp": "Alectinib, Crizotinib",
    "indications": "Neoplasms",
    "sample_size": "200",
    "enrollment_type": "E",
    "start_date_iso": "2017-07-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05091567",
    "title": "A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Lurbinectedin, Carboplatin, Etoposide",
    "indications": "Small-Cell Lung Cancer",
    "sample_size": "660",
    "enrollment_type": "A",
    "start_date_iso": "2021-11-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-07-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-08-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT07158242",
    "title": "A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Afimkibart",
    "indications": "Moderately to Severely Active Ulcerative Colitis",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2026-03-31",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-03-31",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05894239",
    "title": "A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer",
    "phase": "PHASE3",
    "imp": "Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice",
    "indications": "Metastatic Breast Cancer",
    "sample_size": "230",
    "enrollment_type": "E",
    "start_date_iso": "2023-09-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-12-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04408638",
    "title": "A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
    "phase": "PHASE3",
    "imp": "Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin",
    "indications": "Diffuse Large B-cell Lymphoma",
    "sample_size": "270",
    "enrollment_type": "E",
    "start_date_iso": "2021-02-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT06497556",
    "title": "A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Divarasib, Sotorasib, Adagrasib",
    "indications": "Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer",
    "sample_size": "338",
    "enrollment_type": "A",
    "start_date_iso": "2024-09-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-11-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05878769",
    "title": "A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)",
    "phase": "PHASE3",
    "imp": "Astegolimab",
    "indications": "Chronic Obstructive Pulmonary Disease",
    "sample_size": "2000",
    "enrollment_type": "E",
    "start_date_iso": "2023-06-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT05844982",
    "title": "Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy",
    "phase": "PHASE3",
    "imp": "Faricimab, fluocinolone acetonide",
    "indications": "Radiation Retinopathy, Visual Impairment",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT04661358",
    "title": "Fenofibrate for Prevention of DR Worsening",
    "phase": "PHASE3",
    "imp": "Fenofibrate, Placebo",
    "indications": "Diabetic Retinopathy",
    "sample_size": "560",
    "enrollment_type": "E",
    "start_date_iso": "2021-03-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT03799835",
    "title": "Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients",
    "phase": "PHASE3",
    "imp": "BCG, Atezolizumab",
    "indications": "Bladder Cancer",
    "sample_size": "517",
    "enrollment_type": "A",
    "start_date_iso": "2019-01-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT02838420",
    "title": "A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "phase": "PHASE3",
    "imp": "Alectinib, Crizotinib",
    "indications": "Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer",
    "sample_size": "187",
    "enrollment_type": "A",
    "start_date_iso": "2016-08-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2018-05-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05306340",
    "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)",
    "phase": "PHASE3",
    "imp": "Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse",
    "indications": "Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer",
    "sample_size": "373",
    "enrollment_type": "A",
    "start_date_iso": "2022-08-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-16",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-10-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT05904886",
    "title": "A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Bevacizumab, Tiragolumab, Placebo",
    "indications": "Hepatocellular Carcinoma",
    "sample_size": "687",
    "enrollment_type": "A",
    "start_date_iso": "2023-09-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-05-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-09-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT07177352",
    "title": "Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies",
    "phase": "PHASE3",
    "imp": "No Intervention",
    "indications": "Alzheimers Disease",
    "sample_size": "13000",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2035-07-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2035-07-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04432584",
    "title": "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors",
    "phase": "PHASE3",
    "imp": "Crovalimab, Eculizumab",
    "indications": "Paroxysmal Nocturnal Hemoglobinuria",
    "sample_size": "190",
    "enrollment_type": "E",
    "start_date_iso": "2020-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT04603807",
    "title": "A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases",
    "phase": "PHASE3",
    "imp": "Entrectinib, Crizotinib",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "220",
    "enrollment_type": "E",
    "start_date_iso": "2021-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT03768063",
    "title": "A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study",
    "phase": "PHASE3",
    "imp": "Atezolizumab, Bevacizumab, Alectinib, Cobimetinib, Vemurafenib, FAP IL2V, Venetoclax, Enzalutamide, Pembrolizumab, Sunitinib, Niraparib, Cabozantinib, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib",
    "indications": "Cancer",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2019-02-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-07-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-07-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": false,
    "nct_id": "NCT03274492",
    "title": "A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",
    "phase": "PHASE3",
    "imp": "Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo",
    "indications": "Diffuse Large B-Cell Lymphoma",
    "sample_size": "1000",
    "enrollment_type": "A",
    "start_date_iso": "2017-11-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Roche",
    "is_collaborator": true,
    "nct_id": "NCT01996267",
    "title": "Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2",
    "phase": "PHASE3",
    "imp": "PTC+Pertuzumab, FEC-T+Pertuzumab",
    "indications": "Breast Cancer, HER2 Positive",
    "sample_size": "437",
    "enrollment_type": "A",
    "start_date_iso": "2013-12",
    "start_date_type": "E",
    "primary_completion_date_iso": "2018-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2030-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT00223171",
    "title": "Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers",
    "phase": "PHASE3",
    "imp": "Androgen blockade + radiation therapy",
    "indications": "Prostate Cancer",
    "sample_size": "630",
    "enrollment_type": "A",
    "start_date_iso": "2000-10",
    "start_date_type": "E",
    "primary_completion_date_iso": "2026-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06868277",
    "title": "A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Rilvegostomig, Pembrolizumab",
    "indications": "Carcinoma, Non-Small Cell Lung",
    "sample_size": "830",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-01-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04269200",
    "title": "Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer",
    "phase": "PHASE3",
    "imp": "olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel",
    "indications": "Endometrial Neoplasms",
    "sample_size": "805",
    "enrollment_type": "A",
    "start_date_iso": "2020-05-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-07-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-04-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06015737",
    "title": "A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus",
    "phase": "PHASE3",
    "imp": "Anifrolumab, Placebo",
    "indications": "Cutaneous Lupus Erythematosus",
    "sample_size": "302",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT05255653",
    "title": "Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features",
    "phase": "PHASE3",
    "imp": "Olaparib, Pelvic external beam radiotherapy, Chemotherapy, Durvalumab, Medroxyprogesterone Acetate, Megestrol Acetate, Vaginal brachytherapy, Observation",
    "indications": "Endometrial Cancer",
    "sample_size": "1615",
    "enrollment_type": "E",
    "start_date_iso": "2021-11-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-01-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-01-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06023589",
    "title": "A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma",
    "phase": "PHASE3",
    "imp": "Tezepelumab, Placebo",
    "indications": "Asthma",
    "sample_size": "231",
    "enrollment_type": "E",
    "start_date_iso": "2023-08-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-08-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04739761",
    "title": "A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan",
    "indications": "Breast Cancer",
    "sample_size": "506",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-02-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-02-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05925803",
    "title": "Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)",
    "phase": "PHASE3",
    "imp": "Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label)",
    "indications": "Systemic Sclerosis, Scleroderma",
    "sample_size": "306",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT03836261",
    "title": "Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL",
    "phase": "PHASE3",
    "imp": "Acalabrutinib, Venetoclax, Chemoimmunotherapy, Obinutuzumab",
    "indications": "Chronic Lymphocytic Leukemia",
    "sample_size": "984",
    "enrollment_type": "A",
    "start_date_iso": "2019-02-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06764875",
    "title": "A Phase \u2162 Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer",
    "phase": "PHASE3",
    "imp": "Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil, Capecitabine, Cisplatin, Oxaliplatin",
    "indications": "HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma",
    "sample_size": "840",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-04-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06465485",
    "title": "STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma",
    "phase": "PHASE3",
    "imp": "Benralizumab",
    "indications": "Severe Eosinophilic Asthma",
    "sample_size": "504",
    "enrollment_type": "A",
    "start_date_iso": "2024-02-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06268873",
    "title": "A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.",
    "phase": "PHASE3",
    "imp": "Baxdrostat/dapagliflozin, Dapagliflozin in combination with placebo",
    "indications": "Chronic Kidney Disease and Hypertension",
    "sample_size": "2554",
    "enrollment_type": "A",
    "start_date_iso": "2024-03-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02-24",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05984277",
    "title": "A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.",
    "phase": "PHASE3",
    "imp": "Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed",
    "indications": "Metastatic Non-small Cell Lung Cancer",
    "sample_size": "1200",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT05950945",
    "title": "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan",
    "indications": "Breast Cancer",
    "sample_size": "250",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06087835",
    "title": "Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)",
    "phase": "PHASE3",
    "imp": "Zibotentan/Dapagliflozin, Dapagliflozin",
    "indications": "Chronic Kidney Disease With High Proteinuria",
    "sample_size": "1835",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05692180",
    "title": "A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)",
    "phase": "PHASE3",
    "imp": "Benralizumab, Placebo",
    "indications": "Asthma",
    "sample_size": "200",
    "enrollment_type": "E",
    "start_date_iso": "2023-04-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-05-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-05-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT03288532",
    "title": "Renal Adjuvant MultiPle Arm Randomised Trial",
    "phase": "PHASE3",
    "imp": "Durvalumab, Tremelimumab",
    "indications": "Renal Cell Carcinoma",
    "sample_size": "1750",
    "enrollment_type": "E",
    "start_date_iso": "2018-07-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-07-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-12-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03732820",
    "title": "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer",
    "phase": "PHASE3",
    "imp": "olaparib, abiraterone acetate",
    "indications": "Metastatic Castration-resistant Prostate Cancer",
    "sample_size": "895",
    "enrollment_type": "A",
    "start_date_iso": "2018-10-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-07-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-04-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT07129993",
    "title": "Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Carboplatin, Cisplatin, Gemcitabine",
    "indications": "Urothelial Cancer, Bladder Cancer",
    "sample_size": "630",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-06-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01-22",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07007793",
    "title": "A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism",
    "phase": "PHASE3",
    "imp": "Baxdrostat, Placebo",
    "indications": "Primary Hyperaldosteronism",
    "sample_size": "180",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03800134",
    "title": "A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "825",
    "enrollment_type": "A",
    "start_date_iso": "2018-12-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-11-10",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-09-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT05667493",
    "title": "An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)",
    "phase": "PHASE3",
    "imp": "Eplontersen",
    "indications": "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",
    "sample_size": "1400",
    "enrollment_type": "E",
    "start_date_iso": "2022-11-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04960709",
    "title": "Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin",
    "phase": "PHASE3",
    "imp": "Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy",
    "indications": "Muscle Invasive Bladder Cancer",
    "sample_size": "712",
    "enrollment_type": "A",
    "start_date_iso": "2021-08-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05120349",
    "title": "A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection",
    "phase": "PHASE3",
    "imp": "Osimertinib, Placebo",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "390",
    "enrollment_type": "A",
    "start_date_iso": "2022-02-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-11-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07215585",
    "title": "AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL",
    "phase": "PHASE3",
    "imp": "AZD0486, R-mini-CHOP",
    "indications": "Large B-cell Lymphoma",
    "sample_size": "420",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-07-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-07-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03003962",
    "title": "Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)",
    "phase": "PHASE3",
    "imp": "Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin",
    "indications": "Non Small Cell Lung Carcinoma NSCLC",
    "sample_size": "669",
    "enrollment_type": "A",
    "start_date_iso": "2017-01-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-10-27",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03164616",
    "title": "Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).",
    "phase": "PHASE3",
    "imp": "Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin",
    "indications": "Non Small Cell Lung Cancer NSCLC",
    "sample_size": "1186",
    "enrollment_type": "A",
    "start_date_iso": "2017-06-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-03-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-11-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT07281833",
    "title": "Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment",
    "phase": "PHASE3",
    "imp": "Capivasertib",
    "indications": "Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer",
    "sample_size": "250",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04421963",
    "title": "Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib",
    "phase": "PHASE3",
    "imp": "Olaparib",
    "indications": "Ovarian Cancer, Breast Cancer",
    "sample_size": "185",
    "enrollment_type": "A",
    "start_date_iso": "2020-08-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-04-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04862663",
    "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)",
    "phase": "PHASE3",
    "imp": "Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib",
    "indications": "Locally Advanced (Inoperable) or Metastatic Breast Cancer",
    "sample_size": "895",
    "enrollment_type": "E",
    "start_date_iso": "2021-05-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06473779",
    "title": "Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.",
    "phase": "PHASE3",
    "imp": "Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA\u00ae), Mannitol, Salbutamol",
    "indications": "Severe Asthma",
    "sample_size": "296",
    "enrollment_type": "A",
    "start_date_iso": "2024-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03682068",
    "title": "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer",
    "phase": "PHASE3",
    "imp": "Durvalumab, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine",
    "indications": "Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer",
    "sample_size": "1246",
    "enrollment_type": "A",
    "start_date_iso": "2018-09-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-04-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04494425",
    "title": "Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel",
    "indications": "Advanced or Metastatic Breast Cancer",
    "sample_size": "866",
    "enrollment_type": "A",
    "start_date_iso": "2020-07-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-03-18",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07000136",
    "title": "A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH",
    "phase": "PHASE3",
    "imp": "AZD0780, Placebo",
    "indications": "Heterozygous Familial Hypercholesterolaemia",
    "sample_size": "455",
    "enrollment_type": "A",
    "start_date_iso": "2025-06-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06960577",
    "title": "Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)",
    "phase": "PHASE3",
    "imp": "Durvalumab, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Durvalumab, Gemcitabine, Cisplatin",
    "indications": "Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine",
    "sample_size": "150",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03737643",
    "title": "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients",
    "phase": "PHASE3",
    "imp": "Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel",
    "indications": "Advanced Ovarian Cancer",
    "sample_size": "1407",
    "enrollment_type": "A",
    "start_date_iso": "2019-01-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-03-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06307652",
    "title": "Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function",
    "phase": "PHASE3",
    "imp": "balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin",
    "indications": "Heart Failure and Impaired Kidney Function",
    "sample_size": "4800",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06883305",
    "title": "A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)",
    "phase": "PHASE3",
    "imp": "Tezepelumab, Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease (COPD)",
    "sample_size": "990",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT04529772",
    "title": "A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)",
    "phase": "PHASE3",
    "imp": "acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin",
    "indications": "Diffuse Large B-Cell Lymphoma",
    "sample_size": "611",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06921785",
    "title": "Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma",
    "phase": "PHASE3",
    "imp": "Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab",
    "indications": "Hepatocellular Carcinoma",
    "sample_size": "1220",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05221840",
    "title": "A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Durvalumab, Oleclumab, Monalizumab, Placebo",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "1051",
    "enrollment_type": "A",
    "start_date_iso": "2022-02-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-07-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT05555732",
    "title": "Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)",
    "phase": "PHASE3",
    "imp": "Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin",
    "indications": "Metastatic Non Small Cell Lung Cancer",
    "sample_size": "1170",
    "enrollment_type": "E",
    "start_date_iso": "2023-01-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06952803",
    "title": "A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation",
    "phase": "PHASE3",
    "imp": "Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)",
    "indications": "Prostate Cancer",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2036-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03298451",
    "title": "Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma",
    "phase": "PHASE3",
    "imp": "Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2)",
    "indications": "Hepatocellular Carcinoma",
    "sample_size": "1324",
    "enrollment_type": "A",
    "start_date_iso": "2017-10-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-08-27",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-08-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04884360",
    "title": "D9319C00001- 1L OC Mono Global RCT",
    "phase": "PHASE3",
    "imp": "Olaparib, Matching placebo",
    "indications": "Ovarian Cancer",
    "sample_size": "366",
    "enrollment_type": "A",
    "start_date_iso": "2021-05-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05583227",
    "title": "Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis",
    "phase": "PHASE3",
    "imp": "Tezepelumab, Tezepelumab, Placebo",
    "indications": "Eosinophilic Esophagitis",
    "sample_size": "368",
    "enrollment_type": "A",
    "start_date_iso": "2022-11-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06129864",
    "title": "A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy",
    "phase": "PHASE3",
    "imp": "volrustomig",
    "indications": "Locally Advanced Head and Neck Squamous Cell Carcinoma",
    "sample_size": "1145",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04075292",
    "title": "Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia",
    "phase": "PHASE3",
    "imp": "Acalabrutinib, Rituximab, Chlorambucil",
    "indications": "Untreated Chronic Lymphocytic Leukemia",
    "sample_size": "155",
    "enrollment_type": "A",
    "start_date_iso": "2020-01-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-03",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-01-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03847428",
    "title": "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment",
    "phase": "PHASE3",
    "imp": "Durvalumab, Bevacizumab, Placebo",
    "indications": "Hepatocellular Carcinoma",
    "sample_size": "908",
    "enrollment_type": "A",
    "start_date_iso": "2019-04-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT06890598",
    "title": "Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Olomorasib, Pembrolizumab, Durvalumab, Placebo",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04924608",
    "title": "Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas",
    "phase": "PHASE3",
    "imp": "Selumetinib, Placebo",
    "indications": "Neurofibromatosis 1, Plexiform Neurofibroma (PN)",
    "sample_size": "145",
    "enrollment_type": "A",
    "start_date_iso": "2021-11-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-08-05",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-02-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06283966",
    "title": "A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease",
    "phase": "PHASE3",
    "imp": "BGF MDI 320/14.4/9.6 \u03bcg, GFF MDI 14.4/9.6 \u03bcg",
    "indications": "COPD (Chronic Obstructive Pulmonary Disease)",
    "sample_size": "5000",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06380751",
    "title": "Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",
    "phase": "PHASE3",
    "imp": "Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane",
    "indications": "Advanced Breast Cancer",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-10-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT02032823",
    "title": "Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer",
    "phase": "PHASE3",
    "imp": "Olaparib, Placebo",
    "indications": "Breast Cancer",
    "sample_size": "1836",
    "enrollment_type": "A",
    "start_date_iso": "2014-04-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-03-27",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-05-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06750289",
    "title": "Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment",
    "phase": "PHASE3",
    "imp": "ICS-LABA, benralizumab, Placebo for Benralizumab",
    "indications": "Eosinophilic Asthma",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT03529110",
    "title": "DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)",
    "indications": "Breast Cancer",
    "sample_size": "524",
    "enrollment_type": "A",
    "start_date_iso": "2018-08-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-05-21",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-07-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05211895",
    "title": "A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC",
    "phase": "PHASE3",
    "imp": "Durvalumab, Domvanalimab, Placebo",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "860",
    "enrollment_type": "E",
    "start_date_iso": "2022-02-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-07-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-10-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06455449",
    "title": "A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)",
    "phase": "PHASE3",
    "imp": "Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label)",
    "indications": "Polymyositis, Dermatomyositis",
    "sample_size": "240",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05835310",
    "title": "An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants",
    "phase": "PHASE3",
    "imp": "Anifrolumab, Placebo",
    "indications": "Systemic Lupus Erythematosus",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-10-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05687266",
    "title": "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations",
    "phase": "PHASE3",
    "imp": "Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel",
    "indications": "NSCLC",
    "sample_size": "1350",
    "enrollment_type": "A",
    "start_date_iso": "2022-12-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05261399",
    "title": "Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment",
    "phase": "PHASE3",
    "imp": "Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "324",
    "enrollment_type": "E",
    "start_date_iso": "2022-08-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-17",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07291037",
    "title": "Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations",
    "phase": "PHASE3",
    "imp": "Datopotamab deruxtecan (Dato-DXd), Docetaxel",
    "indications": "Non-small Cell Lung Cancer (NSCLC)",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-01-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT05374291",
    "title": "The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD",
    "phase": "PHASE3",
    "imp": "Dapagliflozin 10 mg/day (oral), Placebo",
    "indications": "Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure, Death",
    "sample_size": "1750",
    "enrollment_type": "E",
    "start_date_iso": "2022-11-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05166889",
    "title": "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations",
    "phase": "PHASE3",
    "imp": "Tozorakimab, Tozorakimab, Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease (COPD)",
    "sample_size": "1132",
    "enrollment_type": "A",
    "start_date_iso": "2022-01-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT02511106",
    "title": "AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.",
    "phase": "PHASE3",
    "imp": "AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg",
    "indications": "Stage IB-IIIA Non-small Cell Lung Carcinoma",
    "sample_size": "682",
    "enrollment_type": "A",
    "start_date_iso": "2015-10-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-04-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-01-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT06904170",
    "title": "Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma",
    "phase": "PHASE3",
    "imp": "Durvalumab Plus Tremelimumab, HAIC (GEMOX)",
    "indications": "Hepatocellular Carcinoma",
    "sample_size": "196",
    "enrollment_type": "E",
    "start_date_iso": "2025-11",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06103864",
    "title": "A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab",
    "indications": "Breast Cancer",
    "sample_size": "625",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06635447",
    "title": "Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients",
    "phase": "PHASE3",
    "imp": "Capivasertib, Fulvestrant",
    "indications": "Breast Cancer",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2024-09-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT05047172",
    "title": "Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis",
    "phase": "PHASE3",
    "imp": "Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management",
    "indications": "Intracranial Arteriosclerosis, Stroke",
    "sample_size": "1683",
    "enrollment_type": "E",
    "start_date_iso": "2022-08-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06350097",
    "title": "Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Osimertinib, Datopotamab Deruxtecan",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "582",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-05-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06502366",
    "title": "A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma",
    "phase": "PHASE3",
    "imp": "BDA MDI HFO 160/180 \u03bcg, BDA MDI HFA 160/180 \u03bcg, Placebo MDI HFA",
    "indications": "Asthma",
    "sample_size": "398",
    "enrollment_type": "E",
    "start_date_iso": "2024-07-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04964934",
    "title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)",
    "phase": "PHASE3",
    "imp": "AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib",
    "indications": "ER-Positive HER2-Negative Breast Cancer",
    "sample_size": "315",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-11-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03833154",
    "title": "Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation",
    "phase": "PHASE3",
    "imp": "Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort)",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "724",
    "enrollment_type": "A",
    "start_date_iso": "2019-03-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06467357",
    "title": "Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer",
    "phase": "PHASE3",
    "imp": "Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig",
    "indications": "Biliary Tract Cancer",
    "sample_size": "620",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-05-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07000123",
    "title": "A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event",
    "phase": "PHASE3",
    "imp": "AZD0780, Placebo",
    "indications": "Cardiovascular Disease",
    "sample_size": "3046",
    "enrollment_type": "A",
    "start_date_iso": "2025-05-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05742802",
    "title": "Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).",
    "phase": "PHASE3",
    "imp": "Tozorakimab 1, Tozorakimab 2, Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease (COPD)",
    "sample_size": "1711",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT01602380",
    "title": "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.",
    "phase": "PHASE3",
    "imp": "faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy",
    "indications": "Hormone Receptor Positive Breast Cancer",
    "sample_size": "462",
    "enrollment_type": "A",
    "start_date_iso": "2012-10-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2016-04-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-08-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04157348",
    "title": "Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.",
    "phase": "PHASE3",
    "imp": "Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab",
    "indications": "Eosinophilic Granulomatous Vasculitis",
    "sample_size": "140",
    "enrollment_type": "A",
    "start_date_iso": "2019-10-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-08-10",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06120491",
    "title": "Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents",
    "phase": "PHASE3",
    "imp": "Saruparib, Placebo, Abiraterone Acetate, Darolutamide, Enzalutamide",
    "indications": "Metastatic Castration-Sensitive Prostate Cancer",
    "sample_size": "1800",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05771480",
    "title": "Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)",
    "phase": "PHASE3",
    "imp": "Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel",
    "indications": "Biliary Tract Cancer",
    "sample_size": "142",
    "enrollment_type": "A",
    "start_date_iso": "2023-08-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-10-02",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT03970447",
    "title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma",
    "phase": "PHASE3",
    "imp": "Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390",
    "indications": "Glioblastoma",
    "sample_size": "1280",
    "enrollment_type": "E",
    "start_date_iso": "2019-07-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT04116047",
    "title": "CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)",
    "phase": "PHASE3",
    "imp": "Cisplatin, Durvalumab, Radiotherapy",
    "indications": "Oropharyngeal Cancer",
    "sample_size": "785",
    "enrollment_type": "E",
    "start_date_iso": "2015-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT04622319",
    "title": "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)",
    "phase": "PHASE3",
    "imp": "DS-8201a, T-DM1",
    "indications": "HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer",
    "sample_size": "1600",
    "enrollment_type": "E",
    "start_date_iso": "2020-12-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06344104",
    "title": "A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension",
    "phase": "PHASE3",
    "imp": "Baxdrostat, Placebo",
    "indications": "Uncontrolled Hypertension, Resistant Hypertension",
    "sample_size": "326",
    "enrollment_type": "A",
    "start_date_iso": "2024-04-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-24",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-04-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06989112",
    "title": "DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel",
    "indications": "Endometrial Cancer",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-02-19",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05048797",
    "title": "A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed",
    "indications": "Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
    "sample_size": "454",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03732677",
    "title": "Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC",
    "phase": "PHASE3",
    "imp": "Durvalumab, Cisplatin, Gemcitabine",
    "indications": "Muscle Invasive Bladder Cancer",
    "sample_size": "1063",
    "enrollment_type": "A",
    "start_date_iso": "2018-11-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-04-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04035486",
    "title": "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)",
    "phase": "PHASE3",
    "imp": "Osimertinib, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "587",
    "enrollment_type": "A",
    "start_date_iso": "2019-07-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-04-03",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06040086",
    "title": "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations",
    "phase": "PHASE3",
    "imp": "Placebo, Tozorakimab",
    "indications": "Chronic Obstructive Pulmonary Disease (COPD)",
    "sample_size": "1454",
    "enrollment_type": "A",
    "start_date_iso": "2023-09-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06878261",
    "title": "A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)",
    "phase": "PHASE3",
    "imp": "Tezepelumab, Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease (COPD)",
    "sample_size": "990",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04592913",
    "title": "Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer",
    "phase": "PHASE3",
    "imp": "Durvalumab, FLOT chemotherapy",
    "indications": "Gastrointestinal Neoplasms, Esophagogastric Junction",
    "sample_size": "957",
    "enrollment_type": "A",
    "start_date_iso": "2020-11-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-12-20",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-09-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03706690",
    "title": "A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients",
    "phase": "PHASE3",
    "imp": "Durvalumab, Placebo",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "407",
    "enrollment_type": "A",
    "start_date_iso": "2018-11-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-06-23",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-02-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05348577",
    "title": "Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)",
    "phase": "PHASE3",
    "imp": "capivasertib, docetaxel, placebo",
    "indications": "Prostate Cancer",
    "sample_size": "1035",
    "enrollment_type": "A",
    "start_date_iso": "2022-03-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT07005128",
    "title": "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)",
    "phase": "PHASE3",
    "imp": "Tarlatamab, Durvalumab, Carboplatin, Etoposide",
    "indications": "Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer",
    "sample_size": "330",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06346392",
    "title": "AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2",
    "phase": "PHASE3",
    "imp": "AZD0901, AZD0901, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib",
    "indications": "Gastric Cancer, Gastroesophageal Junction Cancer",
    "sample_size": "572",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03813407",
    "title": "An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia",
    "phase": "PHASE3",
    "imp": "Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1), Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2), Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3), Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase",
    "indications": "Hyperkalaemia",
    "sample_size": "140",
    "enrollment_type": "E",
    "start_date_iso": "2019-04-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-06-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06549595",
    "title": "A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients",
    "phase": "PHASE3",
    "imp": "Surovatamig, R-CHOP, R-CVP, BR",
    "indications": "Untreated Follicular Lymphoma",
    "sample_size": "1015",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-11-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-11-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05629585",
    "title": "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab",
    "indications": "Breast Cancer",
    "sample_size": "1174",
    "enrollment_type": "A",
    "start_date_iso": "2022-11-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03703297",
    "title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy",
    "phase": "PHASE3",
    "imp": "Durvalumab, Tremelimumab, Placebo",
    "indications": "Small Cell Lung Cancer",
    "sample_size": "730",
    "enrollment_type": "A",
    "start_date_iso": "2018-09-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-10-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04550260",
    "title": "Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC",
    "phase": "PHASE3",
    "imp": "Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine, Radiation",
    "indications": "Esophageal Squamous Cell Carcinoma",
    "sample_size": "640",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-06-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03997123",
    "title": "Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC",
    "phase": "PHASE3",
    "imp": "Capivasertib, Paclitaxel, Placebo",
    "indications": "Triple Negative Breast Neoplasms",
    "sample_size": "923",
    "enrollment_type": "A",
    "start_date_iso": "2019-06-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-16",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06109779",
    "title": "Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)",
    "phase": "PHASE3",
    "imp": "Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]",
    "indications": "Biliary Tract Cancer",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-05-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05113251",
    "title": "Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide",
    "indications": "Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer",
    "sample_size": "927",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-03-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-04-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05057494",
    "title": "A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "phase": "PHASE3",
    "imp": "Acalabrutinib, Venetoclax, Obinutuzumab",
    "indications": "Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "sample_size": "607",
    "enrollment_type": "A",
    "start_date_iso": "2022-09-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05943106",
    "title": "BCG in Combination With Durvalumab in Adult BCG-na\u00efve, High-risk NMIBC Participants",
    "phase": "PHASE3",
    "imp": "Durvalumab, BCG",
    "indications": "Non-Muscle- Invasive Bladder Cancer",
    "sample_size": "100",
    "enrollment_type": "A",
    "start_date_iso": "2023-08-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-16",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06112379",
    "title": "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib",
    "indications": "Breast Cancer",
    "sample_size": "1902",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-09-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06677060",
    "title": "Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin",
    "phase": "PHASE3",
    "imp": "Baxdrostat and dapagliflozin, Placebo and dapagliflozin",
    "indications": "Heart Failure",
    "sample_size": "11300",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-17",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT07022483",
    "title": "Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, Chemotherapy",
    "indications": "Endometrial Cancer",
    "sample_size": "710",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-03-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-03-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07363642",
    "title": "Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab",
    "phase": "PHASE3",
    "imp": "Tezepelumab",
    "indications": "Severe Asthma",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-31",
    "start_date_type": "E",
    "primary_completion_date_iso": "2027-08-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-30",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04351555",
    "title": "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Osimertinib, Cisplatin, Carboplatin, Placebo, Pemetrexed",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "358",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-10-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-06-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03521154",
    "title": "A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)",
    "phase": "PHASE3",
    "imp": "Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg",
    "indications": "Non Small Cell Lung Cancer (Stage III)",
    "sample_size": "216",
    "enrollment_type": "A",
    "start_date_iso": "2018-07-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-05",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-04-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06742723",
    "title": "A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure",
    "phase": "PHASE3",
    "imp": "Baxdrostat/dapagliflozin, Placebo/dapagliflozin",
    "indications": "Chronic Kidney Disease and Hypertension",
    "sample_size": "5000",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05774951",
    "title": "A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy",
    "phase": "PHASE3",
    "imp": "Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane",
    "indications": "Breast Cancer, Early Breast Cancer",
    "sample_size": "4300",
    "enrollment_type": "E",
    "start_date_iso": "2023-03-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2036-05-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT02516241",
    "title": "Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer",
    "phase": "PHASE3",
    "imp": "MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine",
    "indications": "Urothelial Cancer",
    "sample_size": "1126",
    "enrollment_type": "A",
    "start_date_iso": "2015-11-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-01-27",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03528694",
    "title": "Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer",
    "phase": "PHASE3",
    "imp": "Durvalumab (MEDI4736), Bacillus Calmette-Guerin (BCG)",
    "indications": "Non-muscle-invasive Bladder Cancer",
    "sample_size": "1018",
    "enrollment_type": "A",
    "start_date_iso": "2018-05-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-04-03",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-10-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07218809",
    "title": "AZD5335 vs. Mirvetuximab Soravtansine in FR\u03b1-high and AZD5335 vs. Chemotherapy in FR\u03b1-low Platinum-resistant Ovarian Cancer",
    "phase": "PHASE3",
    "imp": "AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel, Pegylated liposomal Doxorubicin (PLD), Topotecan",
    "indications": "Epithelial Ovarian Cancer",
    "sample_size": "1100",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-05-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04305496",
    "title": "Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer",
    "phase": "PHASE3",
    "imp": "Fulvestrant, Capivasertib, Placebo",
    "indications": "Locally Advanced (Inoperable) or Metastatic Breast Cancer",
    "sample_size": "818",
    "enrollment_type": "A",
    "start_date_iso": "2020-04-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-05-09",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT03903835",
    "title": "ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer",
    "phase": "PHASE3",
    "imp": "Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin, Cabazitaxel 60 mg Solution for Injection, Docetaxel Injectable Solution, Radium Chloride Ra-223, Niraparib plus Abiraterone acetate plus Prednisone, Capivasertib plus Docetaxel, Apalutamide, Darolutamide",
    "indications": "Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2019-02-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04877691",
    "title": "Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus",
    "phase": "PHASE3",
    "imp": "Medi-546, Placebo",
    "indications": "Systemic Lupus Erythematosus",
    "sample_size": "367",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-08-22",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-11-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04784715",
    "title": "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan, Placebo, Taxane, Pertuzumab, Trastuzumab",
    "indications": "Breast Cancer; HER2-positive; Metastatic",
    "sample_size": "1157",
    "enrollment_type": "A",
    "start_date_iso": "2021-04-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06008093",
    "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS",
    "phase": "PHASE3",
    "imp": "Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, Cisplatin",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "280",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-03-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06417814",
    "title": "A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin",
    "indications": "Metastatic Non-small Cell Lung Cancer",
    "sample_size": "744",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04590963",
    "title": "Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer",
    "phase": "PHASE3",
    "imp": "Monalizumab, Cetuximab, Placebo",
    "indications": "Squamous Cell Carcinoma of the Head and Neck",
    "sample_size": "370",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-05-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-09-24",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06079671",
    "title": "Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)",
    "phase": "PHASE3",
    "imp": "Volrustomig, Placebo",
    "indications": "Locally Advanced Cervical Cancer",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2023-09-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05301842",
    "title": "Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC",
    "phase": "PHASE3",
    "imp": "Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE), Lenvatinib",
    "indications": "Hepatocellular Carcinoma",
    "sample_size": "760",
    "enrollment_type": "A",
    "start_date_iso": "2022-03-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05952557",
    "title": "An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)",
    "phase": "PHASE3",
    "imp": "Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane, Abemaciclib",
    "indications": "Breast Cancer, Early Breast Cancer",
    "sample_size": "5500",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2037-05-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05450692",
    "title": "A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy",
    "phase": "PHASE3",
    "imp": "Ceralasertib, Durvalumab, Docetaxel",
    "indications": "Advanced or Metastatic Non-Small Cell Lung Cancer",
    "sample_size": "594",
    "enrollment_type": "A",
    "start_date_iso": "2022-09-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-10-06",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-10-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT05764057",
    "title": "DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction",
    "phase": "PHASE3",
    "imp": "Dapagliflozin propanediol (FORXIGA\u2122/FARXIGA\u21221), Placebo comparator",
    "indications": "AMI, STEMI, NSTEMI, Left Ventricular Dysfunction",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2023-06-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05883644",
    "title": "Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)",
    "phase": "PHASE3",
    "imp": "Durvalumab, Tremelimumab",
    "indications": "Advanced Hepatocellular Carcinoma",
    "sample_size": "111",
    "enrollment_type": "A",
    "start_date_iso": "2023-06-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04493853",
    "title": "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency",
    "phase": "PHASE3",
    "imp": "Capivasertib, Placebo, Abiraterone Acetate",
    "indications": "Hormone-Sensitive Prostate Cancer",
    "sample_size": "1012",
    "enrollment_type": "A",
    "start_date_iso": "2020-07-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-10-07",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-03-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06307665",
    "title": "Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma",
    "phase": "PHASE3",
    "imp": "BDA MDI, AS MDI",
    "indications": "Asthma",
    "sample_size": "440",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07205822",
    "title": "A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer",
    "phase": "PHASE3",
    "imp": "Dato-DXd",
    "indications": "Breast Cancer",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07000357",
    "title": "A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event",
    "phase": "PHASE3",
    "imp": "AZD0780, Placebo",
    "indications": "Cardiovascular Disease",
    "sample_size": "15100",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05138133",
    "title": "Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis",
    "phase": "PHASE3",
    "imp": "Anifrolumab, Placebo",
    "indications": "Lupus Nephritis",
    "sample_size": "360",
    "enrollment_type": "E",
    "start_date_iso": "2022-02-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06834932",
    "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia",
    "phase": "PHASE3",
    "imp": "Placebo, Rosuvastatin Dose 1, Rosuvastatin dose 2, AZD0780",
    "indications": "Dyslipidaemia",
    "sample_size": "380",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04191304",
    "title": "A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)",
    "phase": "PHASE3",
    "imp": "Benralizumab, Placebo",
    "indications": "Hypereosinophilic Syndrome",
    "sample_size": "134",
    "enrollment_type": "A",
    "start_date_iso": "2020-07-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-05-07",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06357533",
    "title": "Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC \u2265 50%) and Without Actionable Genomic Alterations",
    "phase": "PHASE3",
    "imp": "Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "675",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-05-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT00223145",
    "title": "Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone",
    "phase": "PHASE3",
    "imp": "Radiotherapy 70 Gy, Radiotherapy 76 Gy, Androgen blockade",
    "indications": "Prostate Cancer",
    "sample_size": "600",
    "enrollment_type": "A",
    "start_date_iso": "2000-12",
    "start_date_type": "E",
    "primary_completion_date_iso": "2026-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07221253",
    "title": "A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)",
    "phase": "PHASE3",
    "imp": "Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin",
    "indications": "Biliary Tract Cancer",
    "sample_size": "1100",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-07-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT04711252",
    "title": "A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease",
    "phase": "PHASE3",
    "imp": "AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist",
    "indications": "ER-Positive HER2-Negative Breast Cancer",
    "sample_size": "1370",
    "enrollment_type": "A",
    "start_date_iso": "2021-01-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06627647",
    "title": "A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC",
    "phase": "PHASE3",
    "imp": "Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed",
    "indications": "Non-squamous Non-small Cell Lung Cancer",
    "sample_size": "878",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-05-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06706817",
    "title": "A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab",
    "phase": "PHASE3",
    "imp": "Tezepelumab",
    "indications": "Chronic Rhinosinusitis With Nasal Polyps",
    "sample_size": "180",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT03778957",
    "title": "A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma",
    "phase": "PHASE3",
    "imp": "Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)",
    "indications": "Hepatocellular Carcinoma",
    "sample_size": "724",
    "enrollment_type": "A",
    "start_date_iso": "2018-11-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-09-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06471257",
    "title": "A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma",
    "phase": "PHASE3",
    "imp": "Budesonide/Albuterol metered dose inhaler, MDI, Albuterol sulfate metered dose inhaler, MDI",
    "indications": "Asthma",
    "sample_size": "790",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05171816",
    "title": "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)",
    "phase": "PHASE3",
    "imp": "olaparib, abiraterone acetate",
    "indications": "Metastatic Castration-resistant Prostate Cancer",
    "sample_size": "110",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-22",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-04-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT06284317",
    "title": "A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.",
    "phase": "PHASE3",
    "imp": "Adjuvant durvalumab",
    "indications": "Non Small Cell Lung Cancer",
    "sample_size": "290",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT03150576",
    "title": "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer",
    "phase": "PHASE3",
    "imp": "Olaparib, Paclitaxel and Carboplatin",
    "indications": "Breast Cancer",
    "sample_size": "780",
    "enrollment_type": "E",
    "start_date_iso": "2016-05",
    "start_date_type": "E",
    "primary_completion_date_iso": "2024-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06692738",
    "title": "A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)",
    "phase": "PHASE3",
    "imp": "Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "880",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06764186",
    "title": "A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain",
    "phase": "PHASE3",
    "imp": "Fulvestrant, Capivasertib",
    "indications": "Locally Advanced or Metastatic Breast Cancer",
    "sample_size": "101",
    "enrollment_type": "A",
    "start_date_iso": "2025-01-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT06097728",
    "title": "MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma",
    "phase": "PHASE3",
    "imp": "Volrustomig, Pemetrexed, Carboplatin, Cisplatin, Nivolumab, Ipilimumab",
    "indications": "Unresectable Pleural Mesothelioma",
    "sample_size": "825",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT04704934",
    "title": "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan, Ramucirumab, Paclitaxel",
    "indications": "Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma",
    "sample_size": "490",
    "enrollment_type": "E",
    "start_date_iso": "2021-05-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT04136171",
    "title": "CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",
    "phase": "PHASE3",
    "imp": "Eplontersen, Placebo",
    "indications": "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",
    "sample_size": "1438",
    "enrollment_type": "A",
    "start_date_iso": "2020-03-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT05215340",
    "title": "Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations",
    "phase": "PHASE3",
    "imp": "Datopotamab Deruxtecan, Pembrolizumab",
    "indications": "Metastatic Non Small Cell Lung Cancer",
    "sample_size": "740",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05624450",
    "title": "Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen",
    "phase": "PHASE3",
    "imp": "Tozorakimab, Placebo",
    "indications": "Viral Lung Infection and Acute Respiratory Failure",
    "sample_size": "2870",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-06-19",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05374512",
    "title": "A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate",
    "indications": "Breast Cancer",
    "sample_size": "644",
    "enrollment_type": "A",
    "start_date_iso": "2022-05-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-08-25",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-11-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT03734029",
    "title": "Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel",
    "indications": "Breast Cancer",
    "sample_size": "557",
    "enrollment_type": "A",
    "start_date_iso": "2018-12-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-01-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-08-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT01844986",
    "title": "Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.",
    "phase": "PHASE3",
    "imp": "Olaparib 300mg tablets",
    "indications": "Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy",
    "sample_size": "450",
    "enrollment_type": "A",
    "start_date_iso": "2013-08-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2018-05-17",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-08-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT05820841",
    "title": "Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma",
    "phase": "PHASE3",
    "imp": "R-miniCHOP + Acalabrutinib, R-miniCHOP",
    "indications": "Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma",
    "sample_size": "330",
    "enrollment_type": "E",
    "start_date_iso": "2023-06-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07000149",
    "title": "A Study to Investigate the Efficacy and Safety of Volrustomig \u00b1 Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC",
    "phase": "PHASE3",
    "imp": "Volrustomig, Casdatifan, Nivolumab, Ipilimumab",
    "indications": "Advanced Clear Cell Renal Cell Carcinoma",
    "sample_size": "1116",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-02-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-07-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT05197192",
    "title": "A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL",
    "phase": "PHASE3",
    "imp": "Obinutuzumab, Venetoclax, Acalabrutinib",
    "indications": "Chronic Lymphocytic Leukemia",
    "sample_size": "202",
    "enrollment_type": "E",
    "start_date_iso": "2022-04-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT02446600",
    "title": "Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "phase": "PHASE3",
    "imp": "Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment",
    "indications": "Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma",
    "sample_size": "579",
    "enrollment_type": "A",
    "start_date_iso": "2016-03-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-02-23",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-08-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT07044336",
    "title": "Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)",
    "phase": "PHASE3",
    "imp": "Puxitatug Samrotecan, Doxorubicin, Paclitaxel",
    "indications": "Endometrial Cancer, Malignant Solid Tumour",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": true,
    "nct_id": "NCT06712472",
    "title": "Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer",
    "phase": "PHASE3",
    "imp": "Olaparib (300 mg BID)",
    "indications": "Endometrial Cancer, p53abn",
    "sample_size": "554",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "AstraZeneca",
    "is_collaborator": false,
    "nct_id": "NCT05158387",
    "title": "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.",
    "phase": "PHASE3",
    "imp": "Tozorakimab, Tozorakimab, Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease (COPD)",
    "sample_size": "1172",
    "enrollment_type": "A",
    "start_date_iso": "2022-02-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06744920",
    "title": "A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis",
    "phase": "PHASE3",
    "imp": "Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label)",
    "indications": "Generalized Myasthenia Gravis",
    "sample_size": "180",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-02-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05360446",
    "title": "Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events",
    "phase": "PHASE3",
    "imp": "Inclisiran sodium 300 mg, Placebo",
    "indications": "Coronary Artery Disease",
    "sample_size": "610",
    "enrollment_type": "A",
    "start_date_iso": "2022-07-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT05722886",
    "title": "DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol",
    "phase": "PHASE3",
    "imp": "Alectinib, Atezolizumab, Entrectinib, Trastuzumab in combination with pertuzumab, Vemurafenib in combination with cobimetinib, Capmatinib",
    "indications": "Haematological Malignancy, Solid Tumour",
    "sample_size": "825",
    "enrollment_type": "E",
    "start_date_iso": "2023-03-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05939414",
    "title": "An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.",
    "phase": "PHASE3",
    "imp": "AAA617",
    "indications": "Oligometastatic Prostate Cancer (OMPC)",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-10-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04720157",
    "title": "An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC",
    "phase": "PHASE3",
    "imp": "177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT",
    "indications": "Prostatic Neoplasms",
    "sample_size": "1145",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-01-13",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-02-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06331312",
    "title": "Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)",
    "phase": "PHASE3",
    "imp": "Secukinumab",
    "indications": "Polymyalgia Rheumatica",
    "sample_size": "288",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-08-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06780670",
    "title": "Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy",
    "phase": "PHASE3",
    "imp": "Investigators choice of SoC, AAA817, AAA817, AAA817",
    "indications": "Prostate Cancer",
    "sample_size": "432",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-07-19",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT03814746",
    "title": "Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients",
    "phase": "PHASE3",
    "imp": "Crizanlizumab (SEG101), Placebo",
    "indications": "Sickle Cell Disease (SCD)",
    "sample_size": "255",
    "enrollment_type": "A",
    "start_date_iso": "2019-07-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-08-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-11-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05682378",
    "title": "Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies",
    "phase": "PHASE3",
    "imp": "Inclisiran",
    "indications": "Heterozygous or Homozygous Familial Hypercholesterolemia",
    "sample_size": "131",
    "enrollment_type": "A",
    "start_date_iso": "2023-02-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06439082",
    "title": "A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)",
    "phase": "PHASE3",
    "imp": "Crizanlizumab, Placebo",
    "indications": "Sickle Cell Disease",
    "sample_size": "315",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-04-19",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04689828",
    "title": "177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer",
    "phase": "PHASE3",
    "imp": "177Lu-PSMA-617, 68Ga-PSMA-11, ARDT",
    "indications": "Prostatic Neoplasms",
    "sample_size": "469",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-10-02",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04179175",
    "title": "Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa",
    "phase": "PHASE3",
    "imp": "secukinumab, secukinumab",
    "indications": "Hidradenitis Suppurativa",
    "sample_size": "703",
    "enrollment_type": "A",
    "start_date_iso": "2020-03-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-05-26",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-07-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT06320067",
    "title": "A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer",
    "phase": "PHASE3",
    "imp": "Stereotactic Ablative Body Radiotherapy (SABR), 177Lu-PSMA-617, Androgen Deprivation Therapy (ADT), Androgen Receptor Signalling Inhibitor (ARPI), Radiotherapy to Prostate \u00b1 Pelvic Nodes, Docetaxel",
    "indications": "Prostate Cancer Metastatic",
    "sample_size": "3360",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05795140",
    "title": "Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS",
    "phase": "PHASE3",
    "imp": "Iptcaopan 200 mg",
    "indications": "Atypical Hemolytic Uremic Syndrome",
    "sample_size": "125",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-12-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-01-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT05712200",
    "title": "Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)",
    "phase": "PHASE3",
    "imp": "Abelacimab, Placebo",
    "indications": "Atrial Fibrillation (AF)",
    "sample_size": "1900",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT05285917",
    "title": "Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa",
    "phase": "PHASE3",
    "imp": "Hydroxyurea",
    "indications": "Sickle Cell Anemia in Children, Sickle Cell Disease",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05350072",
    "title": "Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome",
    "phase": "PHASE3",
    "imp": "VAY736, Placebo",
    "indications": "Sjogren Syndrome",
    "sample_size": "276",
    "enrollment_type": "A",
    "start_date_iso": "2022-07-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-05-07",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-05-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06868212",
    "title": "A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines",
    "phase": "PHASE3",
    "imp": "Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection",
    "indications": "Chronic Spontaneous Urticaria (CSU)",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-17",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05562466",
    "title": "A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma",
    "phase": "PHASE3",
    "imp": "QMF149, Budesonide",
    "indications": "Asthma",
    "sample_size": "200",
    "enrollment_type": "E",
    "start_date_iso": "2023-05-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05653219",
    "title": "A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids",
    "phase": "PHASE3",
    "imp": "Ianalumab, Eltrombopag, Placebo",
    "indications": "Primary Immune Thrombocytopenia",
    "sample_size": "152",
    "enrollment_type": "A",
    "start_date_iso": "2023-02-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-04-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06846281",
    "title": "Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.",
    "phase": "PHASE3",
    "imp": "Remibrutinib oral treatment, Ocrelizumab",
    "indications": "Relapsing Multiple Sclerosis",
    "sample_size": "360",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-01-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-12-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT04055493",
    "title": "Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC",
    "phase": "PHASE3",
    "imp": "Ribociclib 200Mg Oral Tablet",
    "indications": "Breast Cancer Female",
    "sample_size": "1684",
    "enrollment_type": "A",
    "start_date_iso": "2019-07-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06799000",
    "title": "A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)",
    "phase": "PHASE3",
    "imp": "Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2",
    "indications": "Hidradenitis Suppurativa",
    "sample_size": "555",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06133972",
    "title": "Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).",
    "phase": "PHASE3",
    "imp": "Placebo, Ianalumab",
    "indications": "Systemic Lupus Erythematosus",
    "sample_size": "550",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-04-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-04-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT03701334",
    "title": "A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer",
    "phase": "PHASE3",
    "imp": "Ribociclib, Endocrine Therapy",
    "indications": "Early Breast Cancer",
    "sample_size": "5101",
    "enrollment_type": "A",
    "start_date_iso": "2018-12-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04023552",
    "title": "Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD",
    "phase": "PHASE3",
    "imp": "TQJ230, Placebo",
    "indications": "Cardiovascular Disease and Lipoprotein(a)",
    "sample_size": "8323",
    "enrollment_type": "A",
    "start_date_iso": "2019-12-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-02-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05852938",
    "title": "A Study of Zigakibart in Adults With IgA Nephropathy",
    "phase": "PHASE3",
    "imp": "BION-1301, Placebo",
    "indications": "IgA Nephropathy, Immunoglobulin A Nephropathy",
    "sample_size": "383",
    "enrollment_type": "A",
    "start_date_iso": "2023-07-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04094311",
    "title": "Study of Out of Specification for Tisagenlecleucel",
    "phase": "PHASE3",
    "imp": "CTL019",
    "indications": "B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma",
    "sample_size": "200",
    "enrollment_type": "E",
    "start_date_iso": "2019-11-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05888493",
    "title": "A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma",
    "phase": "PHASE3",
    "imp": "Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles, Lymphodepleting chemotherapy, Corticosteroids and/or Radiation (Bridging therapy)",
    "indications": "Follicular Lymphoma (FL)",
    "sample_size": "108",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-07-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-01-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05739383",
    "title": "A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.",
    "phase": "PHASE3",
    "imp": "Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml",
    "indications": "Primary Prevention of Atherosclerotic Cardiovascular Disease",
    "sample_size": "14082",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-04-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-16",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04557462",
    "title": "A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy",
    "phase": "PHASE3",
    "imp": "LNP023",
    "indications": "Primary IgA Nephropathy",
    "sample_size": "540",
    "enrollment_type": "E",
    "start_date_iso": "2021-09-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-10-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-10-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT01892722",
    "title": "Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection",
    "indications": "Multiple Sclerosis",
    "sample_size": "240",
    "enrollment_type": "A",
    "start_date_iso": "2013-07-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2017-07-14",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2030-02-18",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05335876",
    "title": "Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials",
    "phase": "PHASE3",
    "imp": "onasemnogene abeparvovec",
    "indications": "Spinal Muscular Atrophy (SMA)",
    "sample_size": "175",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-09-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-02-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT03955445",
    "title": "Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN",
    "phase": "PHASE3",
    "imp": "LNP023",
    "indications": "C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis",
    "sample_size": "225",
    "enrollment_type": "E",
    "start_date_iso": "2019-10-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2036-05-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2036-05-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05677451",
    "title": "24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up",
    "phase": "PHASE3",
    "imp": "LOU064 (blinded), placebo",
    "indications": "Chronic Spontaneous Urticaria",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2023-07-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-03-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05976243",
    "title": "A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines",
    "phase": "PHASE3",
    "imp": "Remibrutinib, Placebo",
    "indications": "Chronic Inducible Urticaria",
    "sample_size": "364",
    "enrollment_type": "A",
    "start_date_iso": "2023-12-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05126277",
    "title": "Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis",
    "phase": "PHASE3",
    "imp": "ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.",
    "indications": "Lupus Nephritis",
    "sample_size": "462",
    "enrollment_type": "E",
    "start_date_iso": "2022-07-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-11-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05639114",
    "title": "Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)",
    "phase": "PHASE3",
    "imp": "Ianalumab, Placebo",
    "indications": "Systemic Lupus Erythematosus",
    "sample_size": "434",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-20",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05156281",
    "title": "Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)",
    "phase": "PHASE3",
    "imp": "Remibrutinib, Teriflunomide",
    "indications": "Relapsing Multiple Sclerosis",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2021-12-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-10-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT04111978",
    "title": "MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)",
    "phase": "PHASE3",
    "imp": "Letrozole 2.5mg, Placebo",
    "indications": "Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma",
    "sample_size": "540",
    "enrollment_type": "E",
    "start_date_iso": "2020-11-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-07-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT06496581",
    "title": "Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)",
    "phase": "PHASE3",
    "imp": "177Lu-PMSA-617, Standard of Care",
    "indications": "Prostate Cancer Metastatic",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2024-09-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-02-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2039-08-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT03570892",
    "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma",
    "phase": "PHASE3",
    "imp": "Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)",
    "indications": "Non-Hodgkin Lymphoma",
    "sample_size": "331",
    "enrollment_type": "A",
    "start_date_iso": "2019-05-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-05-06",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-02-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06869785",
    "title": "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab",
    "phase": "PHASE3",
    "imp": "Ofatumumab approved dose, Ofatumumab new dose",
    "indications": "Relapsing Multiple Sclerosis (RMS)",
    "sample_size": "180",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-05-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05349214",
    "title": "Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome",
    "phase": "PHASE3",
    "imp": "VAY736, Placebo",
    "indications": "Sjogren Syndrome",
    "sample_size": "506",
    "enrollment_type": "A",
    "start_date_iso": "2022-08-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-05-13",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-05-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT07102628",
    "title": "Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes",
    "phase": "PHASE3",
    "imp": "Placebo, Inclisiran",
    "indications": "Acute Coronary Syndrome",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06813911",
    "title": "Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD",
    "phase": "PHASE3",
    "imp": "Pelacarsen, Placebo, Inclisiran",
    "indications": "Atherosclerotic Cardiovascular Disease (ASCVD)",
    "sample_size": "340",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05948943",
    "title": "Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.",
    "phase": "PHASE3",
    "imp": "Alpelisib, Placebo",
    "indications": "Lymphatic Malformations",
    "sample_size": "232",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-05-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06855277",
    "title": "Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC",
    "phase": "PHASE3",
    "imp": "AAA817, ARPI, Standard of Care",
    "indications": "Prostate Cancer",
    "sample_size": "940",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-11-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT05171075",
    "title": "A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE",
    "phase": "PHASE3",
    "imp": "Abelacimab, Dalteparin",
    "indications": "Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism",
    "sample_size": "417",
    "enrollment_type": "A",
    "start_date_iso": "2022-09-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04971226",
    "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP",
    "phase": "PHASE3",
    "imp": "Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib",
    "indications": "Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive",
    "sample_size": "406",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-11-28",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-01-18",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05038735",
    "title": "Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.",
    "phase": "PHASE3",
    "imp": "Alpelisib, Fulvestrant, Alpelisib-matching placebo",
    "indications": "Breast Cancer",
    "sample_size": "212",
    "enrollment_type": "A",
    "start_date_iso": "2021-12-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT00470223",
    "title": "Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma",
    "phase": "PHASE3",
    "imp": "cisplatin, doxorubicin hydrochloride, etoposide, ifosfamide, methotrexate, zoledronic acid, conventional surgery",
    "indications": "Sarcoma",
    "sample_size": "318",
    "enrollment_type": "A",
    "start_date_iso": "2007-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2015-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05624749",
    "title": "Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)",
    "phase": "PHASE3",
    "imp": "ianalumab, placebo",
    "indications": "Systemic Lupus Erythematosus",
    "sample_size": "285",
    "enrollment_type": "A",
    "start_date_iso": "2023-04-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-20",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06711887",
    "title": "Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)",
    "phase": "PHASE3",
    "imp": "Ianalumab",
    "indications": "Lupus Nephritis",
    "sample_size": "315",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-07-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-07-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05776927",
    "title": "A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.",
    "phase": "PHASE3",
    "imp": "QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149, Placebo to Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication, Rescue Medication, Concept 1 Device, Girohaler",
    "indications": "Asthma",
    "sample_size": "304",
    "enrollment_type": "E",
    "start_date_iso": "2026-05-29",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-12-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-24",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06858319",
    "title": "Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.",
    "phase": "PHASE3",
    "imp": "zigakibart",
    "indications": "Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease",
    "sample_size": "223",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-06-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-06-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT07237256",
    "title": "Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib",
    "phase": "PHASE3",
    "imp": "Chemotherapy, De-escalation",
    "indications": "Breast Cancer",
    "sample_size": "3902",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2033-11-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2037-12-31",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06267560",
    "title": "Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD",
    "phase": "PHASE3",
    "imp": "TQJ230, Placebo",
    "indications": "Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease",
    "sample_size": "422",
    "enrollment_type": "A",
    "start_date_iso": "2024-04-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT07357727",
    "title": "A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)",
    "phase": "PHASE3",
    "imp": "Pelabresib, Ruxolitinib, Placebo",
    "indications": "Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)",
    "sample_size": "460",
    "enrollment_type": "E",
    "start_date_iso": "2026-04-15",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-05-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-27",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04948333",
    "title": "Asciminib Treatment Optimization in \u2265 3rd Line CML-CP",
    "phase": "PHASE3",
    "imp": "ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD",
    "indications": "Chronic Myelogenous Leukemia",
    "sample_size": "199",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-03-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-02-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT03836040",
    "title": "Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine",
    "phase": "PHASE3",
    "imp": "Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo",
    "indications": "Migraine",
    "sample_size": "457",
    "enrollment_type": "A",
    "start_date_iso": "2019-07-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-11-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT07223294",
    "title": "Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma",
    "phase": "PHASE3",
    "imp": "Fluticasone furoate and vilanterol inhalation powder, Breo Ellipta, Placebo",
    "indications": "Respiratory",
    "sample_size": "1430",
    "enrollment_type": "E",
    "start_date_iso": "2026-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2026-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-31",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04940052",
    "title": "Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer",
    "phase": "PHASE3",
    "imp": "Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo",
    "indications": "Differentiated Thyroid Cancer (DTC)",
    "sample_size": "153",
    "enrollment_type": "A",
    "start_date_iso": "2021-11-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-01-22",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-06-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05456191",
    "title": "A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (\u226518 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)",
    "phase": "PHASE3",
    "imp": "Asciminib, Nilotinib",
    "indications": "Philadelphia Chromosome-Positive Chronic Myeloid Leukemia",
    "sample_size": "568",
    "enrollment_type": "A",
    "start_date_iso": "2022-11-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-05-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2031-07-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04930094",
    "title": "Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)",
    "phase": "PHASE3",
    "imp": "Secukinumab 300 mg, Placebo, Secukinumab 150 mg",
    "indications": "Giant Cell Arteritis (GCA)",
    "sample_size": "355",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-04-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-07-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05030428",
    "title": "Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease",
    "phase": "PHASE3",
    "imp": "Inclisiran sodium 300 mg, Placebo",
    "indications": "Atherosclerotic Cardiovascular Disease",
    "sample_size": "17004",
    "enrollment_type": "A",
    "start_date_iso": "2021-11-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT02962414",
    "title": "Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment",
    "phase": "PHASE3",
    "imp": "everolimus",
    "indications": "Tuberous Sclerosis Complex",
    "sample_size": "206",
    "enrollment_type": "A",
    "start_date_iso": "2017-06-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT03631199",
    "title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects",
    "phase": "PHASE3",
    "imp": "canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "673",
    "enrollment_type": "A",
    "start_date_iso": "2018-12-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-08-09",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-06-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT03705234",
    "title": "A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease",
    "phase": "PHASE3",
    "imp": "Inclisiran, Placebo",
    "indications": "Atherosclerotic Cardiovascular Disease",
    "sample_size": "16124",
    "enrollment_type": "A",
    "start_date_iso": "2018-10-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2049-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05767034",
    "title": "Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)",
    "phase": "PHASE3",
    "imp": "Secukinumab 300 mg, Secukinumab 150 mg, Placebo to secukinumab",
    "indications": "Polymyalgia Rheumatica",
    "sample_size": "381",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-10",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-02-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05147220",
    "title": "Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)",
    "phase": "PHASE3",
    "imp": "Remibrutinib, Teriflunomide",
    "indications": "Relapsing Multiple Sclerosis",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2021-12-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-10-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT04116502",
    "title": "MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera",
    "phase": "PHASE3",
    "imp": "Ruxolitinib, Hydroxycarbamide, Interferon-Alpha",
    "indications": "Polycythemia Vera",
    "sample_size": "586",
    "enrollment_type": "E",
    "start_date_iso": "2019-10-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-04-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05985915",
    "title": "A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.",
    "phase": "PHASE3",
    "imp": "Ianalumab (VAY736), Placebo",
    "indications": "Sjogrens Syndrome",
    "sample_size": "612",
    "enrollment_type": "A",
    "start_date_iso": "2023-10-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-08-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-07-18",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06042478",
    "title": "Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.",
    "phase": "PHASE3",
    "imp": "Remibrutinib, Placebo to remibrutinib, Placebo to omalizumab, Omalizumab",
    "indications": "Chronic Spontaneous Urticaria",
    "sample_size": "471",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-17",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-07-20",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05653349",
    "title": "Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)",
    "phase": "PHASE3",
    "imp": "Ianalumab, Placebo, Corticosteroids",
    "indications": "Primary Immune Thrombocytopenia (ITP)",
    "sample_size": "226",
    "enrollment_type": "A",
    "start_date_iso": "2023-02-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06517758",
    "title": "A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.",
    "phase": "PHASE3",
    "imp": "Iptacopan, Matching Placebo",
    "indications": "Generalized Myasthenia Gravis",
    "sample_size": "146",
    "enrollment_type": "E",
    "start_date_iso": "2024-07-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-05-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT05207709",
    "title": "Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype",
    "phase": "PHASE3",
    "imp": "Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab",
    "indications": "Metastatic Breast Cancer",
    "sample_size": "456",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT02445222",
    "title": "CAR-T Long Term Follow Up (LTFU) Study",
    "phase": "PHASE3",
    "imp": "Previously treated CAR-T patients",
    "indications": "Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program",
    "sample_size": "1400",
    "enrollment_type": "E",
    "start_date_iso": "2015-11-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2036-02-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2036-02-22",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT07085767",
    "title": "Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer",
    "phase": "PHASE3",
    "imp": "Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo",
    "indications": "Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT07225504",
    "title": "A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Remibrutinib (blinded), Placebo, Remibrutinib (Open label)",
    "indications": "Secondary Progressive Multiple Sclerosis (SPMS)",
    "sample_size": "1275",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-12-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-01-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04765657",
    "title": "Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)",
    "phase": "PHASE3",
    "imp": "inclisiran sodium, Placebo",
    "indications": "Hypercholesterolemia",
    "sample_size": "345",
    "enrollment_type": "A",
    "start_date_iso": "2021-03-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-06-09",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT07326709",
    "title": "A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease",
    "phase": "PHASE3",
    "imp": "Votoplam (blinded), Placebo",
    "indications": "Huntington Disease",
    "sample_size": "770",
    "enrollment_type": "E",
    "start_date_iso": "2026-06-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-04-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-04-30",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04603495",
    "title": "Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)",
    "phase": "PHASE3",
    "imp": "Pelabresib, Ruxolitinib, Placebo",
    "indications": "Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis",
    "sample_size": "430",
    "enrollment_type": "A",
    "start_date_iso": "2021-04-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-08-23",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT03805022",
    "title": "Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas",
    "phase": "PHASE3",
    "imp": "Doxorubicin, Ifosfamide or dacarbazine, Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator",
    "indications": "Non-metastatic Soft-tissue Sarcoma, Resectable",
    "sample_size": "351",
    "enrollment_type": "E",
    "start_date_iso": "2019-02-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04926818",
    "title": "Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo",
    "indications": "Multiple Sclerosis (MS)",
    "sample_size": "129",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-11-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05827081",
    "title": "Phase IIIb Study of Ribociclib + ET in Early Breast Cancer",
    "phase": "PHASE3",
    "imp": "Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane",
    "indications": "Early Breast Cancer",
    "sample_size": "1400",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-09-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06847724",
    "title": "Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "CYB704, Ocrevus-EU, Ocrevus-US",
    "indications": "Relapsing Multiple Sclerosis",
    "sample_size": "175",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05755386",
    "title": "Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN",
    "phase": "PHASE3",
    "imp": "Placebo, iptacopan",
    "indications": "IC-MPGN",
    "sample_size": "106",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-10-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-05-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT04747613",
    "title": "Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria",
    "phase": "PHASE3",
    "imp": "Iptacopan",
    "indications": "Paroxysmal Nocturnal Hemoglobinuria",
    "sample_size": "208",
    "enrollment_type": "A",
    "start_date_iso": "2021-07-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06784752",
    "title": "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET",
    "phase": "PHASE3",
    "imp": "[177Lu]Lu-DOTA-TATE, Octreotide LAR",
    "indications": "Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)",
    "sample_size": "240",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-09-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-01-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": true,
    "nct_id": "NCT05171049",
    "title": "A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE",
    "phase": "PHASE3",
    "imp": "Abelacimab, Apixaban",
    "indications": "Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism",
    "sample_size": "1150",
    "enrollment_type": "A",
    "start_date_iso": "2022-05-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06840392",
    "title": "A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa",
    "phase": "PHASE3",
    "imp": "Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2",
    "indications": "Hidradenitis Suppurativa",
    "sample_size": "555",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-17",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT06875973",
    "title": "Pelacarsen Roll-over Extension Program",
    "phase": "PHASE3",
    "imp": "Pelacarsen (TQJ230)",
    "indications": "Atherosclerotic Cardiovascular Disease",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT05513001",
    "title": "An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib",
    "phase": "PHASE3",
    "imp": "LOU064 (blinded), Placebo, LOU064 (open label)",
    "indications": "Chronic Spontaneous Urticaria",
    "sample_size": "696",
    "enrollment_type": "A",
    "start_date_iso": "2022-12-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-08-26",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-08-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Novartis",
    "is_collaborator": false,
    "nct_id": "NCT03650114",
    "title": "Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",
    "phase": "PHASE3",
    "imp": "Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen",
    "indications": "Relapsing Multiple Sclerosis",
    "sample_size": "1882",
    "enrollment_type": "A",
    "start_date_iso": "2018-12-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07071623",
    "title": "A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)",
    "phase": "PHASE3",
    "imp": "MK-8527, Emtricitabine/tenofovir disoproxil (FTC/TDF), Placebo matched to MK-8527, Placebo matched to FTC/TDF",
    "indications": "Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis",
    "sample_size": "4580",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05224141",
    "title": "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab/Vibostolimab Co-Formulation, Saline placebo, Etoposide, Cisplatin, Atezolizumab, Carboplatin",
    "indications": "Small Cell Lung Carcinoma",
    "sample_size": "460",
    "enrollment_type": "A",
    "start_date_iso": "2022-03-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-06-04",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-06-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06899126",
    "title": "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Chemotherapy",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "686",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-07-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05899049",
    "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib",
    "indications": "Carcinoma, Renal Cell",
    "sample_size": "249",
    "enrollment_type": "E",
    "start_date_iso": "2022-07-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT03815643",
    "title": "Avelumab Program Rollover Study",
    "phase": "PHASE3",
    "imp": "Avelumab",
    "indications": "Solid Tumors",
    "sample_size": "205",
    "enrollment_type": "A",
    "start_date_iso": "2019-03-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06136650",
    "title": "A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)",
    "phase": "PHASE3",
    "imp": "Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide",
    "indications": "Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms",
    "sample_size": "1314",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06052059",
    "title": "A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)",
    "phase": "PHASE3",
    "imp": "IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo",
    "indications": "Ulcerative Colitis",
    "sample_size": "1020",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06623422",
    "title": "A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "680",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-05-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2038-01-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06492291",
    "title": "Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension",
    "phase": "PHASE3",
    "imp": "Enlicitide Decanoate",
    "indications": "Hypercholesterolemia",
    "sample_size": "3000",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-10-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06203210",
    "title": "A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin",
    "indications": "Small Cell Lung Cancer",
    "sample_size": "540",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03765918",
    "title": "Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2",
    "indications": "Head and Neck Neoplasms",
    "sample_size": "714",
    "enrollment_type": "A",
    "start_date_iso": "2018-12-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-07-25",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-09-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07340827",
    "title": "A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)",
    "phase": "PHASE3",
    "imp": "Follitropin alfa/lutropin alfa (MBJ-0011), hMG, Cetrorelix acetate, Coriogonadotropin alfa, Progesterone gel",
    "indications": "Infertility",
    "sample_size": "333",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-31",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-30",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04895358",
    "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)",
    "phase": "PHASE3",
    "imp": "pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose",
    "indications": "Breast Neoplasms",
    "sample_size": "340",
    "enrollment_type": "E",
    "start_date_iso": "2021-06-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-18",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06079879",
    "title": "A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)",
    "phase": "PHASE3",
    "imp": "Bomedemstat, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib",
    "indications": "Essential Thrombocythemia",
    "sample_size": "340",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06651281",
    "title": "Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)",
    "phase": "PHASE3",
    "imp": "Tulisokibart, Placebo to tulisokibart",
    "indications": "Crohn Disease, Colitis, Ulcerative",
    "sample_size": "1380",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2037-12-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2037-12-17",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06008756",
    "title": "Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes",
    "phase": "PHASE3",
    "imp": "Enlicitide Decanoate, Placebo",
    "indications": "Arteriosclerosis, Hypercholesterolaemia",
    "sample_size": "14550",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-11-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-11-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05630755",
    "title": "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)",
    "phase": "PHASE3",
    "imp": "DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL",
    "indications": "HIV-1 Infection",
    "sample_size": "514",
    "enrollment_type": "A",
    "start_date_iso": "2023-02-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-10-25",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-08-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05139017",
    "title": "A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)",
    "phase": "PHASE3",
    "imp": "Zilovertamab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Bendamustine, Granulocyte Colony-Stimulating Factor (G-CSF)",
    "indications": "DLBCL, Diffuse Large B-Cell Lymphoma",
    "sample_size": "290",
    "enrollment_type": "E",
    "start_date_iso": "2022-01-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-09-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT03732820",
    "title": "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer",
    "phase": "PHASE3",
    "imp": "olaparib, abiraterone acetate",
    "indications": "Metastatic Castration-resistant Prostate Cancer",
    "sample_size": "895",
    "enrollment_type": "A",
    "start_date_iso": "2018-10-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-07-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-04-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04380636",
    "title": "Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Thoracic Radiotherapy, Durvalumab",
    "indications": "Lung Neoplasms, Carcinoma, Non-Small-Cell Lung",
    "sample_size": "870",
    "enrollment_type": "E",
    "start_date_iso": "2020-07-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07060807",
    "title": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)",
    "phase": "PHASE3",
    "imp": "Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin, Trastuzumab deruxtecan",
    "indications": "Breast Neoplasms",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-07-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-07-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06161025",
    "title": "A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "phase": "PHASE3",
    "imp": "R-DXd, Paclitaxel, Topotecan, PLD",
    "indications": "Solid Cancer",
    "sample_size": "860",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06731478",
    "title": "Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab, Chemotherapy",
    "indications": "Gastric Cancer, Gastroesophageal Junction Cancer",
    "sample_size": "726",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-02-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04195750",
    "title": "A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)",
    "phase": "PHASE3",
    "imp": "Belzutifan, Everolimus",
    "indications": "Carcinoma, Renal Cell",
    "sample_size": "755",
    "enrollment_type": "A",
    "start_date_iso": "2020-02-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-04-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-09-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06136559",
    "title": "A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)",
    "phase": "PHASE3",
    "imp": "Nemtabrutinib, Ibrutinib, Acalabrutinib",
    "indications": "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",
    "sample_size": "1200",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-09-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-09-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04736706",
    "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib",
    "indications": "Carcinoma, Renal Cell",
    "sample_size": "1653",
    "enrollment_type": "E",
    "start_date_iso": "2021-04-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04776252",
    "title": "Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)",
    "phase": "PHASE3",
    "imp": "MK-8591A",
    "indications": "HIV-1 Infection",
    "sample_size": "2000",
    "enrollment_type": "E",
    "start_date_iso": "2021-09-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-05-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-05-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05631093",
    "title": "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)",
    "phase": "PHASE3",
    "imp": "ART, DOR/ISL",
    "indications": "HIV-1 Infection",
    "sample_size": "553",
    "enrollment_type": "A",
    "start_date_iso": "2023-02-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-10-10",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-07-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06556563",
    "title": "EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma",
    "phase": "PHASE3",
    "imp": "Optune\u00ae device, Temozolomide, Pembrolizumab, Placebo",
    "indications": "Glioblastoma",
    "sample_size": "741",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05173987",
    "title": "Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)",
    "phase": "PHASE3",
    "imp": "pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin",
    "indications": "Endometrial Neoplasms",
    "sample_size": "280",
    "enrollment_type": "E",
    "start_date_iso": "2022-02-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07013487",
    "title": "A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)",
    "phase": "PHASE3",
    "imp": "V181, Placebo",
    "indications": "Healthy",
    "sample_size": "12000",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-02-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-02-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06312137",
    "title": "A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication",
    "indications": "Non Small Cell Lung Cancer",
    "sample_size": "780",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2034-02-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-10-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04634877",
    "title": "Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy",
    "indications": "Endometrial Neoplasms",
    "sample_size": "990",
    "enrollment_type": "E",
    "start_date_iso": "2021-01-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT07004413",
    "title": "Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients",
    "phase": "PHASE3",
    "imp": "FOLFIRI+cetuximab, Guardant360 ctDNA assay",
    "indications": "Colorectal Cancer Metastatic",
    "sample_size": "267",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-01-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-01-01",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06356311",
    "title": "A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel, Rescue medication, Supportive care measures",
    "indications": "Gastroesophageal Cancer",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05705349",
    "title": "DOR/ISL in HIV-1 Antiretroviral Treatment-na\u00efve Participants (MK-8591A-053)",
    "phase": "PHASE3",
    "imp": "DOR/ISL, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF",
    "indications": "HIV-1 Infection",
    "sample_size": "537",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-10-13",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-08-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05239741",
    "title": "Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Oxaliplatin, Leucovorin, 5-fluorouracil, Irinotecan, Bevacizumab, Cetuximab",
    "indications": "Colorectal Neoplasms",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2022-04-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-19",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05924438",
    "title": "A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy",
    "phase": "PHASE3",
    "imp": "Delstrigo, KOCITAF",
    "indications": "HIV-1-infection",
    "sample_size": "600",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05555732",
    "title": "Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)",
    "phase": "PHASE3",
    "imp": "Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin",
    "indications": "Metastatic Non Small Cell Lung Cancer",
    "sample_size": "1170",
    "enrollment_type": "E",
    "start_date_iso": "2023-01-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT04657991",
    "title": "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma",
    "phase": "PHASE3",
    "imp": "Encorafenib, Binimetinib, Pembrolizumab",
    "indications": "Melanoma",
    "sample_size": "257",
    "enrollment_type": "A",
    "start_date_iso": "2021-01-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT02811861",
    "title": "Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma",
    "phase": "PHASE3",
    "imp": "Lenvatinib, Everolimus, Pembrolizumab, Sunitinib",
    "indications": "Renal Cell Carcinoma",
    "sample_size": "1069",
    "enrollment_type": "A",
    "start_date_iso": "2016-10-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-08-28",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04191096",
    "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo",
    "indications": "Metastatic Hormone-Sensitive Prostate Cancer",
    "sample_size": "1251",
    "enrollment_type": "A",
    "start_date_iso": "2020-02-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-10-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-02-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06824467",
    "title": "A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent)",
    "indications": "Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer",
    "sample_size": "770",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-04-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-10-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03553836",
    "title": "Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Placebo",
    "indications": "Melanoma",
    "sample_size": "976",
    "enrollment_type": "A",
    "start_date_iso": "2018-09-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-06-21",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2033-10-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05947851",
    "title": "A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).",
    "phase": "PHASE3",
    "imp": "Nemtabrutinib, Venetoclax, Rituximab",
    "indications": "Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL",
    "sample_size": "735",
    "enrollment_type": "E",
    "start_date_iso": "2023-08-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-06-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2035-07-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04246177",
    "title": "Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)",
    "phase": "PHASE3",
    "imp": "Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE",
    "indications": "Carcinoma, Hepatocellular",
    "sample_size": "480",
    "enrollment_type": "A",
    "start_date_iso": "2020-05-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-08-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-25",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT04924608",
    "title": "Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas",
    "phase": "PHASE3",
    "imp": "Selumetinib, Placebo",
    "indications": "Neurofibromatosis 1, Plexiform Neurofibroma (PN)",
    "sample_size": "145",
    "enrollment_type": "A",
    "start_date_iso": "2021-11-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-08-05",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-02-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05624554",
    "title": "A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)",
    "phase": "PHASE3",
    "imp": "Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab, Truxima, Ruxience, Riabni",
    "indications": "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2023-03-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-03-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04956692",
    "title": "Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab SC, Pembrolizumab IV, Paclitaxel, Nab-Paclitaxel, Carboplatin, Cisplatin, Pemetrexed",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "531",
    "enrollment_type": "A",
    "start_date_iso": "2021-08-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-04-04",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-10-14",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07190248",
    "title": "A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)",
    "phase": "PHASE3",
    "imp": "MK-1084, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "675",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-08-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06351631",
    "title": "A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)",
    "phase": "PHASE3",
    "imp": "Bomedemstat",
    "indications": "Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2034-12-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-12-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06997497",
    "title": "A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)",
    "phase": "PHASE3",
    "imp": "MK-1084, Oxaliplatin, Leucovorin/levofolinate calcium, 5-Fluorouracil, Cetuximab, Bevacizumab, Bevacizumab biosimilar",
    "indications": "Colon Adenocarcinoma, Rectal Adenocarcinoma",
    "sample_size": "477",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-10-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT02032823",
    "title": "Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer",
    "phase": "PHASE3",
    "imp": "Olaparib, Placebo",
    "indications": "Breast Cancer",
    "sample_size": "1836",
    "enrollment_type": "A",
    "start_date_iso": "2014-04-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-03-27",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-05-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03425643",
    "title": "Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "797",
    "enrollment_type": "A",
    "start_date_iso": "2018-04-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-07-10",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06463587",
    "title": "Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)",
    "phase": "PHASE3",
    "imp": "Placebo, Cladribine Low Dose, Cladribine High Dose",
    "indications": "Generalized Myasthenia Gravis",
    "sample_size": "264",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-08-19",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07332481",
    "title": "A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease",
    "phase": "PHASE3",
    "imp": "Enpatoran, Placebo, Standard of care (SoC)",
    "indications": "Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)",
    "sample_size": "202",
    "enrollment_type": "E",
    "start_date_iso": "2026-02-25",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-03-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03-19",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05815927",
    "title": "Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, stereotattic ablation radiotherapy (SABR)",
    "indications": "Oligometastatic Squamous Cell Carcinoma of the Head and Neck",
    "sample_size": "200",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07216482",
    "title": "A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)",
    "phase": "PHASE3",
    "imp": "Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin",
    "indications": "Hyperlipidemia",
    "sample_size": "975",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05633602",
    "title": "Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study",
    "phase": "PHASE3",
    "imp": "Chemotherapy, Pembrolizumab, Ramucirumab",
    "indications": "Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8",
    "sample_size": "838",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06925737",
    "title": "A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)",
    "phase": "PHASE3",
    "imp": "Ifinatamab deruxtecan, Docetaxel, Prednisone",
    "indications": "Prostate Cancer, Prostatic Neoplasms",
    "sample_size": "1440",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-01-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06082167",
    "title": "Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "phase": "PHASE3",
    "imp": "Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab",
    "indications": "Head and Neck Squamous Cell Carcinoma",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT04223856",
    "title": "Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer",
    "phase": "PHASE3",
    "imp": "Enfortumab vedotin, Pembrolizumab, Cisplatin, Carboplatin, Gemcitabine",
    "indications": "Urothelial Cancer",
    "sample_size": "886",
    "enrollment_type": "A",
    "start_date_iso": "2020-03-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-08-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-03-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT04255849",
    "title": "Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV",
    "phase": "PHASE3",
    "imp": "9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Saline Placebo",
    "indications": "HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2021-02-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT04607421",
    "title": "A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer",
    "phase": "PHASE3",
    "imp": "Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab",
    "indications": "Neoplasms",
    "sample_size": "831",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06667700",
    "title": "A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)",
    "phase": "PHASE3",
    "imp": "Molnupiravir, Placebo",
    "indications": "Coronavirus Disease (COVID-19)",
    "sample_size": "3082",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-01-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-01-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05239728",
    "title": "A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)",
    "phase": "PHASE3",
    "imp": "Belzutifan, Pembrolizumab, Placebo",
    "indications": "Carcinoma, Renal Cell",
    "sample_size": "1800",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-09-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06312176",
    "title": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin",
    "indications": "Breast Neoplasms",
    "sample_size": "1200",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-04-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05314023",
    "title": "Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)",
    "phase": "PHASE3",
    "imp": "9vHPV vaccine",
    "indications": "Genital Warts",
    "sample_size": "1590",
    "enrollment_type": "E",
    "start_date_iso": "2022-05-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05714085",
    "title": "Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)",
    "phase": "PHASE3",
    "imp": "Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension",
    "indications": "Heart Failure, Left Ventricular Systolic Dysfunction",
    "sample_size": "342",
    "enrollment_type": "E",
    "start_date_iso": "2023-05-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-04-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-04-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06170788",
    "title": "Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u2265 50% (MK-2870-007)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures",
    "indications": "Non-small Cell Lung Cancer (NSCLC)",
    "sample_size": "614",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-05-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07058077",
    "title": "A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)",
    "phase": "PHASE3",
    "imp": "Enlicitide Decanoate, Placebo",
    "indications": "Heterozygous Familial Hypercholesterolemia (HeFH)",
    "sample_size": "153",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-12-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2037-01-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05766501",
    "title": "A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)",
    "phase": "PHASE3",
    "imp": "DOR/ISL",
    "indications": "HIV Infection",
    "sample_size": "641",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-10-16",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-09-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT02362594",
    "title": "Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)",
    "phase": "PHASE3",
    "imp": "pembrolizumab, placebo",
    "indications": "Melanoma",
    "sample_size": "1019",
    "enrollment_type": "A",
    "start_date_iso": "2015-07-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2018-01-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-11-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06430801",
    "title": "A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)",
    "phase": "PHASE3",
    "imp": "IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo",
    "indications": "Crohn's Disease",
    "sample_size": "1200",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-10-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-11-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06203132",
    "title": "DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-na\u00efve People Living With HIV-1 Infection",
    "phase": "PHASE3",
    "imp": "Doravirine + tenofovir DF + lamivudine, Dolutegravir + tenofovir DF + lamivudine or emtricitabine",
    "indications": "HIV-1-infection",
    "sample_size": "610",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04708041",
    "title": "Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)",
    "phase": "PHASE3",
    "imp": "9vHPV vaccine",
    "indications": "Papillomavirus Infections",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2021-03-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04199689",
    "title": "Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)",
    "phase": "PHASE3",
    "imp": "9vHPV Vaccine, Placebo (Saline for Injection)",
    "indications": "Papillomavirus Infections",
    "sample_size": "6033",
    "enrollment_type": "A",
    "start_date_iso": "2020-02-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04624204",
    "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Na\u00efve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)",
    "indications": "Small Cell Lung Cancer",
    "sample_size": "672",
    "enrollment_type": "E",
    "start_date_iso": "2020-12-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06952504",
    "title": "A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel, Sacituzumab Tirumotecan",
    "indications": "Endometrial Cancer",
    "sample_size": "1123",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-05-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-05-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05155254",
    "title": "IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)",
    "phase": "PHASE3",
    "imp": "IO102-IO103, Pembrolizumab",
    "indications": "Metastatic Melanoma, Unresectable Melanoma",
    "sample_size": "407",
    "enrollment_type": "A",
    "start_date_iso": "2022-05-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-05-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06655883",
    "title": "A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)",
    "phase": "PHASE3",
    "imp": "Suvorexant, Placebo",
    "indications": "Insomnia",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07216703",
    "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications",
    "indications": "Cervical Cancer",
    "sample_size": "1023",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-10-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-10-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04210115",
    "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)",
    "phase": "PHASE3",
    "imp": "pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin",
    "indications": "Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)",
    "sample_size": "703",
    "enrollment_type": "E",
    "start_date_iso": "2020-02-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05933577",
    "title": "A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)",
    "phase": "PHASE3",
    "imp": "Intismeran autogene, Pembrolizumab, Placebo",
    "indications": "Melanoma",
    "sample_size": "1089",
    "enrollment_type": "E",
    "start_date_iso": "2023-07-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06697301",
    "title": "Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.",
    "phase": "PHASE3",
    "imp": "EIK1001, Pembrolizumab (KEYTRUDA\u00ae )",
    "indications": "Advanced Melanoma",
    "sample_size": "740",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2035-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2040-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05625633",
    "title": "Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts",
    "phase": "PHASE3",
    "imp": "Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline",
    "indications": "Warts",
    "sample_size": "120",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06644781",
    "title": "A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)",
    "phase": "PHASE3",
    "imp": "Ifinatamab deruxtecan, Docetaxel, Paclitaxel, Irinotecan hydrochloride (HCl)",
    "indications": "Esophageal Squamous Cell Carcinoma",
    "sample_size": "510",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-11-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06726265",
    "title": "Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)",
    "phase": "PHASE3",
    "imp": "eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed, pembrolizumab (KEYTRUDA\u00ae), Placebo",
    "indications": "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)",
    "sample_size": "756",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03711032",
    "title": "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, BCG",
    "indications": "High-risk Non-muscle Invasive Bladder Cancer",
    "sample_size": "1397",
    "enrollment_type": "E",
    "start_date_iso": "2018-12-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-11-20",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06422143",
    "title": "Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel",
    "indications": "Non-small Cell Lung Cancer, NSCLC",
    "sample_size": "851",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-02-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05298423",
    "title": "Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)",
    "phase": "PHASE3",
    "imp": "pembrolizumab/vibostolimab, durvalumab, cisplatin, pemetrexed, etoposide, carboplatin, paclitaxel, thoracic radiotherapy",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "611",
    "enrollment_type": "A",
    "start_date_iso": "2022-05-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07355218",
    "title": "A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)",
    "phase": "PHASE3",
    "imp": "Enpatoran, Placebo, Standard of care (SoC)",
    "indications": "Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus",
    "sample_size": "202",
    "enrollment_type": "E",
    "start_date_iso": "2026-02-25",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-03-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03-19",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07318558",
    "title": "A Clinical Trial of Sacituzumab Tirumotecan in People With Ovarian Cancer (MK-2870-021)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Bevacizumab, Rescue Medications",
    "indications": "Ovarian Neoplasms, Ovarian Cancer",
    "sample_size": "900",
    "enrollment_type": "E",
    "start_date_iso": "2026-02-25",
    "start_date_type": "E",
    "primary_completion_date_iso": "2033-02-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-05-20",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06630299",
    "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1",
    "phase": "PHASE3",
    "imp": "ISL/LEN, Antiretroviral Combinations",
    "indications": "HIV-1-Infection",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06081244",
    "title": "NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)",
    "phase": "PHASE3",
    "imp": "Sacituzumab govitecan, Pembrolizumab",
    "indications": "Triple Negative Breast Cancer",
    "sample_size": "348",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06456346",
    "title": "Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)",
    "phase": "PHASE3",
    "imp": "Bomedemstat, Hydroxyurea, Bomedemstat placebo, Hydroxyurea placebo",
    "indications": "Essential Thrombocythemia",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2024-07-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06074588",
    "title": "Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Docetaxel, Pemetrexed",
    "indications": "Non-small Cell Lung Cancer (NSCLC)",
    "sample_size": "556",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT03682536",
    "title": "A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Na\u00efve",
    "phase": "PHASE3",
    "imp": "Luspatercept, Epoetin alfa",
    "indications": "Myelodysplastic Syndromes",
    "sample_size": "363",
    "enrollment_type": "A",
    "start_date_iso": "2019-01-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-03-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-09-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06393374",
    "title": "Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Sacituzumab tirumotecan, Capecitabine",
    "indications": "Triple-Negative Breast Cancer",
    "sample_size": "1530",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-12-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2037-12-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT04695080",
    "title": "ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Cladribine (MAVENCLAD\u00ae), Placebo",
    "indications": "Advanced Multiple Sclerosis, Progressive Multiple Sclerosis",
    "sample_size": "204",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06630286",
    "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1",
    "phase": "PHASE3",
    "imp": "ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN",
    "indications": "HIV-1-infection",
    "sample_size": "609",
    "enrollment_type": "A",
    "start_date_iso": "2024-10-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07227402",
    "title": "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)",
    "phase": "PHASE3",
    "imp": "Belzutifan, Zanzalintinib, Cabozantinib",
    "indications": "Renal Cell Carcinoma",
    "sample_size": "904",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-02-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-02-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05338970",
    "title": "HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy",
    "phase": "PHASE3",
    "imp": "Patritumab Deruxtecan, Platinum-based chemotherapy",
    "indications": "Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion",
    "sample_size": "586",
    "enrollment_type": "A",
    "start_date_iso": "2022-07-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05722015",
    "title": "A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pembrolizumab, Filgrastim, Pegylated filgrastim",
    "indications": "Metastatic Non-small Cell Lung Cancer",
    "sample_size": "377",
    "enrollment_type": "A",
    "start_date_iso": "2023-02-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-07-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-05-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07044297",
    "title": "A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)",
    "phase": "PHASE3",
    "imp": "MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF",
    "indications": "Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis",
    "sample_size": "4390",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-22",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05285826",
    "title": "Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)",
    "phase": "PHASE3",
    "imp": "9vHPV Vaccine, Placebo",
    "indications": "Papillomavirus Infections",
    "sample_size": "8100",
    "enrollment_type": "E",
    "start_date_iso": "2022-02-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-05-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-05-25",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04241185",
    "title": "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), Cisplatin, Fluorouracil (5-FU), Mitomycin C (MMC), Gemcitabine, Placebo to Pembrolizumab",
    "indications": "Urinary Bladder Neoplasms",
    "sample_size": "520",
    "enrollment_type": "E",
    "start_date_iso": "2020-05-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-11-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06077760",
    "title": "A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)",
    "phase": "PHASE3",
    "imp": "Intismeran autogene, Pembrolizumab, Placebo",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "868",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-06-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2035-12-21",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06305754",
    "title": "Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)",
    "indications": "Non-small Cell Lung Cancer (NSCLC)",
    "sample_size": "520",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-06-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05911295",
    "title": "Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2",
    "phase": "PHASE3",
    "imp": "disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin",
    "indications": "Urothelial Carcinoma",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2023-09-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04586231",
    "title": "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)",
    "phase": "PHASE3",
    "imp": "Belzutifan, Lenvatinib, Cabozantinib",
    "indications": "Carcinoma, Renal Cell",
    "sample_size": "708",
    "enrollment_type": "E",
    "start_date_iso": "2021-02-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04662710",
    "title": "Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Lenvatinib, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU",
    "indications": "Advanced/Metastatic Gastroesophageal Adenocarcinoma",
    "sample_size": "895",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-10-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05450705",
    "title": "V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)",
    "phase": "PHASE3",
    "imp": "9vHPV vaccine",
    "indications": "Papillomavirus Infections",
    "sample_size": "1500",
    "enrollment_type": "E",
    "start_date_iso": "2022-07-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-08-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT07365319",
    "title": "A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.",
    "phase": "PHASE3",
    "imp": "EIK1001, Pembrolizumab (KEYTRUDA\u00ae), Placebo, Paclitaxel + Carboplatin, Nab-paclitaxel + Carboplatin, Pemetrexed + Cisplatin /Carboplatin",
    "indications": "Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2026-05-18",
    "start_date_type": "E",
    "primary_completion_date_iso": "2035-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2040-12-31",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07266831",
    "title": "A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)",
    "phase": "PHASE3",
    "imp": "ISL, ULO, BIC/FTC/TAF, Placebo for BIC/FTC/TAF, Placebo to ISL/ULO, ISL/ULO",
    "indications": "Human Immunodeficiency Virus Type 1 (HIV-1) Infection",
    "sample_size": "570",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-04-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03486873",
    "title": "Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A",
    "indications": "Solid Tumors, Hematologic Malignancies",
    "sample_size": "3500",
    "enrollment_type": "E",
    "start_date_iso": "2018-08-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2043-08-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2043-08-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT01252953",
    "title": "REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification",
    "phase": "PHASE3",
    "imp": "Anacetrapib, Placebo anacetrapib",
    "indications": "Atherosclerotic Cardiovascular Disease",
    "sample_size": "30449",
    "enrollment_type": "A",
    "start_date_iso": "2011-06",
    "start_date_type": "E",
    "primary_completion_date_iso": "2017-01-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2037-01-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06717347",
    "title": "A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)",
    "phase": "PHASE3",
    "imp": "Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Vincristine, Rescue medication",
    "indications": "Diffuse Large B-Cell Lymphoma",
    "sample_size": "1046",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-07-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-03-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06966700",
    "title": "A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib",
    "indications": "Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms",
    "sample_size": "2400",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-03-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-12-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06841354",
    "title": "A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin",
    "indications": "Triple Negative Breast Neoplasms",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-05-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-05-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05382286",
    "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",
    "phase": "PHASE3",
    "imp": "Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin",
    "indications": "Triple Negative Breast Cancer, PD-L1 Positive",
    "sample_size": "443",
    "enrollment_type": "A",
    "start_date_iso": "2022-07-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05171816",
    "title": "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)",
    "phase": "PHASE3",
    "imp": "olaparib, abiraterone acetate",
    "indications": "Metastatic Castration-resistant Prostate Cancer",
    "sample_size": "110",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-22",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-04-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03834493",
    "title": "Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Enzalutamide, Placebo",
    "indications": "Prostatic Neoplasms",
    "sample_size": "1244",
    "enrollment_type": "A",
    "start_date_iso": "2019-07-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-12-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-05-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05609968",
    "title": "Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-3475-D46)",
    "phase": "PHASE3",
    "imp": "Sacituzumab Govitecan, Pembrolizumab",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "614",
    "enrollment_type": "E",
    "start_date_iso": "2023-02-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03725059",
    "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery",
    "indications": "Breast Cancer",
    "sample_size": "1240",
    "enrollment_type": "E",
    "start_date_iso": "2018-12-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-01-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-01-24",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04700124",
    "title": "Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin",
    "indications": "Bladder Cancer",
    "sample_size": "808",
    "enrollment_type": "E",
    "start_date_iso": "2021-04-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03998254",
    "title": "Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)",
    "phase": "PHASE3",
    "imp": "V503, Gardasil",
    "indications": "Papillomavirus Infections",
    "sample_size": "6000",
    "enrollment_type": "E",
    "start_date_iso": "2019-06-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT07218029",
    "title": "A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)",
    "phase": "PHASE3",
    "imp": "Sotatercept",
    "indications": "Pulmonary Arterial Hypertension",
    "sample_size": "815",
    "enrollment_type": "E",
    "start_date_iso": "2021-05-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT05215340",
    "title": "Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations",
    "phase": "PHASE3",
    "imp": "Datopotamab Deruxtecan, Pembrolizumab",
    "indications": "Metastatic Non Small Cell Lung Cancer",
    "sample_size": "740",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06459180",
    "title": "A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)",
    "phase": "PHASE3",
    "imp": "Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan",
    "indications": "Cervical Cancer",
    "sample_size": "686",
    "enrollment_type": "E",
    "start_date_iso": "2024-07-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06136624",
    "title": "Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)",
    "phase": "PHASE3",
    "imp": "Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone",
    "indications": "Prostate Cancer Metastatic",
    "sample_size": "1310",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-08-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03924856",
    "title": "Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo",
    "indications": "Bladder Cancer",
    "sample_size": "907",
    "enrollment_type": "A",
    "start_date_iso": "2019-06-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03924895",
    "title": "Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin",
    "indications": "Urinary Bladder Cancer, Muscle-invasive",
    "sample_size": "595",
    "enrollment_type": "A",
    "start_date_iso": "2019-07-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-06",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-12-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT01844986",
    "title": "Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.",
    "phase": "PHASE3",
    "imp": "Olaparib 300mg tablets",
    "indications": "Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy",
    "sample_size": "450",
    "enrollment_type": "A",
    "start_date_iso": "2013-08-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2018-05-17",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-08-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT04949256",
    "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Lenvatinib, Cisplatin, 5-FU, Oxaliplatin, Leucovorin, Levoleucovorin, Paclitaxel",
    "indications": "Metastatic Esophageal Squamous Cell Carcinoma",
    "sample_size": "864",
    "enrollment_type": "A",
    "start_date_iso": "2021-07-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-05-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06132958",
    "title": "Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)",
    "phase": "PHASE3",
    "imp": "Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel",
    "indications": "Endometrial Cancer",
    "sample_size": "710",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT03740165",
    "title": "Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Placebo for pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Placebo for olaparib, Bevacizumab, Docetaxel",
    "indications": "Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms",
    "sample_size": "1367",
    "enrollment_type": "A",
    "start_date_iso": "2018-12-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-08-26",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-05-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT06624644",
    "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
    "phase": "PHASE3",
    "imp": "LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide), Immunotherapy (Pembrolizumab), Immunotherapy (nivolumab and relatlimab), Immunotherapy (ipilimumab and nivolumab)",
    "indications": "Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma",
    "sample_size": "135",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": true,
    "nct_id": "NCT00626990",
    "title": "Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)",
    "phase": "PHASE3",
    "imp": "temozolomide, DNA methylation analysis, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment, radiation therapy",
    "indications": "Brain and Central Nervous System Tumors",
    "sample_size": "751",
    "enrollment_type": "A",
    "start_date_iso": "2007-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2018-09-05",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT06345729",
    "title": "A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-1084-004/KANDLELIT-004)",
    "phase": "PHASE3",
    "imp": "MK-1084, Placebo, Pembrolizumab",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-02-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Merck",
    "is_collaborator": false,
    "nct_id": "NCT05116189",
    "title": "Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)",
    "phase": "PHASE3",
    "imp": "Pembrolizumab, Paclitaxel, Bevacizumab, Placebo for pembrolizumab, Docetaxel",
    "indications": "Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms",
    "sample_size": "643",
    "enrollment_type": "A",
    "start_date_iso": "2021-12-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-03-05",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-10-25",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT03820830",
    "title": "Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer",
    "phase": "PHASE3",
    "imp": "Palbociclib 125mg, Standard endocrine therapy",
    "indications": "Breast Cancer Recurrent",
    "sample_size": "405",
    "enrollment_type": "A",
    "start_date_iso": "2019-08-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-01-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05431088",
    "title": "A Phase 2/3 Study in Adult and Pediatric Participants With SCD",
    "phase": "PHASE3",
    "imp": "Osivelotor",
    "indications": "Sickle Cell Disease",
    "sample_size": "429",
    "enrollment_type": "A",
    "start_date_iso": "2022-09-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-12-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-12-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06679140",
    "title": "A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease",
    "phase": "PHASE3",
    "imp": "ibuzatrelvir, placebo",
    "indications": "COVID-19 SARS-CoV-2 Infection",
    "sample_size": "2330",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT03950232",
    "title": "An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Etrasimod",
    "indications": "Ulcerative Colitis",
    "sample_size": "896",
    "enrollment_type": "A",
    "start_date_iso": "2019-09-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-06-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05583526",
    "title": "A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo",
    "phase": "PHASE3",
    "imp": "Ritlecitinib, Placebo",
    "indications": "Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo",
    "sample_size": "592",
    "enrollment_type": "A",
    "start_date_iso": "2022-12-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06072183",
    "title": "A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2",
    "phase": "PHASE3",
    "imp": "Ritlecitinib, Ritlecitinib, Placebo",
    "indications": "Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo",
    "sample_size": "1571",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06758401",
    "title": "This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.",
    "phase": "PHASE3",
    "imp": "Sigvotatug Vedotin, Pembrolizumab",
    "indications": "Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)",
    "sample_size": "714",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05623020",
    "title": "A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy",
    "phase": "PHASE3",
    "imp": "Elranatamab, Daratumumab, Lenalidomide, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "1116",
    "enrollment_type": "E",
    "start_date_iso": "2022-11-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-10-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-10-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06163326",
    "title": "A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo",
    "phase": "PHASE3",
    "imp": "Ritlecitinib, Ritlecitinib 100 mg, Placebo",
    "indications": "Vitiligo",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2024-01-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-04-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT04281485",
    "title": "Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy",
    "phase": "PHASE3",
    "imp": "PF-06939926, Placebo, Placebo, PF-06939926",
    "indications": "Duchenne Muscular Dystrophy",
    "sample_size": "114",
    "enrollment_type": "A",
    "start_date_iso": "2020-11-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2039-04-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT07174336",
    "title": "A Study of LY4064809 (Tersolisib) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)",
    "phase": "PHASE3",
    "imp": "LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant",
    "indications": "Breast Neoplasms, Neoplasm Metastasis",
    "sample_size": "920",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06551324",
    "title": "A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).",
    "phase": "PHASE3",
    "imp": "PF-06821497, Docetaxel, Enzalutamide",
    "indications": "Metastatic Castrate Resistant Prostate Cancer (mCRPC)",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-10-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT03395197",
    "title": "Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC",
    "phase": "PHASE3",
    "imp": "Talazoparib with enzalutamide, Placebo with enzalutamide",
    "indications": "mCRPC",
    "sample_size": "1054",
    "enrollment_type": "A",
    "start_date_iso": "2017-12-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-10-03",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT04743141",
    "title": "Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine",
    "phase": "PHASE3",
    "imp": "Rimegepant (PF-07899801)",
    "indications": "Acute Treatment of Migraine",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2021-04-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-07-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-07-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05035212",
    "title": "Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.",
    "phase": "PHASE3",
    "imp": "RSVpreF, Placebo",
    "indications": "Lower Respiratory Tract Illness",
    "sample_size": "38861",
    "enrollment_type": "A",
    "start_date_iso": "2021-08-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-18",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07029711",
    "title": "A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata",
    "phase": "PHASE3",
    "imp": "Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo",
    "indications": "Severe Alopecia Areata",
    "sample_size": "225",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT06918002",
    "title": "Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients",
    "phase": "PHASE3",
    "imp": "Elranatamab, Lenalidomide (Revlimid\u00ae), Daratumumab SC (Darzalex), Autologous Stem Cell Transplantation, Bortezomib (Velcade\u00ae), Dexamethasone",
    "indications": "Multiple Myeloma, Newly Diagnosed",
    "sample_size": "824",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2036-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2036-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT06439524",
    "title": "The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial",
    "phase": "PHASE3",
    "imp": "40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate",
    "indications": "Endometriosis",
    "sample_size": "110",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05156398",
    "title": "Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects",
    "phase": "PHASE3",
    "imp": "Rimegepant, Placebo",
    "indications": "Migraine",
    "sample_size": "640",
    "enrollment_type": "E",
    "start_date_iso": "2022-02-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-11-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-11-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT02947685",
    "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer",
    "phase": "PHASE3",
    "imp": "palbociclib, trastuzumab, pertuzumab, letrozole, Anastrozole, Exemestane, Fulvestrant",
    "indications": "HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer",
    "sample_size": "518",
    "enrollment_type": "A",
    "start_date_iso": "2017-06-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-10-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-07-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07226882",
    "title": "A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults",
    "phase": "PHASE3",
    "imp": "VLA15, Placebo",
    "indications": "Lyme Borreliosis",
    "sample_size": "200",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05611801",
    "title": "A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B",
    "phase": "PHASE3",
    "imp": "marstacimab",
    "indications": "Hemophilia A, Hemophilia B",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06152575",
    "title": "MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)",
    "phase": "PHASE3",
    "imp": "Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib",
    "indications": "Multiple Myeloma",
    "sample_size": "492",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06760637",
    "title": "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease",
    "phase": "PHASE3",
    "imp": "PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib",
    "indications": "Breast Cancer",
    "sample_size": "1020",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2037-12-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT04657991",
    "title": "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma",
    "phase": "PHASE3",
    "imp": "Encorafenib, Binimetinib, Pembrolizumab",
    "indications": "Melanoma",
    "sample_size": "257",
    "enrollment_type": "A",
    "start_date_iso": "2021-01-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06866405",
    "title": "A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose",
    "phase": "PHASE3",
    "imp": "RSVpreF, Placebo",
    "indications": "RSV Infection",
    "sample_size": "550",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05132582",
    "title": "A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer",
    "phase": "PHASE3",
    "imp": "Tucatinib, Trastuzumab, Pertuzumab, Combination product: Trastuzumab + Pertuzumab, Placebo",
    "indications": "HER2 Positive Breast Cancer",
    "sample_size": "654",
    "enrollment_type": "A",
    "start_date_iso": "2022-03-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-05",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-09-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT04821622",
    "title": "Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC",
    "phase": "PHASE3",
    "imp": "talazoparib plus enzalutamide, Placebo plus enzalutamide",
    "indications": "Prostate Cancer",
    "sample_size": "599",
    "enrollment_type": "A",
    "start_date_iso": "2021-05-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05253651",
    "title": "A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer",
    "phase": "PHASE3",
    "imp": "tucatinib, trastuzumab, bevacizumab, cetuximab, oxaliplatin, leucovorin, levoleucovorin, fluorouracil",
    "indications": "Colorectal Neoplasms",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2022-10-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06629779",
    "title": "A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.",
    "phase": "PHASE3",
    "imp": "PF-06821497, Placebo, Enzalutamide",
    "indications": "Metastatic Castration-Resistant Prostate Cancer",
    "sample_size": "900",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05317416",
    "title": "Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant",
    "phase": "PHASE3",
    "imp": "Elranatamab, Lenalidomide, Lenalidomide, Elranatamab",
    "indications": "Multiple Myeloma",
    "sample_size": "811",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07144280",
    "title": "A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)",
    "phase": "PHASE3",
    "imp": "PF-08046054, Docetaxel monotherapy",
    "indications": "Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma",
    "sample_size": "680",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-03-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT04607421",
    "title": "A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer",
    "phase": "PHASE3",
    "imp": "Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab",
    "indications": "Neoplasms",
    "sample_size": "831",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT02513394",
    "title": "PALbociclib CoLlaborative Adjuvant Study",
    "phase": "PHASE3",
    "imp": "Palbociclib, Standard Adjuvant Endocrine Therapy",
    "indications": "Breast Cancer",
    "sample_size": "5796",
    "enrollment_type": "A",
    "start_date_iso": "2015-08",
    "start_date_type": "E",
    "primary_completion_date_iso": "2020-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05895786",
    "title": "A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]",
    "phase": "PHASE3",
    "imp": "PF-06823859, Placebo",
    "indications": "Myositis",
    "sample_size": "318",
    "enrollment_type": "E",
    "start_date_iso": "2023-05-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06641466",
    "title": "A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine",
    "phase": "PHASE3",
    "imp": "Rimegepant, Placebo Comparator, Standard of Care, Rimegepant",
    "indications": "Menstrual Migraine",
    "sample_size": "723",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06873945",
    "title": "A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata",
    "phase": "PHASE3",
    "imp": "Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg",
    "indications": "Alopecia Areata",
    "sample_size": "550",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06012435",
    "title": "A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "sigvotatug vedotin, docetaxel",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "703",
    "enrollment_type": "A",
    "start_date_iso": "2024-02-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT04307576",
    "title": "A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia",
    "phase": "PHASE3",
    "imp": "Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab",
    "indications": "Leukemia, Acute Lymphoblastic",
    "sample_size": "6430",
    "enrollment_type": "E",
    "start_date_iso": "2020-07-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT05543616",
    "title": "A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children",
    "phase": "PHASE3",
    "imp": "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose",
    "indications": "SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19",
    "sample_size": "4292",
    "enrollment_type": "E",
    "start_date_iso": "2022-09-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-06-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06989437",
    "title": "A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue",
    "phase": "PHASE3",
    "imp": "ponsegromab, placebo",
    "indications": "Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma",
    "sample_size": "982",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT03975647",
    "title": "A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer",
    "phase": "PHASE3",
    "imp": "tucatinib, placebo, T-DM1",
    "indications": "HER2-positive Breast Cancer",
    "sample_size": "466",
    "enrollment_type": "A",
    "start_date_iso": "2019-10-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-06-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-03-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT07300839",
    "title": "A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age",
    "phase": "PHASE3",
    "imp": "BNT162b2 Vaccine, Placebo",
    "indications": "COVID-19, SARS-COV-2 Infection",
    "sample_size": "25500",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07222800",
    "title": "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer",
    "phase": "PHASE3",
    "imp": "PF-08634404, Bevacizumab, Chemotherapy",
    "indications": "Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-08-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07013474",
    "title": "A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised",
    "phase": "PHASE3",
    "imp": "ibuzatrelvir, remdesivir, placebo for ibuzatrelvir, placebo for remdesivir",
    "indications": "COVID-19 Infection",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07282665",
    "title": "A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older",
    "phase": "PHASE3",
    "imp": "C.difficile vaccine, Saline Placebo",
    "indications": "Clostridioides Difficile Associated Disease",
    "sample_size": "32000",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT07069309",
    "title": "A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages \u226565 Years",
    "phase": "PHASE3",
    "imp": "BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)",
    "indications": "COVID-19, SARS-COV-2 Infection",
    "sample_size": "760",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06807281",
    "title": "A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema",
    "phase": "PHASE3",
    "imp": "Abrocitinib",
    "indications": "Atopic Dermatitis",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-02-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-02-22",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06807268",
    "title": "A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema",
    "phase": "PHASE3",
    "imp": "Abrocitinib, Placebo",
    "indications": "Eczema",
    "sample_size": "150",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07363694",
    "title": "A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease",
    "phase": "PHASE3",
    "imp": "PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3",
    "indications": "Moderate to Severe Chronic Obstructive Pulmonary Disease",
    "sample_size": "1156",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-26",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-10-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-01-16",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07160244",
    "title": "BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies",
    "phase": "PHASE3",
    "imp": "Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix",
    "indications": "Healthy",
    "sample_size": "6000",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06698796",
    "title": "A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies",
    "phase": "PHASE3",
    "imp": "Dazukibart",
    "indications": "Dermatomyositis, Polymyositis",
    "sample_size": "211",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05020236",
    "title": "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments",
    "phase": "PHASE3",
    "imp": "Elranatamab, Daratumumab, Pomalidomide, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "944",
    "enrollment_type": "E",
    "start_date_iso": "2021-10-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT07222384",
    "title": "A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19",
    "phase": "PHASE3",
    "imp": "BNT162b2 (2025/2026 formulation)",
    "indications": "COVID-19, SARS-COV-2 Infection",
    "sample_size": "330",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT02724163",
    "title": "International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia",
    "phase": "PHASE3",
    "imp": "Gemtuzumab ozogamicin, Liposomal daunorubicin, Mitoxantrone, Fludarabine, Cytarabine, Busulfan, Cyclophosphamide",
    "indications": "Acute Myeloid Leukaemia",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2016-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05145127",
    "title": "Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors",
    "phase": "PHASE3",
    "imp": "PF-06741086",
    "indications": "Hemophilia A, Hemophilia B",
    "sample_size": "245",
    "enrollment_type": "E",
    "start_date_iso": "2021-11-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-07-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-07-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT02319837",
    "title": "Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)",
    "phase": "PHASE3",
    "imp": "Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label",
    "indications": "Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate",
    "sample_size": "1068",
    "enrollment_type": "A",
    "start_date_iso": "2014-12-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-01-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-09-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05911295",
    "title": "Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2",
    "phase": "PHASE3",
    "imp": "disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin",
    "indications": "Urothelial Carcinoma",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2023-09-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07028853",
    "title": "This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI na\u00efve.",
    "phase": "PHASE3",
    "imp": "Mevrometostat, Placebo, Enzalutamide",
    "indications": "Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-12-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07226999",
    "title": "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "PF-08634404, Atezolizumab, Chemotherapy",
    "indications": "Small Cell Lung Cancer (SCLC)",
    "sample_size": "550",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-06-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-03-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT04624230",
    "title": "Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "tofacitinib",
    "indications": "Ulcerative Colitis",
    "sample_size": "120",
    "enrollment_type": "E",
    "start_date_iso": "2021-08-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-05-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT04165317",
    "title": "A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer",
    "phase": "PHASE3",
    "imp": "PF-06801591, Bacillus Calmette-Guerin",
    "indications": "Non-muscle Invasive Bladder Cancer",
    "sample_size": "1068",
    "enrollment_type": "A",
    "start_date_iso": "2019-12-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-12-02",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-12-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07222566",
    "title": "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "PF-08634404, Pembrolizumab, Chemotherapy Regimen 1, Chemotherapy Regimen 2",
    "indications": "Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer",
    "sample_size": "1410",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-08-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05654623",
    "title": "A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer",
    "phase": "PHASE3",
    "imp": "ARV-471, Fulvestrant",
    "indications": "Advanced Breast Cancer",
    "sample_size": "624",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-01-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-05-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05261139",
    "title": "EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease",
    "phase": "PHASE3",
    "imp": "nirmatrelvir, ritonavir",
    "indications": "COVID-19",
    "sample_size": "160",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07311850",
    "title": "Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity",
    "phase": "PHASE3",
    "imp": "MET097, Placebo",
    "indications": "Obesity and Overweight",
    "sample_size": "3500",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT04649242",
    "title": "Randomized Study in Children and Adolescents With Migraine: Acute Treatment",
    "phase": "PHASE3",
    "imp": "Rimegepant/BHV3000, Matching placebo",
    "indications": "Pediatric Migraine",
    "sample_size": "2100",
    "enrollment_type": "E",
    "start_date_iso": "2021-01-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-01-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07062965",
    "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.",
    "phase": "PHASE3",
    "imp": "PF-07248144, Fulvestrant, Everolimus, Exemestane",
    "indications": "Breast Cancer",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-11-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT05568719",
    "title": "Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively",
    "phase": "PHASE3",
    "imp": "Testing of hepatic AAV Vector integration",
    "indications": "Hemophilia A, Hemophilia B",
    "sample_size": "263",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2040-02-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2040-02-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT04404283",
    "title": "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL",
    "phase": "PHASE3",
    "imp": "Brentuximab vedotin, Rituximab, Lenalidomide, Placebo",
    "indications": "Diffuse Large B-cell Lymphoma",
    "sample_size": "238",
    "enrollment_type": "A",
    "start_date_iso": "2020-08-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT06616194",
    "title": "A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine",
    "phase": "PHASE3",
    "imp": "Rimegepant, Placebo",
    "indications": "Migraine",
    "sample_size": "200",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT03052608",
    "title": "A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC",
    "phase": "PHASE3",
    "imp": "Lorlatinib, Crizotinib",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "296",
    "enrollment_type": "A",
    "start_date_iso": "2017-04-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-03-20",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT04697628",
    "title": "Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer",
    "phase": "PHASE3",
    "imp": "tisotumab vedotin, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed",
    "indications": "Cervical Cancer",
    "sample_size": "502",
    "enrollment_type": "A",
    "start_date_iso": "2021-02-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-07-24",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-05-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT07226089",
    "title": "Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.",
    "phase": "PHASE3",
    "imp": "Somatrogon, Genotropin",
    "indications": "ISS, SGA",
    "sample_size": "254",
    "enrollment_type": "E",
    "start_date_iso": "2026-02",
    "start_date_type": "E",
    "primary_completion_date_iso": "2027-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": true,
    "nct_id": "NCT04801589",
    "title": "Goal-Directed Sedation in Mechanically Ventilated Infants and Children",
    "phase": "PHASE3",
    "imp": "Dexmedetomidine, Midazolam",
    "indications": "Delirium, Critical Illness, Sedation Complication, Executive Dysfunction, Post Traumatic Stress Disorder",
    "sample_size": "372",
    "enrollment_type": "E",
    "start_date_iso": "2021-05-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Pfizer",
    "is_collaborator": false,
    "nct_id": "NCT07029828",
    "title": "A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.",
    "phase": "PHASE3",
    "imp": "Ritlecitinib higher dose, Ritlecitinib lower dose",
    "indications": "Severe Alopecia Areata",
    "sample_size": "140",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-06-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-06-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": true,
    "nct_id": "NCT05327894",
    "title": "Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia",
    "phase": "PHASE3",
    "imp": "Blinatumomab, Blinatumomab",
    "indications": "Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia",
    "sample_size": "160",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": true,
    "nct_id": "NCT06023589",
    "title": "A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma",
    "phase": "PHASE3",
    "imp": "Tezepelumab, Placebo",
    "indications": "Asthma",
    "sample_size": "231",
    "enrollment_type": "E",
    "start_date_iso": "2023-08-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-08-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT04303780",
    "title": "Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).",
    "phase": "PHASE3",
    "imp": "AMG 510, Docetaxel",
    "indications": "KRAS p, G12c Mutated /Advanced Metastatic NSCLC",
    "sample_size": "345",
    "enrollment_type": "A",
    "start_date_iso": "2020-06-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-08-02",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-02-25",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06252649",
    "title": "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-na\u00efve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation",
    "phase": "PHASE3",
    "imp": "FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb",
    "indications": "Metastatic Colorectal Cancer",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2024-07-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-08-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT05111626",
    "title": "Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.",
    "phase": "PHASE3",
    "imp": "Bemarituzumab, Nivolumab, Chemotherapy, Placebo",
    "indications": "Gastric Cancer, Gastroesophageal Junction Adenocarcinoma",
    "sample_size": "515",
    "enrollment_type": "A",
    "start_date_iso": "2022-03-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-10-14",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-01-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06858839",
    "title": "Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight",
    "phase": "PHASE3",
    "imp": "Maridebart Cafraglutide, Placebo",
    "indications": "Obesity",
    "sample_size": "3853",
    "enrollment_type": "A",
    "start_date_iso": "2025-03-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-04-16",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT04540497",
    "title": "A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease",
    "phase": "PHASE3",
    "imp": "Inebilizumab, Placebo",
    "indications": "IgG4 Related Disease",
    "sample_size": "135",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-04-09",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-10-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT07136012",
    "title": "OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events",
    "phase": "PHASE3",
    "imp": "Olpasiran, Placebo",
    "indications": "Cardiovascular Disease",
    "sample_size": "11000",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-10-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-10-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06527404",
    "title": "A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis",
    "phase": "PHASE3",
    "imp": "Rocatinlimab, Placebo",
    "indications": "Prurigo Nodularis",
    "sample_size": "469",
    "enrollment_type": "A",
    "start_date_iso": "2024-07-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": true,
    "nct_id": "NCT06883305",
    "title": "A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)",
    "phase": "PHASE3",
    "imp": "Tezepelumab, Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease (COPD)",
    "sample_size": "990",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT07213674",
    "title": "A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer",
    "phase": "PHASE3",
    "imp": "Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel",
    "indications": "Metastatic Castration-resistant Prostate Cancer",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-01-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-08-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": true,
    "nct_id": "NCT05583227",
    "title": "Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis",
    "phase": "PHASE3",
    "imp": "Tezepelumab, Tezepelumab, Placebo",
    "indications": "Eosinophilic Esophagitis",
    "sample_size": "368",
    "enrollment_type": "A",
    "start_date_iso": "2022-11-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT07037433",
    "title": "Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity",
    "phase": "PHASE3",
    "imp": "Maridebart Cafraglutide, Placebo",
    "indications": "Atherosclerotic Cardiovascular Disease, Overweight, Obesity",
    "sample_size": "12800",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06747949",
    "title": "A Long-term Extension Study of Dazodalibep in Participants With Sj\u00f6gren's Syndrome (SS)",
    "phase": "PHASE3",
    "imp": "Dazodalibep",
    "indications": "Sj\u00f6gren's Syndrome",
    "sample_size": "844",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT05581303",
    "title": "Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial",
    "phase": "PHASE3",
    "imp": "Placebo, Olpasiran",
    "indications": "Atherosclerotic Cardiovascular Disease",
    "sample_size": "7297",
    "enrollment_type": "A",
    "start_date_iso": "2022-12-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": true,
    "nct_id": "NCT04934475",
    "title": "MInimal Residual Disease Adapted Strategy",
    "phase": "PHASE3",
    "imp": "Isatuximab, ASCT",
    "indications": "Multiple Myeloma",
    "sample_size": "791",
    "enrollment_type": "A",
    "start_date_iso": "2021-12-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-09-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT07225686",
    "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy",
    "phase": "PHASE3",
    "imp": "Maridebart cafraglutide, Placebo",
    "indications": "Obesity, Obstructive Sleep Apnea",
    "sample_size": "250",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": true,
    "nct_id": "NCT03117751",
    "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma",
    "phase": "PHASE3",
    "imp": "Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase\u00ae, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol",
    "indications": "Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma",
    "sample_size": "790",
    "enrollment_type": "A",
    "start_date_iso": "2017-03-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT05052801",
    "title": "Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression",
    "phase": "PHASE3",
    "imp": "Bemarituzumab, mFOLFOX6, Placebo",
    "indications": "Gastric Cancer, Gastroesophageal Junction Adenocarcinoma",
    "sample_size": "547",
    "enrollment_type": "A",
    "start_date_iso": "2022-03-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-20",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-20",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": true,
    "nct_id": "NCT04307576",
    "title": "A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia",
    "phase": "PHASE3",
    "imp": "Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab",
    "indications": "Leukemia, Acute Lymphoblastic",
    "sample_size": "6430",
    "enrollment_type": "E",
    "start_date_iso": "2020-07-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT07037459",
    "title": "Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity",
    "phase": "PHASE3",
    "imp": "Maridebart cafraglutide, Placebo",
    "indications": "Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity",
    "sample_size": "5056",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT04524273",
    "title": "Myasthenia Gravis Inebilizumab Trial",
    "phase": "PHASE3",
    "imp": "inebilizumab, IV Placebo",
    "indications": "Myasthenia Gravis",
    "sample_size": "238",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-28",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-11-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT03937154",
    "title": "Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",
    "phase": "PHASE3",
    "imp": "Romiplostim, Placebo",
    "indications": "Chemotherapy-induced Thrombocytopenia",
    "sample_size": "145",
    "enrollment_type": "A",
    "start_date_iso": "2020-02-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-20",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT05972551",
    "title": "Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta",
    "phase": "PHASE3",
    "imp": "Romosozumab, Bisphosphonate",
    "indications": "Osteogenesis Imperfecta",
    "sample_size": "106",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT07226765",
    "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy",
    "phase": "PHASE3",
    "imp": "Maridebart cafraglutide, Placebo",
    "indications": "Obstructive Sleep Apnea",
    "sample_size": "250",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06858878",
    "title": "Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight",
    "phase": "PHASE3",
    "imp": "Maridebart cafraglutide, Placebo",
    "indications": "Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight",
    "sample_size": "1105",
    "enrollment_type": "A",
    "start_date_iso": "2025-03-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-04-16",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": true,
    "nct_id": "NCT06878261",
    "title": "A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)",
    "phase": "PHASE3",
    "imp": "Tezepelumab, Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease (COPD)",
    "sample_size": "990",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT03836040",
    "title": "Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine",
    "phase": "PHASE3",
    "imp": "Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo",
    "indications": "Migraine",
    "sample_size": "457",
    "enrollment_type": "A",
    "start_date_iso": "2019-07-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-11-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06104124",
    "title": "A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sj\u00f6gren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity",
    "phase": "PHASE3",
    "imp": "Dazodalibep, Placebo",
    "indications": "Sjogren's Syndrome",
    "sample_size": "651",
    "enrollment_type": "A",
    "start_date_iso": "2024-01-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT04994717",
    "title": "Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia",
    "phase": "PHASE3",
    "imp": "Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen",
    "indications": "Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)",
    "sample_size": "304",
    "enrollment_type": "E",
    "start_date_iso": "2021-11-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-09-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-09-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06987695",
    "title": "Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease",
    "phase": "PHASE3",
    "imp": "Maridebart cafraglutide, Placebo",
    "indications": "Obesity Disease",
    "sample_size": "279",
    "enrollment_type": "A",
    "start_date_iso": "2025-06-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-21",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT07005128",
    "title": "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)",
    "phase": "PHASE3",
    "imp": "Tarlatamab, Durvalumab, Carboplatin, Etoposide",
    "indications": "Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer",
    "sample_size": "330",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT05882877",
    "title": "A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)",
    "phase": "PHASE3",
    "imp": "Rocatinlimab, Placebo",
    "indications": "Atopic Dermatitis",
    "sample_size": "2621",
    "enrollment_type": "A",
    "start_date_iso": "2023-05-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06245408",
    "title": "A Safety and Efficacy Study of Dazodalibep in Participants With Sj\u00f6gren's Syndrome (SS) With Moderate-to-Severe Symptom State",
    "phase": "PHASE3",
    "imp": "Dazodalibep, Placebo",
    "indications": "Sj\u00f6gren's Syndrome (SS)",
    "sample_size": "434",
    "enrollment_type": "A",
    "start_date_iso": "2024-04-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT05920356",
    "title": "A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)",
    "phase": "PHASE3",
    "imp": "Sotorasib, Pembrolizumab",
    "indications": "Non-Small Cell Lung Cancer (NSCLC)",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-06-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06117774",
    "title": "Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)",
    "phase": "PHASE3",
    "imp": "Tarlatamab, Placebo",
    "indications": "Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-05-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-05-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06211036",
    "title": "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab",
    "phase": "PHASE3",
    "imp": "Tarlatamab, Durvalumab",
    "indications": "Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer",
    "sample_size": "563",
    "enrollment_type": "A",
    "start_date_iso": "2024-06-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06691984",
    "title": "Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)",
    "phase": "PHASE3",
    "imp": "Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel",
    "indications": "Metastatic Castration-resistant Prostate Cancer",
    "sample_size": "675",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT07223190",
    "title": "A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia",
    "phase": "PHASE3",
    "imp": "Blinatumomab, Blinatumomab, HyperCVAD",
    "indications": "Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia",
    "sample_size": "560",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-30",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-03-30",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06054555",
    "title": "A Study to Evaluate ABP 206 Compared With OPDIVO\u00ae (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma",
    "phase": "PHASE3",
    "imp": "ABP 206, Nivolumab",
    "indications": "Melanoma",
    "sample_size": "633",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01-25",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT05740566",
    "title": "Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Tarlatamab, Lurbinectedin, Topotecan, Amrubicin",
    "indications": "Small Cell Lung Cancer (SCLC)",
    "sample_size": "509",
    "enrollment_type": "A",
    "start_date_iso": "2023-05-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-01-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-03-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06224192",
    "title": "A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis",
    "phase": "PHASE3",
    "imp": "Rocatinlimab Prefilled Syringe, Rocatinlimab AI",
    "indications": "Atopic Dermatitis",
    "sample_size": "151",
    "enrollment_type": "A",
    "start_date_iso": "2024-04-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-04-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06311721",
    "title": "A Study to Compare ABP 234 and Keytruda\u00ae (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "ABP 234, Pembrolizumab (US), Pembrolizumab (EU)",
    "indications": "Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer",
    "sample_size": "315",
    "enrollment_type": "A",
    "start_date_iso": "2024-09-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT07293260",
    "title": "Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial",
    "phase": "PHASE3",
    "imp": "Olpasiran, Placebo",
    "indications": "Cardiovascular Disease",
    "sample_size": "406",
    "enrollment_type": "E",
    "start_date_iso": "2026-03-21",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-06-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-02",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06430866",
    "title": "Pharmacokinetic Similarity Between ABP 234 and Keytruda\u00ae (Pembrolizumab)",
    "phase": "PHASE3",
    "imp": "ABP 234, Pembrolizumab",
    "indications": "Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)",
    "sample_size": "154",
    "enrollment_type": "E",
    "start_date_iso": "2024-09-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": false,
    "nct_id": "NCT06700343",
    "title": "Comparison Between ABP 692 and Ocrevus\u00ae (Ocrelizumab)",
    "phase": "PHASE3",
    "imp": "Ocrelizumab (US), Ocrelizumab (EU), ABP 692",
    "indications": "Relapsing-remitting Multiple Sclerosis (RRMS)",
    "sample_size": "444",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-17",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Amgen",
    "is_collaborator": true,
    "nct_id": "NCT04483739",
    "title": "Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)",
    "phase": "PHASE3",
    "imp": "Carfilzomib Lenalidomide Dexamethasone, Isatuximab Carfilzomib Lenalidomide Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "302",
    "enrollment_type": "A",
    "start_date_iso": "2020-09-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07184931",
    "title": "An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Duvakitug, Placebo",
    "indications": "Crohn's Disease",
    "sample_size": "980",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-05-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-05-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06975878",
    "title": "Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",
    "phase": "PHASE3",
    "imp": "PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine, M-M-RvaxPro vaccine, Varivax vaccine",
    "indications": "Pneumococcal Immunization, Healthy Volunteers",
    "sample_size": "1080",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06143891",
    "title": "A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.",
    "phase": "PHASE3",
    "imp": "Belumosudil, Placebo, Prednisone, Prednisolone",
    "indications": "Chronic Graft Versus Host Disease",
    "sample_size": "260",
    "enrollment_type": "E",
    "start_date_iso": "2024-01-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06687980",
    "title": "A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)",
    "phase": "PHASE3",
    "imp": "Dupilumab, Placebo",
    "indications": "Lichen Simplex Chronicus",
    "sample_size": "138",
    "enrollment_type": "A",
    "start_date_iso": "2024-11-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06824194",
    "title": "Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",
    "phase": "PHASE3",
    "imp": "PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix",
    "indications": "Pneumococcal Immunization",
    "sample_size": "2320",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT04936685",
    "title": "Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers",
    "phase": "PHASE3",
    "imp": "Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine",
    "indications": "Meningococcal Immunisation, Healthy Volunteers",
    "sample_size": "209",
    "enrollment_type": "A",
    "start_date_iso": "2022-08-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-03-09",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-12-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06141473",
    "title": "Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal",
    "indications": "Multiple Sclerosis",
    "sample_size": "1600",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07088068",
    "title": "A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes",
    "phase": "PHASE3",
    "imp": "Teplizumab, Placebo",
    "indications": "Type 1 Diabetes Mellitus",
    "sample_size": "723",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT03754790",
    "title": "Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX",
    "phase": "PHASE3",
    "imp": "Fitusiran",
    "indications": "Hemophilia",
    "sample_size": "281",
    "enrollment_type": "A",
    "start_date_iso": "2019-01-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-11-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07190196",
    "title": "A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease",
    "phase": "PHASE3",
    "imp": "Rilzabrutinib, Placebo, Glucocorticoid",
    "indications": "Immunoglobulin G4 Related Disease",
    "sample_size": "124",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07135986",
    "title": "Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China",
    "phase": "PHASE3",
    "imp": "MenACYW conjugate vaccine, MenACYW135 polysaccharide vaccine, MenAC conjugate vaccine",
    "indications": "Meningococcal Infection, Healthy Volunteers",
    "sample_size": "1602",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-11-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06687967",
    "title": "A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)",
    "phase": "PHASE3",
    "imp": "Dupilumab, Placebo",
    "indications": "Lichen Simplex Chronicus",
    "sample_size": "142",
    "enrollment_type": "A",
    "start_date_iso": "2024-11-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06407934",
    "title": "A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis",
    "phase": "PHASE3",
    "imp": "Amlitelimab, Placebo",
    "indications": "Dermatitis Atopic",
    "sample_size": "1541",
    "enrollment_type": "A",
    "start_date_iso": "2024-05-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06838000",
    "title": "Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents",
    "phase": "PHASE3",
    "imp": "PCV21, 20vPCV",
    "indications": "Pneumococcal Infections",
    "sample_size": "1268",
    "enrollment_type": "A",
    "start_date_iso": "2025-02-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT04154956",
    "title": "SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients",
    "phase": "PHASE3",
    "imp": "SAR408701, Docetaxel",
    "indications": "Non-small Cell Lung Cancer Metastatic",
    "sample_size": "389",
    "enrollment_type": "A",
    "start_date_iso": "2020-02-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-09-22",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT06216158",
    "title": "Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Iberdomide, Isatuximab, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "411",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT04751877",
    "title": "Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (\u2265 65; < 80 Years).",
    "phase": "PHASE3",
    "imp": "Isatuximab, Lenalidomide, Bortezomib, Dexamethasone",
    "indications": "Multiple Myeloma, Myeloma",
    "sample_size": "270",
    "enrollment_type": "A",
    "start_date_iso": "2021-07-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-04-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06736041",
    "title": "Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",
    "phase": "PHASE3",
    "imp": "PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine",
    "indications": "Pneumococcal Immunization",
    "sample_size": "1630",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-17",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT05804032",
    "title": "Lenalidomide, Bortezomib and Dexamethasone Induction Therapy with Either Intravenous or Subcutaneous Isatuximab in Patients with Newly Diagnosed Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Isatuximab, Isatuximab, Lenalidomide, Bortezomib, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "514",
    "enrollment_type": "E",
    "start_date_iso": "2023-04-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07-24",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07190222",
    "title": "Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype",
    "phase": "PHASE3",
    "imp": "Lunsekimig, Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease",
    "sample_size": "942",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-11-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01-22",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06082037",
    "title": "A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction",
    "phase": "PHASE3",
    "imp": "Belumosudil, Azithromycin, Placebo",
    "indications": "Lung Transplant Rejection",
    "sample_size": "180",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06805513",
    "title": "Actual Use Trial of Tadalafil 5 mg",
    "phase": "PHASE3",
    "imp": "Tadalafil 5 mg tablets with a digital tool.",
    "indications": "Erectile Dysfunction",
    "sample_size": "2250",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-02-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT04644575",
    "title": "Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A",
    "phase": "PHASE3",
    "imp": "efanesoctocog alfa (BIVV001)",
    "indications": "Hemophilia A",
    "sample_size": "261",
    "enrollment_type": "A",
    "start_date_iso": "2021-02-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT05280548",
    "title": "A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease",
    "phase": "PHASE3",
    "imp": "Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828), Migalastat",
    "indications": "Fabry Disease",
    "sample_size": "104",
    "enrollment_type": "A",
    "start_date_iso": "2022-05-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07348692",
    "title": "Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age",
    "phase": "PHASE3",
    "imp": "PCV21 vaccine, 20vPCV licensed vaccine, Vaxelis Vaccine, Rotavirus vaccine, Measles Mumps and Rubella Vaccine, Varivax vaccine, Hepatitis A Vaccine",
    "indications": "Pneumococcal Immunization, Healthy Volunteers",
    "sample_size": "896",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01-19",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT04934475",
    "title": "MInimal Residual Disease Adapted Strategy",
    "phase": "PHASE3",
    "imp": "Isatuximab, ASCT",
    "indications": "Multiple Myeloma",
    "sample_size": "791",
    "enrollment_type": "A",
    "start_date_iso": "2021-12-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-09-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06208306",
    "title": "A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD",
    "phase": "PHASE3",
    "imp": "Itepekimab (SAR440340), Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2024-01-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT01957436",
    "title": "A Phase III Study for Patients With Metastatic Hormone-na\u00efve Prostate Cancer",
    "phase": "PHASE3",
    "imp": "abiraterone acetate, radiotherapy, Androgen Deprivation Therapy, Docetaxel",
    "indications": "Metastatic Prostate Cancer",
    "sample_size": "1173",
    "enrollment_type": "A",
    "start_date_iso": "2013-11-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-08-18",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2032-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT01952223",
    "title": "A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse",
    "phase": "PHASE3",
    "imp": "Cabazitaxel, Pelvic radiotherapy, prostate radiotherapy",
    "indications": "Adenocarcinoma of Prostate, Progression of Prostate Cancer",
    "sample_size": "761",
    "enrollment_type": "A",
    "start_date_iso": "2013-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2041-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07103148",
    "title": "A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population",
    "phase": "PHASE3",
    "imp": "Yellow fever vaccine (live), Yellow fever vaccine (live), Yellow fever vaccine (live), Measles, combinations with mumps and rubella, live attenuated",
    "indications": "Yellow Fever Immunization",
    "sample_size": "2440",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06252285",
    "title": "Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers",
    "phase": "PHASE3",
    "imp": "RSVt Vaccine, Placebo",
    "indications": "RSV Immunisation",
    "sample_size": "6300",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06241118",
    "title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor",
    "phase": "PHASE3",
    "imp": "Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus",
    "indications": "Dermatitis Atopic",
    "sample_size": "390",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT06081894",
    "title": "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM",
    "phase": "PHASE3",
    "imp": "Aficamten, Placebo",
    "indications": "Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2023-08-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT04562766",
    "title": "Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)",
    "phase": "PHASE3",
    "imp": "Rilzabrutinib, Placebo",
    "indications": "Immune Thrombocytopenia",
    "sample_size": "232",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-01-15",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-08-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07247188",
    "title": "Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease",
    "phase": "PHASE3",
    "imp": "PCV21, 20vPCV",
    "indications": "Sickle Cell Disease",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06290141",
    "title": "A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
    "phase": "PHASE3",
    "imp": "riliprubart, Placebo, riliprubart, Placebo, IVIg, Placebo",
    "indications": "Chronic Inflammatory Demyelinating Polyneuropathy",
    "sample_size": "160",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-01-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06181435",
    "title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)",
    "phase": "PHASE3",
    "imp": "Amlitelimab, Placebo",
    "indications": "Dermatitis Atopic",
    "sample_size": "589",
    "enrollment_type": "A",
    "start_date_iso": "2023-12-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-25",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-18",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT05492578",
    "title": "Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials",
    "phase": "PHASE3",
    "imp": "Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors, Oral corticosteroids",
    "indications": "Dermatitis Atopic",
    "sample_size": "1663",
    "enrollment_type": "E",
    "start_date_iso": "2022-08-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-01-22",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT03319667",
    "title": "A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant",
    "phase": "PHASE3",
    "imp": "Isatuximab SAR650984, Bortezomib, Lenalidomide, Dexamethasone",
    "indications": "Plasma Cell Myeloma",
    "sample_size": "475",
    "enrollment_type": "A",
    "start_date_iso": "2017-12-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06141486",
    "title": "Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Frexalimab, Placebo, MRI contrast-enhancing agents",
    "indications": "Multiple Sclerosis",
    "sample_size": "900",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT05405166",
    "title": "SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM",
    "phase": "PHASE3",
    "imp": "Isatuximab IV, Isatuximab SC, Dexamethasone, Pomalidomide, Dexamethasone, Montelukast, Paracetamol / Acetaminophen, Diphenhydramine, Methylprednisolone",
    "indications": "Plasma Cell Myeloma Recurrent",
    "sample_size": "531",
    "enrollment_type": "A",
    "start_date_iso": "2022-06-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-11-06",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-03-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07184996",
    "title": "An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Duvakitug, Placebo",
    "indications": "Ulcerative Colitis",
    "sample_size": "980",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-05-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT05263206",
    "title": "Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)",
    "phase": "PHASE3",
    "imp": "Dupilumab, Placebo, Fexofenadine (loratadine if not available)",
    "indications": "Pruritus",
    "sample_size": "284",
    "enrollment_type": "E",
    "start_date_iso": "2022-02-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07184944",
    "title": "A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Duvakitug, Placebo",
    "indications": "Crohn's Disease",
    "sample_size": "671",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-29",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-08-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-03-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07190209",
    "title": "Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype",
    "phase": "PHASE3",
    "imp": "Lunsekimig, Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease",
    "sample_size": "942",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-11-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01-22",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06705140",
    "title": "A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers",
    "phase": "PHASE3",
    "imp": "Low Dose (LD) RSVt vaccine, Standard Dose (SD) RSVt vaccine, High Dose (HD) RSVt vaccine, Placebo",
    "indications": "RSV Immunisation",
    "sample_size": "947",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-04-17",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT04270409",
    "title": "Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent",
    "indications": "Plasma Cell Myeloma",
    "sample_size": "337",
    "enrollment_type": "A",
    "start_date_iso": "2020-06-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-10-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-10-21",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06834360",
    "title": "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps",
    "phase": "PHASE3",
    "imp": "Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)",
    "indications": "Chronic Rhinosinusitis With Nasal Polyps",
    "sample_size": "210",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT05206773",
    "title": "A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants \u226516 Years of Age With Fabry Disease",
    "phase": "PHASE3",
    "imp": "Venglustat (GZ402671), Placebo",
    "indications": "Fabry Disease",
    "sample_size": "122",
    "enrollment_type": "A",
    "start_date_iso": "2022-03-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT05558319",
    "title": "NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide",
    "phase": "PHASE3",
    "imp": "Bortezomib, Isatuximab, Iberdomide, Lenalidomide, Dexamethasone",
    "indications": "Newly Diagnosed Multiple Myeloma",
    "sample_size": "480",
    "enrollment_type": "E",
    "start_date_iso": "2022-10",
    "start_date_type": "E",
    "primary_completion_date_iso": "2027-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06859099",
    "title": "Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP",
    "phase": "PHASE3",
    "imp": "Riliprubart Prefilled Pen (PFP)",
    "indications": "Polyneuropathy, Inflammatory Demyelinating, Chronic",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10-03",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06834347",
    "title": "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps",
    "phase": "PHASE3",
    "imp": "Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)",
    "indications": "Chronic Rhinosinusitis With Nasal Polyps",
    "sample_size": "210",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT02612454",
    "title": "Study to Assess the Long-term Safety of Dupilumab Administered in Participants \u22656 Months to <18 Years of Age With Atopic Dermatitis (AD)",
    "phase": "PHASE3",
    "imp": "Dupilumab",
    "indications": "Atopic Dermatitis",
    "sample_size": "880",
    "enrollment_type": "A",
    "start_date_iso": "2015-10-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06290128",
    "title": "A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work",
    "phase": "PHASE3",
    "imp": "Riliprubart, Placebo, Riliprubart, Placebo",
    "indications": "Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic",
    "sample_size": "140",
    "enrollment_type": "E",
    "start_date_iso": "2024-07-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06824181",
    "title": "Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",
    "phase": "PHASE3",
    "imp": "PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix",
    "indications": "Pneumococcal Immunization",
    "sample_size": "580",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07185009",
    "title": "A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Duvakitug, Placebo",
    "indications": "Ulcerative Colitis",
    "sample_size": "671",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-04-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06975865",
    "title": "The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease",
    "phase": "PHASE3",
    "imp": "Rilzabrutinib, Placebo",
    "indications": "Sickle Cell Disease",
    "sample_size": "192",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT07325292",
    "title": "Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis",
    "phase": "PHASE3",
    "imp": "Frexalimab, Frexalimab, MRI contrast-enhancing preparations",
    "indications": "Multiple Sclerosis",
    "sample_size": "160",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2027-07-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11-30",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": false,
    "nct_id": "NCT06372145",
    "title": "A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.",
    "phase": "PHASE3",
    "imp": "Tolebrutinib, Placebo, Teriflunomide",
    "indications": "Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis",
    "sample_size": "2500",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-04-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT04483739",
    "title": "Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)",
    "phase": "PHASE3",
    "imp": "Carfilzomib Lenalidomide Dexamethasone, Isatuximab Carfilzomib Lenalidomide Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "302",
    "enrollment_type": "A",
    "start_date_iso": "2020-09-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Sanofi",
    "is_collaborator": true,
    "nct_id": "NCT07309614",
    "title": "A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma",
    "phase": "PHASE3",
    "imp": "Dupilumab Prefilled Syringe, Placebo Injection",
    "indications": "Asthma Control",
    "sample_size": "150",
    "enrollment_type": "E",
    "start_date_iso": "2026-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": true,
    "nct_id": "NCT05338190",
    "title": "Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia",
    "phase": "PHASE3",
    "imp": "Combination of Rituximab with subcutaneous belimumab, Combination of Rituximab with subcutaneous placebo",
    "indications": "Primary Immune Thrombocytopenia (ITP)",
    "sample_size": "132",
    "enrollment_type": "E",
    "start_date_iso": "2022-11-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-11-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": true,
    "nct_id": "NCT06134362",
    "title": "Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)",
    "phase": "PHASE3",
    "imp": "CAB LA",
    "indications": "HIV Infections",
    "sample_size": "3508",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-01-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT04246047",
    "title": "Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Belantamab mafodotin, Daratumumab, Bortezomib, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "494",
    "enrollment_type": "A",
    "start_date_iso": "2020-05-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-10-02",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT05600777",
    "title": "A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough",
    "phase": "PHASE3",
    "imp": "BLU-5937, Placebo",
    "indications": "Cough, Refractory Chronic Cough",
    "sample_size": "975",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT04162210",
    "title": "Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)",
    "phase": "PHASE3",
    "imp": "Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone)",
    "indications": "Multiple Myeloma",
    "sample_size": "325",
    "enrollment_type": "A",
    "start_date_iso": "2020-04-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-09-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-07-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06256588",
    "title": "A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma",
    "phase": "PHASE3",
    "imp": "Dostarlimab, Placebo",
    "indications": "Neoplasms, Head and Neck",
    "sample_size": "864",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT07286266",
    "title": "A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)",
    "phase": "PHASE3",
    "imp": "GSK5733584, Paclitaxel, Pegylated liposomal doxorubicin (PLD), Topotecan, Gemcitabine",
    "indications": "Ovarian Neoplasms",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2026-03-03",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-01-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01-16",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT05757102",
    "title": "A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma",
    "phase": "PHASE3",
    "imp": "FF/UMEC/VI, ELLIPTA, FF/VI",
    "indications": "Asthma",
    "sample_size": "292",
    "enrollment_type": "E",
    "start_date_iso": "2023-04-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT04475939",
    "title": "Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Niraparib, Pembrolizumab, Placebo",
    "indications": "Lung Cancer, Non-Small Cell",
    "sample_size": "666",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-02-26",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT07099898",
    "title": "A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)",
    "phase": "PHASE3",
    "imp": "GSK5764227, Topotecan",
    "indications": "Neoplasms, Lung",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06961214",
    "title": "Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)",
    "phase": "PHASE3",
    "imp": "Depemokimab, Placebo",
    "indications": "Pulmonary Disease, Chronic Obstructive",
    "sample_size": "960",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-08-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-21",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT05878717",
    "title": "A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease",
    "phase": "PHASE3",
    "imp": "Belimumab, Placebo",
    "indications": "Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2023-09-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-05-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT05263934",
    "title": "Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)",
    "phase": "PHASE3",
    "imp": "Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab",
    "indications": "Eosinophilic Granulomatosis With Polyangiitis",
    "sample_size": "163",
    "enrollment_type": "A",
    "start_date_iso": "2022-07-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT04167358",
    "title": "Linerixibat Long-term Safety, and Tolerability Study",
    "phase": "PHASE3",
    "imp": "Linerixibat",
    "indications": "Cholestasis",
    "sample_size": "245",
    "enrollment_type": "A",
    "start_date_iso": "2020-07-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": true,
    "nct_id": "NCT02951052",
    "title": "Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults",
    "phase": "PHASE3",
    "imp": "Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI",
    "indications": "Infection, Human Immunodeficiency Virus, HIV Infections",
    "sample_size": "618",
    "enrollment_type": "A",
    "start_date_iso": "2016-10-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2018-05-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06855160",
    "title": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age",
    "phase": "PHASE3",
    "imp": "Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance",
    "indications": "Chickenpox",
    "sample_size": "900",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT05630820",
    "title": "Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)",
    "phase": "PHASE3",
    "imp": "Bepirovirsen, Placebo",
    "indications": "Chronic Hepatitis B, Hepatitis B, Chronic",
    "sample_size": "857",
    "enrollment_type": "A",
    "start_date_iso": "2022-12-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-03",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-04-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06572384",
    "title": "A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease",
    "phase": "PHASE3",
    "imp": "Belimumab, Placebo",
    "indications": "Lung Diseases, Interstitial",
    "sample_size": "440",
    "enrollment_type": "E",
    "start_date_iso": "2024-09-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-10-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": true,
    "nct_id": "NCT05659381",
    "title": "Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer",
    "phase": "PHASE3",
    "imp": "Cisplatin, No treatment",
    "indications": "Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer",
    "sample_size": "220",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-08-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-08-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": true,
    "nct_id": "NCT06388733",
    "title": "A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma",
    "phase": "PHASE3",
    "imp": "Niraparib, Temozolomide",
    "indications": "Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT05334368",
    "title": "Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial",
    "phase": "PHASE3",
    "imp": "Depemokimab, Placebo",
    "indications": "Hypereosinophilic Syndrome",
    "sample_size": "123",
    "enrollment_type": "E",
    "start_date_iso": "2022-09-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-19",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT05599191",
    "title": "A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough",
    "phase": "PHASE3",
    "imp": "BLU-5937, Placebo",
    "indications": "Cough, Refractory Chronic Cough",
    "sample_size": "825",
    "enrollment_type": "E",
    "start_date_iso": "2022-10-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT07221188",
    "title": "A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH",
    "phase": "PHASE3",
    "imp": "Efimosfermin Alfa, Placebo",
    "indications": "Non-alcoholic Fatty Liver Disease",
    "sample_size": "1250",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT04655976",
    "title": "Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy",
    "phase": "PHASE3",
    "imp": "Cobolimab, Dostarlimab, Docetaxel",
    "indications": "Lung Cancer, Non-Small Cell",
    "sample_size": "758",
    "enrollment_type": "A",
    "start_date_iso": "2020-12-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-05",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-03-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06693895",
    "title": "A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age",
    "phase": "PHASE3",
    "imp": "Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance",
    "indications": "Chickenpox",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-11-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06534892",
    "title": "An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study",
    "phase": "PHASE3",
    "imp": "RSVPreF3 OA vaccine",
    "indications": "Respiratory Syncytial Virus Infections",
    "sample_size": "10212",
    "enrollment_type": "A",
    "start_date_iso": "2024-08-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT05371080",
    "title": "A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults",
    "phase": "PHASE3",
    "imp": "HZ/su vaccine",
    "indications": "Herpes Zoster",
    "sample_size": "3038",
    "enrollment_type": "E",
    "start_date_iso": "2022-08-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT04484623",
    "title": "Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib",
    "indications": "Multiple Myeloma",
    "sample_size": "302",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-10-25",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06740630",
    "title": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age",
    "phase": "PHASE3",
    "imp": "Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance",
    "indications": "Chickenpox",
    "sample_size": "1840",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT04732871",
    "title": "Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above",
    "phase": "PHASE3",
    "imp": "RSVPreF3 OA investigational vaccine",
    "indications": "Respiratory Syncytial Virus Infections",
    "sample_size": "1720",
    "enrollment_type": "A",
    "start_date_iso": "2021-02-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-06-06",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-02-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06716606",
    "title": "A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)",
    "phase": "PHASE3",
    "imp": "Belimumab",
    "indications": "Connective Tissue Diseases",
    "sample_size": "514",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT07218926",
    "title": "A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy",
    "phase": "PHASE3",
    "imp": "IDRX-42, Sunitinib",
    "indications": "Gastrointestinal Neoplasms",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-11-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06959095",
    "title": "Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)",
    "phase": "PHASE3",
    "imp": "Depemokimab, Placebo",
    "indications": "Pulmonary Disease, Chronic Obstructive",
    "sample_size": "981",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-08-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": true,
    "nct_id": "NCT05917509",
    "title": "A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy",
    "phase": "PHASE3",
    "imp": "DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA",
    "indications": "HIV Infections",
    "sample_size": "171",
    "enrollment_type": "A",
    "start_date_iso": "2023-07-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-16",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-04-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06666491",
    "title": "An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older",
    "phase": "PHASE3",
    "imp": "Tafenoquine, Primaquine, Chloroquine",
    "indications": "Malaria, Vivax",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT05630807",
    "title": "Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)",
    "phase": "PHASE3",
    "imp": "Bepirovirsen, Placebo",
    "indications": "Chronic Hepatitis B, Hepatitis B, Chronic",
    "sample_size": "981",
    "enrollment_type": "A",
    "start_date_iso": "2022-12-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-05-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": true,
    "nct_id": "NCT05201547",
    "title": "Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line",
    "phase": "PHASE3",
    "imp": "Carboplatin-Paclitaxel, Dostarlimab",
    "indications": "Endometrial Cancer",
    "sample_size": "260",
    "enrollment_type": "E",
    "start_date_iso": "2022-04-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06679101",
    "title": "A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)",
    "phase": "PHASE3",
    "imp": "Belantamab mafodotin, Lenalidomide, Dexamethasone, Daratumumab",
    "indications": "Multiple Myeloma, Newly Diagnosed Multiple Myeloma",
    "sample_size": "520",
    "enrollment_type": "E",
    "start_date_iso": "2024-12-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-03-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06806137",
    "title": "A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age",
    "phase": "PHASE3",
    "imp": "Investigational varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance",
    "indications": "Chickenpox",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT07286331",
    "title": "A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)",
    "phase": "PHASE3",
    "imp": "GSK5733584, Paclitaxel, Doxorubicin",
    "indications": "Neoplasms, Endometrial",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2026-03-05",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-01-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03-02",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT07221227",
    "title": "A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH",
    "phase": "PHASE3",
    "imp": "Efimosfermin alfa, Efimosfermin alfa, Placebo",
    "indications": "Non-alcoholic Fatty Liver Disease",
    "sample_size": "1200",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-12-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": true,
    "nct_id": "NCT07285239",
    "title": "Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib, Lenalidomide, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2026-05",
    "start_date_type": "E",
    "primary_completion_date_iso": "2031-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-04",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT05855200",
    "title": "Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer",
    "phase": "PHASE3",
    "imp": "Dostarlimab, CAPEOX, FOLFOX",
    "indications": "Colonic Neoplasms, Neoplasms, Colon",
    "sample_size": "892",
    "enrollment_type": "E",
    "start_date_iso": "2023-08-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-03-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT06979323",
    "title": "Depemokimab Asthma Imaging and Bronchoscopy Sub-Study",
    "phase": "PHASE3",
    "imp": "Depemokimab",
    "indications": "Asthma",
    "sample_size": "150",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT07177339",
    "title": "eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation",
    "phase": "PHASE3",
    "imp": "Depemokimab, Placebo",
    "indications": "Pulmonary Disease, Chronic Obstructive",
    "sample_size": "1196",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-11-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "GSK",
    "is_collaborator": false,
    "nct_id": "NCT07220109",
    "title": "A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease",
    "phase": "PHASE3",
    "imp": "RSVPreF3 OA vaccine, Placebo",
    "indications": "Respiratory Syncytial Virus Infections",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06646276",
    "title": "A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).",
    "phase": "PHASE3",
    "imp": "BMS-986489 (BMS-986012+Nivolumab), Atezolizumab, Carboplatin, Etoposide",
    "indications": "Extensive-Stage Small Cell Lung Cancer",
    "sample_size": "530",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-09-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT05076175",
    "title": "A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Ozanimod",
    "indications": "Colitis, Ulcerative",
    "sample_size": "120",
    "enrollment_type": "E",
    "start_date_iso": "2022-05-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-08-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06947941",
    "title": "A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)",
    "phase": "PHASE3",
    "imp": "KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo",
    "indications": "Alzheimer Disease, Psychosis",
    "sample_size": "1046",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-31",
    "start_date_type": "E",
    "primary_completion_date_iso": "2027-09-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10-25",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT05617677",
    "title": "A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)",
    "phase": "PHASE3",
    "imp": "Deucravacitinib, Placebo",
    "indications": "Systemic Lupus Erythematosus",
    "sample_size": "516",
    "enrollment_type": "A",
    "start_date_iso": "2023-01-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT05754957",
    "title": "A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome",
    "phase": "PHASE3",
    "imp": "Milvexian, Placebo",
    "indications": "Acute Coronary Syndrome",
    "sample_size": "14194",
    "enrollment_type": "A",
    "start_date_iso": "2023-04-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07011732",
    "title": "A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)",
    "phase": "PHASE3",
    "imp": "Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo",
    "indications": "Alzheimer Disease",
    "sample_size": "352",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06140836",
    "title": "A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na\u00efve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)",
    "phase": "PHASE3",
    "imp": "Repotrectinib, Crizotinib",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "190",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT05757869",
    "title": "A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation",
    "phase": "PHASE3",
    "imp": "Milvexian, Apixaban, Placebo, Apixaban Placebo",
    "indications": "Atrial Fibrillation",
    "sample_size": "20283",
    "enrollment_type": "A",
    "start_date_iso": "2023-04-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT06712355",
    "title": "Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated)",
    "indications": "Extensive-stage Small-cell Lung Cancer",
    "sample_size": "621",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07284745",
    "title": "A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism",
    "phase": "PHASE3",
    "imp": "KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo",
    "indications": "Irritability Associated With Autism Spectrum Disorder",
    "sample_size": "176",
    "enrollment_type": "E",
    "start_date_iso": "2026-02-27",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-07-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-05",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04810078",
    "title": "A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread",
    "phase": "PHASE3",
    "imp": "Nivolumab and rHuPH20, Nivolumab",
    "indications": "Clear Cell Renal Cell Carcinoma",
    "sample_size": "681",
    "enrollment_type": "A",
    "start_date_iso": "2021-05-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-05-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT04879368",
    "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC",
    "phase": "PHASE3",
    "imp": "Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil",
    "indications": "Gastro-Oesophageal Cancer",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2021-06-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-09",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07106762",
    "title": "Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy",
    "phase": "PHASE3",
    "imp": "Iza-bren, Cisplatin, Gemcitabine, Carboplatin",
    "indications": "Urothelial Cancer",
    "sample_size": "470",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-11-18",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT07173751",
    "title": "ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer",
    "phase": "PHASE3",
    "imp": "Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo",
    "indications": "Breast Neoplasms",
    "sample_size": "558",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT05827016",
    "title": "A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Iberdomide, Lenalidomide",
    "indications": "Multiple Myeloma",
    "sample_size": "1216",
    "enrollment_type": "E",
    "start_date_iso": "2023-06-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2036-01-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT06216158",
    "title": "Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Iberdomide, Isatuximab, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "411",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06951711",
    "title": "A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)",
    "phase": "PHASE3",
    "imp": "KarXT, Placebo",
    "indications": "Bipolar Disorder Type I With Mania or Mania With Mixed Features",
    "sample_size": "274",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-11-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT05662241",
    "title": "A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease",
    "phase": "PHASE3",
    "imp": "Obexelimab, Placebo",
    "indications": "IgG4 Related Disease",
    "sample_size": "194",
    "enrollment_type": "A",
    "start_date_iso": "2022-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT03522246",
    "title": "A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy",
    "phase": "PHASE3",
    "imp": "Rucaparib, Nivolumab, Placebo Oral Tablet, Placebo IV Infusion",
    "indications": "Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response",
    "sample_size": "1097",
    "enrollment_type": "A",
    "start_date_iso": "2018-05-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-20",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2030-12-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT05946941",
    "title": "A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sj\u00f6gren's Syndrome",
    "phase": "PHASE3",
    "imp": "Deucravacitinib, Placebo",
    "indications": "Sj\u00f6gren's Syndrome",
    "sample_size": "756",
    "enrollment_type": "E",
    "start_date_iso": "2023-09-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04099251",
    "title": "Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma",
    "phase": "PHASE3",
    "imp": "Nivolumab, Placebo",
    "indications": "Melanoma",
    "sample_size": "790",
    "enrollment_type": "A",
    "start_date_iso": "2019-10-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-06-28",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-06-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04772079",
    "title": "A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis",
    "phase": "PHASE3",
    "imp": "Deucravacitinib, Placebo matching deucravacitinib",
    "indications": "Plaque Psoriasis",
    "sample_size": "153",
    "enrollment_type": "E",
    "start_date_iso": "2021-03-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-09-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06615479",
    "title": "A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)",
    "phase": "PHASE3",
    "imp": "BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib",
    "indications": "Relapsed or Refractory Multiple Myeloma (RRMM)",
    "sample_size": "440",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-06-22",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04039607",
    "title": "A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma",
    "phase": "PHASE3",
    "imp": "Nivolumab, Ipilimumab, Sorafenib, lenvatinib",
    "indications": "Hepatocellular Carcinoma",
    "sample_size": "732",
    "enrollment_type": "A",
    "start_date_iso": "2019-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07221357",
    "title": "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer",
    "phase": "PHASE3",
    "imp": "Pumitamig, FOLFOX, FOLFIRI, Bevacizumab, CAPOX",
    "indications": "Untreated, Unresectable, or Metastatic Colorectal Cancer",
    "sample_size": "990",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-02-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-03-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT05335928",
    "title": "Abatacept in Immune Checkpoint Inhibitor Myocarditis",
    "phase": "PHASE3",
    "imp": "Abatacept plus, Placebo",
    "indications": "Myocarditis Acute, Cancer",
    "sample_size": "390",
    "enrollment_type": "E",
    "start_date_iso": "2022-07-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-04-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07285798",
    "title": "A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder",
    "phase": "PHASE3",
    "imp": "KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo",
    "indications": "Irritability Associated With Autism Spectrum Disorder",
    "sample_size": "176",
    "enrollment_type": "E",
    "start_date_iso": "2026-02-27",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-08-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-04",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07076121",
    "title": "A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)",
    "phase": "PHASE3",
    "imp": "BMS-986504, Gemcitabine, Nab-paclitaxel, Placebo",
    "indications": "Pancreatic Ductal Adenocarcinoma",
    "sample_size": "470",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-05-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-05-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06976216",
    "title": "A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease",
    "phase": "PHASE3",
    "imp": "KarXT, KarX-EC, Placebo",
    "indications": "Alzheimer's Disease",
    "sample_size": "586",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT05552976",
    "title": "A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)",
    "phase": "PHASE3",
    "imp": "Mezigdomide, Carfilzomib, Dexamethasone",
    "indications": "Relapsed or Refractory Multiple Myeloma",
    "sample_size": "525",
    "enrollment_type": "E",
    "start_date_iso": "2023-01-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07361497",
    "title": "A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)",
    "phase": "PHASE3",
    "imp": "Pumitamig, Durvalumab",
    "indications": "Non-small Cell Lung Cancer (NSCLC)",
    "sample_size": "850",
    "enrollment_type": "E",
    "start_date_iso": "2026-04-09",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-09-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-12-31",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT04934475",
    "title": "MInimal Residual Disease Adapted Strategy",
    "phase": "PHASE3",
    "imp": "Isatuximab, ASCT",
    "indications": "Multiple Myeloma",
    "sample_size": "791",
    "enrollment_type": "A",
    "start_date_iso": "2021-12-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-09-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-09-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04909801",
    "title": "A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate",
    "phase": "PHASE3",
    "imp": "Abatacept, Adalimumab, Methotrexate",
    "indications": "Rheumatoid Arthritis",
    "sample_size": "338",
    "enrollment_type": "A",
    "start_date_iso": "2021-09-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-06-14",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-09-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07063745",
    "title": "A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion",
    "phase": "PHASE3",
    "imp": "BMS-986504, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel",
    "indications": "Metastatic Non-small Cell Lung Cancer With MTAP Deletion",
    "sample_size": "590",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-08-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-08-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07100080",
    "title": "Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)",
    "phase": "PHASE3",
    "imp": "Iza-bren, Carboplatin, Cisplatin, Pemetrexed",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "596",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-05-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04877288",
    "title": "A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications",
    "phase": "PHASE3",
    "imp": "Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids",
    "indications": "Renal Allograft Recipients",
    "sample_size": "102",
    "enrollment_type": "E",
    "start_date_iso": "2021-07-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-12-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-06-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT05949684",
    "title": "ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions",
    "phase": "PHASE3",
    "imp": "Luspatercept, Epoetin Alfa",
    "indications": "Myelodysplastic Syndromes",
    "sample_size": "360",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03-11",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06045689",
    "title": "A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants",
    "phase": "PHASE3",
    "imp": "Luspatercept",
    "indications": "Myelodysplastic Syndromes",
    "sample_size": "106",
    "enrollment_type": "A",
    "start_date_iso": "2023-10-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-10-01",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-12-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07140913",
    "title": "A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine",
    "phase": "PHASE3",
    "imp": "Xanomeline/Trospium Chloride, Lithium, Valproate, Lamotrigine, Placebo",
    "indications": "Mania, Bipolar Disorder",
    "sample_size": "424",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT04674683",
    "title": "Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma",
    "phase": "PHASE3",
    "imp": "HBI-8000 in combination with nivolumab, Placebo in combination with nivolumab",
    "indications": "Unresectable or Metastatic Melanoma, Progressive Brain Metastasis",
    "sample_size": "450",
    "enrollment_type": "A",
    "start_date_iso": "2021-08-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04008030",
    "title": "A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)",
    "phase": "PHASE3",
    "imp": "Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab",
    "indications": "Metastatic Colorectal Cancer",
    "sample_size": "839",
    "enrollment_type": "A",
    "start_date_iso": "2019-08-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-08-28",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07221149",
    "title": "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)",
    "phase": "PHASE3",
    "imp": "Pumitamig, Folfox, Capox, Nivolumab",
    "indications": "Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma",
    "sample_size": "690",
    "enrollment_type": "E",
    "start_date_iso": "2026-03-09",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-11-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-09-11",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06003426",
    "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis",
    "phase": "PHASE3",
    "imp": "BMS-986278, BMS-986278 Placebo",
    "indications": "Idiopathic Pulmonary Fibrosis",
    "sample_size": "1255",
    "enrollment_type": "A",
    "start_date_iso": "2023-09-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06937229",
    "title": "A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)",
    "phase": "PHASE3",
    "imp": "KarXT, KarX-EC",
    "indications": "Alzheimer Disease, Agitation",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-06-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-20",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04036435",
    "title": "Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis",
    "phase": "PHASE3",
    "imp": "BMS-986165, Placebo",
    "indications": "Psoriasis",
    "sample_size": "1466",
    "enrollment_type": "A",
    "start_date_iso": "2019-08-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06313996",
    "title": "A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma",
    "phase": "PHASE3",
    "imp": "Cyclophosphamide, Doxorubicin, Vincristine, Rituximab, Prednisone, Bendamustine, Lenalidomide, Fludarabine, Liso-cel",
    "indications": "Relapsed or Refractory Follicular Lymphoma",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2024-03-29",
    "start_date_type": "E",
    "primary_completion_date_iso": "2031-10-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-10-16",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06882785",
    "title": "A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia",
    "phase": "PHASE3",
    "imp": "KarXT, Placebo",
    "indications": "Schizophrenia",
    "sample_size": "250",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07361510",
    "title": "A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 \u2265 50%. (ROSETTA Lung-202)",
    "phase": "PHASE3",
    "imp": "Pumitamig, Pembrolizumab",
    "indications": "Non-Small Cell Lung Cancer (NSCLC)",
    "sample_size": "750",
    "enrollment_type": "E",
    "start_date_iso": "2026-04-09",
    "start_date_type": "E",
    "primary_completion_date_iso": "2031-10-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-10-14",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT03383458",
    "title": "A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation",
    "phase": "PHASE3",
    "imp": "Nivolumab, Placebo",
    "indications": "Hepatocellular Carcinoma, Liver Cancer",
    "sample_size": "545",
    "enrollment_type": "A",
    "start_date_iso": "2018-04-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-02-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04025879",
    "title": "A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Nivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, Docetaxel",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "461",
    "enrollment_type": "A",
    "start_date_iso": "2019-11-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2023-07-26",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-07-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT03661320",
    "title": "A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer",
    "phase": "PHASE3",
    "imp": "Nivolumab, Gemcitabine, Cisplatin",
    "indications": "Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer",
    "sample_size": "855",
    "enrollment_type": "A",
    "start_date_iso": "2018-11-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-11-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT05620407",
    "title": "A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus",
    "phase": "PHASE3",
    "imp": "Deucravacitinib, Placebo",
    "indications": "Systemic Lupus Erythematosus",
    "sample_size": "513",
    "enrollment_type": "A",
    "start_date_iso": "2023-01-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11-13",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06025578",
    "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis",
    "phase": "PHASE3",
    "imp": "BMS-986278, BMS-986278 Placebo",
    "indications": "Progressive Pulmonary Fibrosis",
    "sample_size": "1092",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-27",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07288567",
    "title": "A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents",
    "phase": "PHASE3",
    "imp": "KarXT, KarXT Matching Placebo",
    "indications": "Schizophrenia",
    "sample_size": "166",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-27",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-12-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-18",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT03036098",
    "title": "Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer",
    "phase": "PHASE3",
    "imp": "Nivolumab, Ipilimumab, Gemcitabine, Cisplatin, Carboplatin",
    "indications": "Urothelial Cancer",
    "sample_size": "1314",
    "enrollment_type": "A",
    "start_date_iso": "2017-03-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-08-30",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-02-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06926868",
    "title": "A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)",
    "phase": "PHASE3",
    "imp": "Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin, Gemcitabine",
    "indications": "Breast Neoplasms",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-05-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06929273",
    "title": "A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)",
    "phase": "PHASE3",
    "imp": "KarXT, Lithium, Valproate, Lamotrigine",
    "indications": "Bipolar Disorder Type I With Mania",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-13",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT05469737",
    "title": "A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)",
    "phase": "PHASE3",
    "imp": "Oral Azacitidine, Placebo for Oral Azacitidine",
    "indications": "Myelodysplastic Syndromes",
    "sample_size": "230",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-01-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06979453",
    "title": "A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis",
    "phase": "PHASE3",
    "imp": "Deucravacitinib, Placebo",
    "indications": "Plaque Psoriasis",
    "sample_size": "366",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-08-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT03470922",
    "title": "A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma",
    "phase": "PHASE3",
    "imp": "Relatlimab, Nivolumab",
    "indications": "Melanoma",
    "sample_size": "714",
    "enrollment_type": "A",
    "start_date_iso": "2018-04-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-01-25",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2030-12-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT05558319",
    "title": "NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide",
    "phase": "PHASE3",
    "imp": "Bortezomib, Isatuximab, Iberdomide, Lenalidomide, Dexamethasone",
    "indications": "Newly Diagnosed Multiple Myeloma",
    "sample_size": "480",
    "enrollment_type": "E",
    "start_date_iso": "2022-10",
    "start_date_type": "E",
    "primary_completion_date_iso": "2027-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07116967",
    "title": "Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)",
    "phase": "PHASE3",
    "imp": "Deucravacitinib, Ustekinumab",
    "indications": "Plaque Psoriasis",
    "sample_size": "3040",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-01-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-01-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06561386",
    "title": "A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression \u2265 1%",
    "phase": "PHASE3",
    "imp": "Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-07-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-08-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06951698",
    "title": "A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder",
    "phase": "PHASE3",
    "imp": "KarXT, Placebo",
    "indications": "Bipolar-I Disorder With Mania or Mania With Mixed Features",
    "sample_size": "274",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-11-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT03873402",
    "title": "A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer",
    "phase": "PHASE3",
    "imp": "Nivolumab, Ipilimumab, Ipilimumab placebo",
    "indications": "Renal Cell Carcinoma",
    "sample_size": "437",
    "enrollment_type": "A",
    "start_date_iso": "2019-06-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT07011745",
    "title": "A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)",
    "phase": "PHASE3",
    "imp": "Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo",
    "indications": "Alzheimer Disease",
    "sample_size": "352",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT06712316",
    "title": "Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer",
    "phase": "PHASE3",
    "imp": "Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "1260",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT04949113",
    "title": "Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma",
    "phase": "PHASE3",
    "imp": "Neoadjuvant ipilimumab + nivolumab, Adjuvant nivolumab",
    "indications": "Malignant Melanoma Stage III",
    "sample_size": "423",
    "enrollment_type": "A",
    "start_date_iso": "2021-07-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-12-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT05625399",
    "title": "A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma",
    "phase": "PHASE3",
    "imp": "Nivolumab + Relatlimab, rHuPH20",
    "indications": "Melanoma",
    "sample_size": "579",
    "enrollment_type": "A",
    "start_date_iso": "2023-03-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-08-04",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-11-18",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT06976203",
    "title": "A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)",
    "phase": "PHASE3",
    "imp": "KarXT, KarX-EC, Placebo",
    "indications": "Alzheimer's Disease",
    "sample_size": "586",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT07084831",
    "title": "A Prospective, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy of One Year Treatment With Xanomeline/Trospium on Cognitive Impairment in Clinically Stable Adult Participants With Schizophrenia.",
    "phase": "PHASE3",
    "imp": "Xanomeline/trospium",
    "indications": "Schizophrenia; Psychosis, Cognitive Impairment",
    "sample_size": "171",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-01-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-07-01",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": true,
    "nct_id": "NCT05702034",
    "title": "A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE",
    "phase": "PHASE3",
    "imp": "Milvexian, Placebo",
    "indications": "Ischemic Stroke; Ischemic Attack, Transient",
    "sample_size": "15000",
    "enrollment_type": "E",
    "start_date_iso": "2023-02-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04908202",
    "title": "A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Na\u00efve to Biologic Disease-modifying Anti-rheumatic Drugs",
    "phase": "PHASE3",
    "imp": "Deucravacitinib, Placebo",
    "indications": "Psoriatic Arthritis",
    "sample_size": "670",
    "enrollment_type": "A",
    "start_date_iso": "2021-07-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-09-05",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-06-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT02632409",
    "title": "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer",
    "phase": "PHASE3",
    "imp": "Nivolumab, Placebo",
    "indications": "Various Advanced Cancer",
    "sample_size": "709",
    "enrollment_type": "A",
    "start_date_iso": "2016-03-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2020-07-17",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-05-27",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bristol Myers Squibb",
    "is_collaborator": false,
    "nct_id": "NCT04908189",
    "title": "A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Na\u00efve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF\u03b1 Inhibitor Treatment",
    "phase": "PHASE3",
    "imp": "Deucravacitinib, Placebo, Apremilast",
    "indications": "Psoriatic Arthritis",
    "sample_size": "729",
    "enrollment_type": "A",
    "start_date_iso": "2021-07-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-02-06",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-11-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT02842086",
    "title": "Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection",
    "phase": "PHASE3",
    "imp": "F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo",
    "indications": "Pre-Exposure Prophylaxis of HIV-1 Infection",
    "sample_size": "5399",
    "enrollment_type": "A",
    "start_date_iso": "2016-09-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2019-01-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT06486441",
    "title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)",
    "phase": "PHASE3",
    "imp": "Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel",
    "indications": "Endometrial Cancer",
    "sample_size": "640",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT07047716",
    "title": "Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)",
    "phase": "PHASE3",
    "imp": "Lenacapavir Injection, Lenacapavir Tablet",
    "indications": "HIV Pre-exposure Prophylaxis",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT05371093",
    "title": "Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma",
    "phase": "PHASE3",
    "imp": "Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine",
    "indications": "Relapsed/Refractory Follicular Lymphoma",
    "sample_size": "231",
    "enrollment_type": "A",
    "start_date_iso": "2022-09-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-10",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT06613685",
    "title": "Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated",
    "phase": "PHASE3",
    "imp": "GS-1720, GS-4182, Bictegravir/emtricitabine/tenofovir alafenamide, GS-1720/GS-4182 FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC",
    "indications": "HIV-1-infection",
    "sample_size": "675",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": true,
    "nct_id": "NCT05813964",
    "title": "Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.",
    "phase": "PHASE3",
    "imp": "TDF/FTC 300mg/200mg fixed-dose combination tablets, TAF/FTC 25mg/200mg fixed-dose combination tablets",
    "indications": "HIV/AIDS",
    "sample_size": "524",
    "enrollment_type": "E",
    "start_date_iso": "2024-06-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT06333808",
    "title": "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy",
    "phase": "PHASE3",
    "imp": "Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN",
    "indications": "HIV-1-infection",
    "sample_size": "577",
    "enrollment_type": "A",
    "start_date_iso": "2024-03-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-10-27",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2029-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT04994509",
    "title": "Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection",
    "phase": "PHASE3",
    "imp": "Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN), F/TAF, F/TDF, Placebo SC LEN, PTM Oral LEN, PTM F/TAF, PTM F/TDF",
    "indications": "Pre-Exposure Prophylaxis of HIV Infection",
    "sample_size": "5368",
    "enrollment_type": "A",
    "start_date_iso": "2021-08-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-27",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT05382299",
    "title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",
    "phase": "PHASE3",
    "imp": "Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin",
    "indications": "Triple Negative Breast Cancer, PD-L1 Negative",
    "sample_size": "623",
    "enrollment_type": "A",
    "start_date_iso": "2022-07-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT05502341",
    "title": "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen",
    "phase": "PHASE3",
    "imp": "Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen",
    "indications": "HIV-1-infection",
    "sample_size": "689",
    "enrollment_type": "A",
    "start_date_iso": "2022-08-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-09-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": true,
    "nct_id": "NCT03945448",
    "title": "Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia",
    "phase": "PHASE3",
    "imp": "Single dose liposomal Amphotericin and Fluconazole, Fluconazole",
    "indications": "Cryptococcal Meningitis",
    "sample_size": "356",
    "enrollment_type": "E",
    "start_date_iso": "2019-06-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT05502237",
    "title": "Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "1021",
    "enrollment_type": "A",
    "start_date_iso": "2022-10-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": true,
    "nct_id": "NCT02914535",
    "title": "Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Filgotinib, Placebo",
    "indications": "Ulcerative Colitis",
    "sample_size": "1173",
    "enrollment_type": "A",
    "start_date_iso": "2017-02-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": true,
    "nct_id": "NCT06525389",
    "title": "Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)",
    "phase": "PHASE3",
    "imp": "Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill, Deoxycholate Amphotericin B (DAmB)",
    "indications": "Talaromycosis",
    "sample_size": "428",
    "enrollment_type": "E",
    "start_date_iso": "2026-04-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-11-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-11-01",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT05840211",
    "title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy",
    "phase": "PHASE3",
    "imp": "Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine",
    "indications": "Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer",
    "sample_size": "654",
    "enrollment_type": "E",
    "start_date_iso": "2023-05-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": true,
    "nct_id": "NCT05568095",
    "title": "A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body",
    "phase": "PHASE3",
    "imp": "Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab",
    "indications": "Advanced Upper Gastrointestinal Tract Adenocarcinoma",
    "sample_size": "1040",
    "enrollment_type": "A",
    "start_date_iso": "2022-11-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT06630299",
    "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1",
    "phase": "PHASE3",
    "imp": "ISL/LEN, Antiretroviral Combinations",
    "indications": "HIV-1-Infection",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": true,
    "nct_id": "NCT06081244",
    "title": "NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)",
    "phase": "PHASE3",
    "imp": "Sacituzumab govitecan, Pembrolizumab",
    "indications": "Triple Negative Breast Cancer",
    "sample_size": "348",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT06544733",
    "title": "Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed",
    "phase": "PHASE3",
    "imp": "GS-1720, GS-4182, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, GS-1720/GS-4182 FDC, Placebo to Match GS1720/GS-4182 FDC",
    "indications": "HIV-1-Infection",
    "sample_size": "675",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT05605899",
    "title": "Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma",
    "phase": "PHASE3",
    "imp": "Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone",
    "indications": "High-risk Large B-cell Lymphoma (LBCL)",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2023-02-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT06630286",
    "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1",
    "phase": "PHASE3",
    "imp": "ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN",
    "indications": "HIV-1-infection",
    "sample_size": "609",
    "enrollment_type": "A",
    "start_date_iso": "2024-10-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": true,
    "nct_id": "NCT04595565",
    "title": "Sacituzumab Govitecan in Primary HER2-negative Breast Cancer",
    "phase": "PHASE3",
    "imp": "Capecitabine, Carboplatin, Cisplatin, Sacituzumab govitecan",
    "indications": "HER2-negative Breast Cancer, Triple Negative Breast Cancer",
    "sample_size": "1332",
    "enrollment_type": "E",
    "start_date_iso": "2020-10-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT02881320",
    "title": "Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1",
    "phase": "PHASE3",
    "imp": "B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS), B/F/TAF (TOS), B/F/TAF (TOS), B/F/TAF (TOS)",
    "indications": "HIV-1 Infection",
    "sample_size": "177",
    "enrollment_type": "A",
    "start_date_iso": "2016-09-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-03-24",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT06413498",
    "title": "A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib",
    "indications": "Multiple Myeloma",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT05633654",
    "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)",
    "phase": "PHASE3",
    "imp": "Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine",
    "indications": "Triple Negative Breast Cancer",
    "sample_size": "1514",
    "enrollment_type": "E",
    "start_date_iso": "2022-12-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT02016924",
    "title": "Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV",
    "phase": "PHASE3",
    "imp": "ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS",
    "indications": "Acquired Immune Deficiency Syndrome (AIDS), HIV Infections",
    "sample_size": "133",
    "enrollment_type": "A",
    "start_date_iso": "2014-01-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-06-13",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": true,
    "nct_id": "NCT07178730",
    "title": "NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer",
    "phase": "PHASE3",
    "imp": "Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy",
    "indications": "Breast Cancer, Triple-negative Breast Cancer",
    "sample_size": "765",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-31",
    "start_date_type": "E",
    "primary_completion_date_iso": "2033-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-03-31",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT04925752",
    "title": "Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection",
    "phase": "PHASE3",
    "imp": "Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)",
    "indications": "Pre-Exposure Prophylaxis of HIV Infection",
    "sample_size": "3292",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-08-21",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-08",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT05382286",
    "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",
    "phase": "PHASE3",
    "imp": "Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin",
    "indications": "Triple Negative Breast Cancer, PD-L1 Positive",
    "sample_size": "443",
    "enrollment_type": "A",
    "start_date_iso": "2022-07-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": true,
    "nct_id": "NCT05609968",
    "title": "Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-3475-D46)",
    "phase": "PHASE3",
    "imp": "Sacituzumab Govitecan, Pembrolizumab",
    "indications": "Carcinoma, Non-Small-Cell Lung",
    "sample_size": "614",
    "enrollment_type": "E",
    "start_date_iso": "2023-02-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT03301506",
    "title": "Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)",
    "phase": "PHASE3",
    "imp": "Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule",
    "indications": "Primary Biliary Cirrhosis",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2017-12-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT06801834",
    "title": "Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only)",
    "indications": "Extensive Stage Small Cell Lung Cancer (ES-SCLC)",
    "sample_size": "695",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": true,
    "nct_id": "NCT05814432",
    "title": "Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS",
    "phase": "PHASE3",
    "imp": "Single high dose of liposomal amphotericin B, L-AmB standard dose",
    "indications": "Disseminated Histoplasma Capsulatum Infection, AIDS and Infections, Immunosuppression, Fungal Infection",
    "sample_size": "279",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-11-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Gilead Sciences",
    "is_collaborator": false,
    "nct_id": "NCT06051617",
    "title": "Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis",
    "phase": "PHASE3",
    "imp": "Seladelpar, Placebo",
    "indications": "Primary Biliary Cholangitis",
    "sample_size": "318",
    "enrollment_type": "E",
    "start_date_iso": "2023-09-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Vertex Pharmaceuticals",
    "is_collaborator": false,
    "nct_id": "NCT07204275",
    "title": "A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)",
    "phase": "PHASE3",
    "imp": "Povetacicept, Tacrolimus",
    "indications": "Primary Membranous Nephropathy",
    "sample_size": "176",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-12-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Vertex Pharmaceuticals",
    "is_collaborator": false,
    "nct_id": "NCT06696443",
    "title": "Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)",
    "phase": "PHASE3",
    "imp": "Suzetrigine",
    "indications": "Diabetic Peripheral Neuropathic Pain",
    "sample_size": "455",
    "enrollment_type": "A",
    "start_date_iso": "2024-12-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-25",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-25",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Vertex Pharmaceuticals",
    "is_collaborator": false,
    "nct_id": "NCT05844449",
    "title": "Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older",
    "phase": "PHASE3",
    "imp": "VNZ/TEZ/D-IVA",
    "indications": "Cystic Fibrosis",
    "sample_size": "174",
    "enrollment_type": "E",
    "start_date_iso": "2023-08-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-07-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-30",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Vertex Pharmaceuticals",
    "is_collaborator": false,
    "nct_id": "NCT05444257",
    "title": "A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy",
    "phase": "PHASE3",
    "imp": "VX-121/TEZ/D-IVA",
    "indications": "Cystic Fibrosis",
    "sample_size": "822",
    "enrollment_type": "A",
    "start_date_iso": "2022-11-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Vertex Pharmaceuticals",
    "is_collaborator": false,
    "nct_id": "NCT06628908",
    "title": "Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy",
    "phase": "PHASE3",
    "imp": "Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)",
    "indications": "Diabetic Peripheral Neuropathic Pain",
    "sample_size": "1100",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Vertex Pharmaceuticals",
    "is_collaborator": false,
    "nct_id": "NCT05312879",
    "title": "Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease",
    "phase": "PHASE3",
    "imp": "VX-147, Placebo",
    "indications": "Proteinuric Kidney Disease",
    "sample_size": "466",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Vertex Pharmaceuticals",
    "is_collaborator": false,
    "nct_id": "NCT05331183",
    "title": "Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del",
    "phase": "PHASE3",
    "imp": "ELX/TEZ/IVA, IVA",
    "indications": "Cystic Fibrosis",
    "sample_size": "297",
    "enrollment_type": "A",
    "start_date_iso": "2022-11-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-04-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Vertex Pharmaceuticals",
    "is_collaborator": false,
    "nct_id": "NCT04208529",
    "title": "A Long-term Follow-up Study in Participants Who Received CTX001",
    "phase": "PHASE3",
    "imp": "CTX001",
    "indications": "Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia",
    "sample_size": "160",
    "enrollment_type": "E",
    "start_date_iso": "2021-01-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2039-09-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2039-09-30",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Vertex Pharmaceuticals",
    "is_collaborator": false,
    "nct_id": "NCT05422222",
    "title": "Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age",
    "phase": "PHASE3",
    "imp": "VX-121/TEZ/D-IVA",
    "indications": "Cystic Fibrosis",
    "sample_size": "210",
    "enrollment_type": "E",
    "start_date_iso": "2022-06-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-06-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-06-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Vertex Pharmaceuticals",
    "is_collaborator": false,
    "nct_id": "NCT07231419",
    "title": "Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy",
    "phase": "PHASE3",
    "imp": "Suzetrigine, Placebo (matched to SUZ)",
    "indications": "Diabetic Peripheral Neuropathic Pain",
    "sample_size": "734",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-04-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT07222761",
    "title": "A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)",
    "phase": "PHASE3",
    "imp": "Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib",
    "indications": "Relapsed and/or Refractory Multiple Myeloma (RRMM)",
    "sample_size": "915",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-06-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2034-09-17",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT07318610",
    "title": "Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease",
    "phase": "PHASE3",
    "imp": "REGN7508, REGN9933, Placebo, Rivaroxaban",
    "indications": "Peripheral Artery Disease (PAD)",
    "sample_size": "7050",
    "enrollment_type": "E",
    "start_date_iso": "2026-03-31",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-05-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-03",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT06687980",
    "title": "A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)",
    "phase": "PHASE3",
    "imp": "Dupilumab, Placebo",
    "indications": "Lichen Simplex Chronicus",
    "sample_size": "138",
    "enrollment_type": "A",
    "start_date_iso": "2024-11-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT06541704",
    "title": "A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy",
    "phase": "PHASE3",
    "imp": "Pozelimab, Cemdisiran, Placebo",
    "indications": "Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)",
    "sample_size": "975",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-11-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-05-21",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT06932562",
    "title": "A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant",
    "phase": "PHASE3",
    "imp": "Linvoseltamab, Daratumumab, Lenalidomide, Dexamethasone",
    "indications": "Multiple Myeloma",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2036-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2036-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT06246916",
    "title": "A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)",
    "phase": "PHASE3",
    "imp": "fianlimab, cemiplimab, relatlimab+nivolumab",
    "indications": "Melanoma",
    "sample_size": "560",
    "enrollment_type": "E",
    "start_date_iso": "2024-09-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-07-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT05744921",
    "title": "A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works",
    "phase": "PHASE3",
    "imp": "Pozelimab, Cemdisiran",
    "indications": "Paroxysmal Nocturnal Hemoglobinuria",
    "sample_size": "202",
    "enrollment_type": "E",
    "start_date_iso": "2023-03-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-02-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT06931717",
    "title": "A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy",
    "phase": "PHASE3",
    "imp": "Cemiplimab",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "390",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT06687967",
    "title": "A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)",
    "phase": "PHASE3",
    "imp": "Dupilumab, Placebo",
    "indications": "Lichen Simplex Chronicus",
    "sample_size": "142",
    "enrollment_type": "A",
    "start_date_iso": "2024-11-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT05991388",
    "title": "A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma",
    "phase": "PHASE3",
    "imp": "Odronextamab, Loncastuximab tesirine, Rituximab, Ifosfamide, Carboplatin, Etoposide, Etoposide Phosphate, Dexamethasone, CAR T-cells (TBC)",
    "indications": "B-cell Non Hodgkin Lymphoma",
    "sample_size": "210",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-05-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-05-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT06128629",
    "title": "MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)",
    "phase": "PHASE3",
    "imp": "NTLA-2001, Placebo",
    "indications": "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy",
    "sample_size": "1200",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT05608291",
    "title": "A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery",
    "phase": "PHASE3",
    "imp": "Fianlimab, Cemiplimab, Pembrolizumab, Placebo",
    "indications": "Melanoma",
    "sample_size": "1564",
    "enrollment_type": "A",
    "start_date_iso": "2023-01-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-02-15",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT05352672",
    "title": "Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma",
    "phase": "PHASE3",
    "imp": "Fianlimab, Cemiplimab, Pembrolizumab, Placebo",
    "indications": "Melanoma",
    "sample_size": "1546",
    "enrollment_type": "A",
    "start_date_iso": "2022-07-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-09-16",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT06097364",
    "title": "A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma",
    "phase": "PHASE3",
    "imp": "Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prenisolone",
    "indications": "Follicular Lymphoma (FL)",
    "sample_size": "733",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-07-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT06149286",
    "title": "A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",
    "phase": "PHASE3",
    "imp": "Odronextamab, Lenalidomide, Rituximab",
    "indications": "Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL)",
    "sample_size": "470",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-01-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT05133531",
    "title": "A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment",
    "phase": "PHASE3",
    "imp": "Ravulizumab, Pozelimab, Cemdisiran, Eculizumab",
    "indications": "Paroxysmal Nocturnal Hemoglobinuria",
    "sample_size": "190",
    "enrollment_type": "E",
    "start_date_iso": "2022-08-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT06208306",
    "title": "A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD",
    "phase": "PHASE3",
    "imp": "Itepekimab (SAR440340), Placebo",
    "indications": "Chronic Obstructive Pulmonary Disease",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2024-01-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-12-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT06091254",
    "title": "A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Follicular Lymphoma",
    "phase": "PHASE3",
    "imp": "Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine",
    "indications": "Follicular Lymphoma (FL)",
    "sample_size": "462",
    "enrollment_type": "A",
    "start_date_iso": "2023-12-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-11-06",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT06616584",
    "title": "Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)",
    "phase": "PHASE3",
    "imp": "Biospecimen Collection, Cemiplimab, Computed Tomography, Dexamethasone, Docetaxel, Magnetic Resonance Imaging, Ramucirumab",
    "indications": "Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8",
    "sample_size": "378",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-12-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT06091865",
    "title": "A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma",
    "phase": "PHASE3",
    "imp": "Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone",
    "indications": "Diffuse Large B-cell Lymphoma (DLBCL)",
    "sample_size": "904",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-04-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT06585410",
    "title": "Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma",
    "phase": "PHASE3",
    "imp": "Cemiplimab, Standard of care",
    "indications": "Cutaneous Squamous Cell Carcinoma (CSCC)",
    "sample_size": "369",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-05-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-05-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT07309432",
    "title": "Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy",
    "phase": "PHASE3",
    "imp": "REGN5713, REGN5715, Placebo",
    "indications": "Allergic Conjunctivitis",
    "sample_size": "350",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-19",
    "start_date_type": "E",
    "primary_completion_date_iso": "2027-02-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-15",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT06230224",
    "title": "A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma",
    "phase": "PHASE3",
    "imp": "Odronextamab, Ifosfamide, Carboplatin, Etoposide, Rituximab, Dexamethasone, Cisplatin, Cytarabine, Gemcitabine",
    "indications": "B-Cell Non-Hodgkin Lymphoma (B-NHL)",
    "sample_size": "216",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT07015905",
    "title": "REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults",
    "phase": "PHASE3",
    "imp": "REGN7508, Apixaban, Enoxaparin, Placebo",
    "indications": "Venous Thromboembolism (VTE)",
    "sample_size": "2000",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-02-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT05785767",
    "title": "A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "phase": "PHASE3",
    "imp": "fianlimab, cemiplimab, Placebo",
    "indications": "Advanced Non-Small Cell Lung Cancer",
    "sample_size": "850",
    "enrollment_type": "E",
    "start_date_iso": "2023-06-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-02-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT06422507",
    "title": "A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema",
    "phase": "PHASE3",
    "imp": "8 mg aflibercept (BAY 86-5321) (High Dose), 2 mg aflibercept (EYLEA, BAY 86-5321), Sham",
    "indications": "Diabetic Macular Edema",
    "sample_size": "333",
    "enrollment_type": "A",
    "start_date_iso": "2024-05-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT06491914",
    "title": "A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)",
    "phase": "PHASE3",
    "imp": "Aflibercept 8 mg",
    "indications": "Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema",
    "sample_size": "1118",
    "enrollment_type": "A",
    "start_date_iso": "2024-07-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-08-26",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-01-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT06834360",
    "title": "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps",
    "phase": "PHASE3",
    "imp": "Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)",
    "indications": "Chronic Rhinosinusitis With Nasal Polyps",
    "sample_size": "210",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT03969004",
    "title": "Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma",
    "phase": "PHASE3",
    "imp": "Cemiplimab, Placebo",
    "indications": "Cutaneous Squamous Cell Carcinoma",
    "sample_size": "415",
    "enrollment_type": "A",
    "start_date_iso": "2019-06-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-11-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-03-26",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT06834347",
    "title": "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps",
    "phase": "PHASE3",
    "imp": "Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)",
    "indications": "Chronic Rhinosinusitis With Nasal Polyps",
    "sample_size": "210",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-01-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-13",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT02612454",
    "title": "Study to Assess the Long-term Safety of Dupilumab Administered in Participants \u22656 Months to <18 Years of Age With Atopic Dermatitis (AD)",
    "phase": "PHASE3",
    "imp": "Dupilumab",
    "indications": "Atopic Dermatitis",
    "sample_size": "880",
    "enrollment_type": "A",
    "start_date_iso": "2015-10-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT05730036",
    "title": "A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone",
    "indications": "Relapsed Refractory Multiple Myeloma (RRMM)",
    "sample_size": "410",
    "enrollment_type": "E",
    "start_date_iso": "2023-09-18",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-04-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-04-19",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT05070858",
    "title": "A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis",
    "phase": "PHASE3",
    "imp": "Pozelimab + Cemdisiran, Cemdisiran, Placebo, Pozelimab",
    "indications": "Generalized Myasthenia Gravis",
    "sample_size": "288",
    "enrollment_type": "A",
    "start_date_iso": "2021-12-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-18",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-11-11",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT05800015",
    "title": "A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "950",
    "enrollment_type": "E",
    "start_date_iso": "2023-08-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-01-16",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-12-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": true,
    "nct_id": "NCT07309614",
    "title": "A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma",
    "phase": "PHASE3",
    "imp": "Dupilumab Prefilled Syringe, Placebo Injection",
    "indications": "Asthma Control",
    "sample_size": "150",
    "enrollment_type": "E",
    "start_date_iso": "2026-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Regeneron",
    "is_collaborator": false,
    "nct_id": "NCT07213778",
    "title": "REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants",
    "phase": "PHASE3",
    "imp": "REGN7508, Acetylsalicylic Acid (ASA), Placebo",
    "indications": "Symptomatic Venous Thromboembolism (VTE)",
    "sample_size": "2000",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-16",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "CSL",
    "is_collaborator": false,
    "nct_id": "NCT05485961",
    "title": "Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis",
    "phase": "PHASE3",
    "imp": "CSL300, Placebo",
    "indications": "Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD",
    "sample_size": "2310",
    "enrollment_type": "E",
    "start_date_iso": "2022-10-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-08-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-08-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "CSL",
    "is_collaborator": false,
    "nct_id": "NCT03805789",
    "title": "The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant",
    "phase": "PHASE3",
    "imp": "AAT, Placebo",
    "indications": "Acute-graft-versus-host Disease",
    "sample_size": "222",
    "enrollment_type": "A",
    "start_date_iso": "2019-03-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "CSL",
    "is_collaborator": false,
    "nct_id": "NCT07094087",
    "title": "Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)",
    "phase": "PHASE3",
    "imp": "BE1116, FFP",
    "indications": "Complex Cardiovascular Surgery With Cardiopulmonary Bypass",
    "sample_size": "200",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-06-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT06899126",
    "title": "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Chemotherapy",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "686",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-07-05",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT06578247",
    "title": "Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML",
    "phase": "PHASE3",
    "imp": "Quizartinib, Placebo, Chemotherapy",
    "indications": "Leukemia",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2024-11-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-06-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-06-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT06203210",
    "title": "A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin",
    "indications": "Small Cell Lung Cancer",
    "sample_size": "540",
    "enrollment_type": "E",
    "start_date_iso": "2024-05-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT04739761",
    "title": "A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan",
    "indications": "Breast Cancer",
    "sample_size": "506",
    "enrollment_type": "A",
    "start_date_iso": "2021-06-22",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-02-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-02-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT05950945",
    "title": "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan",
    "indications": "Breast Cancer",
    "sample_size": "250",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-10-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT07129993",
    "title": "Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Carboplatin, Cisplatin, Gemcitabine",
    "indications": "Urothelial Cancer, Bladder Cancer",
    "sample_size": "630",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-06-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01-22",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT07060807",
    "title": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)",
    "phase": "PHASE3",
    "imp": "Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin, Trastuzumab deruxtecan",
    "indications": "Breast Neoplasms",
    "sample_size": "1000",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-07-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-07-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT06161025",
    "title": "A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "phase": "PHASE3",
    "imp": "R-DXd, Paclitaxel, Topotecan, PLD",
    "indications": "Solid Cancer",
    "sample_size": "860",
    "enrollment_type": "E",
    "start_date_iso": "2024-02-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT06731478",
    "title": "Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab, Chemotherapy",
    "indications": "Gastric Cancer, Gastroesophageal Junction Cancer",
    "sample_size": "726",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-02-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT04494425",
    "title": "Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel",
    "indications": "Advanced or Metastatic Breast Cancer",
    "sample_size": "866",
    "enrollment_type": "A",
    "start_date_iso": "2020-07-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-03-18",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-19",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT05555732",
    "title": "Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)",
    "phase": "PHASE3",
    "imp": "Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin",
    "indications": "Metastatic Non Small Cell Lung Cancer",
    "sample_size": "1170",
    "enrollment_type": "E",
    "start_date_iso": "2023-01-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-08-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT03529110",
    "title": "DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)",
    "indications": "Breast Cancer",
    "sample_size": "524",
    "enrollment_type": "A",
    "start_date_iso": "2018-08-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2021-05-21",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-07-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT06925737",
    "title": "A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)",
    "phase": "PHASE3",
    "imp": "Ifinatamab deruxtecan, Docetaxel, Prednisone",
    "indications": "Prostate Cancer, Prostatic Neoplasms",
    "sample_size": "1440",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-01-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT07291037",
    "title": "Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations",
    "phase": "PHASE3",
    "imp": "Datopotamab deruxtecan (Dato-DXd), Docetaxel",
    "indications": "Non-small Cell Lung Cancer (NSCLC)",
    "sample_size": "400",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-01-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT06103864",
    "title": "A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab",
    "indications": "Breast Cancer",
    "sample_size": "625",
    "enrollment_type": "E",
    "start_date_iso": "2023-11-23",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-09-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT06350097",
    "title": "Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Osimertinib, Datopotamab Deruxtecan",
    "indications": "Non-small Cell Lung Cancer",
    "sample_size": "582",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03-21",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-05-25",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT04622319",
    "title": "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)",
    "phase": "PHASE3",
    "imp": "DS-8201a, T-DM1",
    "indications": "HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer",
    "sample_size": "1600",
    "enrollment_type": "E",
    "start_date_iso": "2020-12-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT06989112",
    "title": "DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel",
    "indications": "Endometrial Cancer",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-19",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-02-19",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT05048797",
    "title": "A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed",
    "indications": "Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
    "sample_size": "454",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT06644781",
    "title": "A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)",
    "phase": "PHASE3",
    "imp": "Ifinatamab deruxtecan, Docetaxel, Paclitaxel, Irinotecan hydrochloride (HCl)",
    "indications": "Esophageal Squamous Cell Carcinoma",
    "sample_size": "510",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-11-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT05629585",
    "title": "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab",
    "indications": "Breast Cancer",
    "sample_size": "1174",
    "enrollment_type": "A",
    "start_date_iso": "2022-11-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT03777631",
    "title": "STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study",
    "phase": "PHASE3",
    "imp": "Catheter ablation",
    "indications": "Ischemic Stroke, Atrial Fibrillation Non-Rheumatic",
    "sample_size": "251",
    "enrollment_type": "A",
    "start_date_iso": "2018-04-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT05113251",
    "title": "Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide",
    "indications": "Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer",
    "sample_size": "927",
    "enrollment_type": "A",
    "start_date_iso": "2021-10-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-03-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-04-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT06112379",
    "title": "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib",
    "indications": "Breast Cancer",
    "sample_size": "1902",
    "enrollment_type": "A",
    "start_date_iso": "2023-11-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11-20",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-09-23",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT07022483",
    "title": "Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, Chemotherapy",
    "indications": "Endometrial Cancer",
    "sample_size": "710",
    "enrollment_type": "E",
    "start_date_iso": "2025-09-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2032-03-23",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-03-23",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT05338970",
    "title": "HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy",
    "phase": "PHASE3",
    "imp": "Patritumab Deruxtecan, Platinum-based chemotherapy",
    "indications": "Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion",
    "sample_size": "586",
    "enrollment_type": "A",
    "start_date_iso": "2022-07-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-05-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT04784715",
    "title": "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan, Placebo, Taxane, Pertuzumab, Trastuzumab",
    "indications": "Breast Cancer; HER2-positive; Metastatic",
    "sample_size": "1157",
    "enrollment_type": "A",
    "start_date_iso": "2021-04-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-30",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT06417814",
    "title": "A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin",
    "indications": "Metastatic Non-small Cell Lung Cancer",
    "sample_size": "744",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-09-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT07205822",
    "title": "A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer",
    "phase": "PHASE3",
    "imp": "Dato-DXd",
    "indications": "Breast Cancer",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT06819007",
    "title": "Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)",
    "phase": "PHASE3",
    "imp": "Trastuzumab Deruxtecan, Bevacizumab",
    "indications": "Ovarian Cancer",
    "sample_size": "582",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-01-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT06357533",
    "title": "Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC \u2265 50%) and Without Actionable Genomic Alterations",
    "phase": "PHASE3",
    "imp": "Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab",
    "indications": "Non-Small Cell Lung Cancer",
    "sample_size": "675",
    "enrollment_type": "E",
    "start_date_iso": "2024-04-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-05-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT04704934",
    "title": "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan, Ramucirumab, Paclitaxel",
    "indications": "Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma",
    "sample_size": "490",
    "enrollment_type": "E",
    "start_date_iso": "2021-05-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT05215340",
    "title": "Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations",
    "phase": "PHASE3",
    "imp": "Datopotamab Deruxtecan, Pembrolizumab",
    "indications": "Metastatic Non Small Cell Lung Cancer",
    "sample_size": "740",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": true,
    "nct_id": "NCT05374512",
    "title": "A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)",
    "phase": "PHASE3",
    "imp": "Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate",
    "indications": "Breast Cancer",
    "sample_size": "644",
    "enrollment_type": "A",
    "start_date_iso": "2022-05-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-08-25",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-11-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Daiichi Sankyo",
    "is_collaborator": false,
    "nct_id": "NCT03734029",
    "title": "Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]",
    "phase": "PHASE3",
    "imp": "Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel",
    "indications": "Breast Cancer",
    "sample_size": "557",
    "enrollment_type": "A",
    "start_date_iso": "2018-12-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-01-11",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-08-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": true,
    "nct_id": "NCT04446117",
    "title": "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC",
    "phase": "PHASE3",
    "imp": "Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone",
    "indications": "Metastatic Prostate Cancer, Prostate Adenocarcinoma",
    "sample_size": "575",
    "enrollment_type": "A",
    "start_date_iso": "2020-10-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-04-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-10-16",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06722235",
    "title": "A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia",
    "phase": "PHASE3",
    "imp": "Mezagitamab, Placebo",
    "indications": "Immune Thrombocytopenic Purpura (ITP)",
    "sample_size": "171",
    "enrollment_type": "E",
    "start_date_iso": "2025-02-27",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-12-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-12-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06980480",
    "title": "A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma",
    "phase": "PHASE3",
    "imp": "IGI, 10%",
    "indications": "Multiple Myeloma, Secondary Immunodeficiency",
    "sample_size": "183",
    "enrollment_type": "E",
    "start_date_iso": "2026-01-28",
    "start_date_type": "E",
    "primary_completion_date_iso": "2028-09-11",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-09-11",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": true,
    "nct_id": "NCT04685616",
    "title": "Brentuximab Vedotin in Early Stage Hodgkin Lymphoma",
    "phase": "PHASE3",
    "imp": "Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor",
    "indications": "Hodgkin Lymphoma",
    "sample_size": "1042",
    "enrollment_type": "E",
    "start_date_iso": "2022-04-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT04779320",
    "title": "A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)",
    "phase": "PHASE3",
    "imp": "Vedolizumab IV",
    "indications": "Crohn's Disease (CD)",
    "sample_size": "120",
    "enrollment_type": "E",
    "start_date_iso": "2022-02-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-22",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05-22",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT05837897",
    "title": "A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Vedolizumab IV, Placebo",
    "indications": "Crohn's Disease",
    "sample_size": "408",
    "enrollment_type": "E",
    "start_date_iso": "2023-06-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-05-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06227910",
    "title": "A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease",
    "phase": "PHASE3",
    "imp": "Vedolizumab, Upadacitinib, Placebo",
    "indications": "Crohn's Disease",
    "sample_size": "396",
    "enrollment_type": "E",
    "start_date_iso": "2025-01-02",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-06-08",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-08-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06671496",
    "title": "A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines",
    "phase": "PHASE3",
    "imp": "Zasocitinib, Placebo",
    "indications": "Psoriatic Arthritis",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT07047521",
    "title": "A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults",
    "phase": "PHASE3",
    "imp": "Tetravalent Dengue Vaccine (TDV)",
    "indications": "Dengue Fever",
    "sample_size": "496",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-08-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-07-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06973291",
    "title": "A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis",
    "phase": "PHASE3",
    "imp": "Zasocitinib, Deucravacitinib, Placebo to match zasocitinib, Placebo to match deucravacitinib",
    "indications": "Plaque Psoriasis",
    "sample_size": "606",
    "enrollment_type": "A",
    "start_date_iso": "2025-07-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07-03",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": true,
    "nct_id": "NCT07270991",
    "title": "Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma",
    "phase": "PHASE3",
    "imp": "trifluridine/tipiracil, fruquintinib",
    "indications": "Metastatic Oeso-gastric Adenocarcinoma",
    "sample_size": "324",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-31",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-11-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-11-30",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT05442567",
    "title": "A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)",
    "phase": "PHASE3",
    "imp": "Vedolizumab IV, No Intervention",
    "indications": "Ulcerative Colitis, Crohn's Disease",
    "sample_size": "240",
    "enrollment_type": "E",
    "start_date_iso": "2023-05-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2031-08-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2031-08-15",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT03221036",
    "title": "Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis",
    "phase": "PHASE3",
    "imp": "Vedolizumab IV, Placebo",
    "indications": "Moderately to Severely Active Ulcerative Colitis",
    "sample_size": "402",
    "enrollment_type": "E",
    "start_date_iso": "2017-08-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-09-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT07286058",
    "title": "Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis",
    "phase": "PHASE3",
    "imp": "Zasocitinib",
    "indications": "Psoriatic Arthritis",
    "sample_size": "1182",
    "enrollment_type": "E",
    "start_date_iso": "2026-02-27",
    "start_date_type": "E",
    "primary_completion_date_iso": "2029-12-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-18",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": true,
    "nct_id": "NCT03562169",
    "title": "The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)",
    "phase": "PHASE3",
    "imp": "Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy",
    "indications": "Multiple Myeloma",
    "sample_size": "406",
    "enrollment_type": "E",
    "start_date_iso": "2017-03-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT05156983",
    "title": "A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery",
    "phase": "PHASE3",
    "imp": "TAK-330, SOC 4F-PCC",
    "indications": "Coagulation Disorder",
    "sample_size": "328",
    "enrollment_type": "E",
    "start_date_iso": "2022-08-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-04-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04-12",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT07250802",
    "title": "A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis",
    "phase": "PHASE3",
    "imp": "Zasocitinib, Placebo, Zasocitinib",
    "indications": "Plaque Psoriasis",
    "sample_size": "110",
    "enrollment_type": "E",
    "start_date_iso": "2025-12-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-01-24",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2033-01-24",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06550076",
    "title": "A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis",
    "phase": "PHASE3",
    "imp": "TAK-279",
    "indications": "Plaque Psoriasis",
    "sample_size": "1950",
    "enrollment_type": "E",
    "start_date_iso": "2024-09-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-05-07",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06963827",
    "title": "A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition",
    "phase": "PHASE3",
    "imp": "Mezagitamab, Placebo",
    "indications": "Kidney Disease",
    "sample_size": "347",
    "enrollment_type": "E",
    "start_date_iso": "2025-07-15",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-09-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-01-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT05816382",
    "title": "A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions",
    "phase": "PHASE3",
    "imp": "TAK-861",
    "indications": "Narcolepsy Type 1",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2023-04-05",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-02-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06671483",
    "title": "A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines",
    "phase": "PHASE3",
    "imp": "Zasocitinib, Active Comparator, Placebo",
    "indications": "Psoriatic Arthritis",
    "sample_size": "1088",
    "enrollment_type": "E",
    "start_date_iso": "2025-03-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-18",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-01-28",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": true,
    "nct_id": "NCT07217301",
    "title": "IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed",
    "phase": "PHASE3",
    "imp": "IBI363, Control Arm",
    "indications": "iO Resistant sqNSCLC",
    "sample_size": "600",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-26",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-11-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06499285",
    "title": "A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions",
    "phase": "PHASE3",
    "imp": "Elritercept, Placebo",
    "indications": "Myelodysplastic Syndromes",
    "sample_size": "225",
    "enrollment_type": "E",
    "start_date_iso": "2025-05-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-05-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-05-01",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT05677971",
    "title": "Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein",
    "phase": "PHASE3",
    "imp": "Fazirsiran Injection, Placebo",
    "indications": "Alpha1-Antitrypsin Deficiency",
    "sample_size": "160",
    "enrollment_type": "E",
    "start_date_iso": "2023-03-06",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-02-17",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-08-14",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06579755",
    "title": "A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)",
    "phase": "PHASE3",
    "imp": "TDV, Placebo",
    "indications": "Dengue Fever",
    "sample_size": "800",
    "enrollment_type": "E",
    "start_date_iso": "2026-04-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2027-04-14",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-04-14",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT07204314",
    "title": "A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder",
    "phase": "PHASE3",
    "imp": "Vortioxetine tablets, Placebo tablets",
    "indications": "Major Depressive Disorder",
    "sample_size": "180",
    "enrollment_type": "E",
    "start_date_iso": "2025-10-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-09-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-09-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT04129502",
    "title": "TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations",
    "phase": "PHASE3",
    "imp": "TAK-788, Pemetrexed, Cisplatin, Carboplatin",
    "indications": "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)",
    "sample_size": "354",
    "enrollment_type": "A",
    "start_date_iso": "2020-01-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-10-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-10-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT03589326",
    "title": "A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia",
    "phase": "PHASE3",
    "imp": "Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone",
    "indications": "Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)",
    "sample_size": "245",
    "enrollment_type": "A",
    "start_date_iso": "2018-10-04",
    "start_date_type": "A",
    "primary_completion_date_iso": "2022-08-12",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2027-07-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06665035",
    "title": "A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers",
    "phase": "PHASE3",
    "imp": "TDV, Placebo",
    "indications": "Dengue Fever",
    "sample_size": "212",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-03-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Takeda",
    "is_collaborator": false,
    "nct_id": "NCT06948318",
    "title": "A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia",
    "phase": "PHASE3",
    "imp": "Mezagitamab",
    "indications": "Immune Thrombocytopenic Purpura (ITP)",
    "sample_size": "150",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-07-29",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-07-29",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT07188805",
    "title": "A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction",
    "phase": "PHASE3",
    "imp": "Finerenone (Kerendia, BAY94-8862), Placebo",
    "indications": "Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)",
    "sample_size": "111",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-11-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-12-30",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT05116475",
    "title": "Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases",
    "phase": "PHASE3",
    "imp": "Darolutamide 300 mg, Placebo of Darolutamide",
    "indications": "Prostate Cancer",
    "sample_size": "152",
    "enrollment_type": "E",
    "start_date_iso": "2022-08-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT04879368",
    "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC",
    "phase": "PHASE3",
    "imp": "Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil",
    "indications": "Gastro-Oesophageal Cancer",
    "sample_size": "450",
    "enrollment_type": "E",
    "start_date_iso": "2021-06-01",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07-09",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-06-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT06024746",
    "title": "A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)",
    "phase": "PHASE3",
    "imp": "Finerenone, Empagliflozin",
    "indications": "Heart Failure",
    "sample_size": "1500",
    "enrollment_type": "E",
    "start_date_iso": "2024-07-09",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-08",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT04136353",
    "title": "Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate",
    "phase": "PHASE3",
    "imp": "Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy",
    "indications": "Prostate Cancer",
    "sample_size": "1100",
    "enrollment_type": "A",
    "start_date_iso": "2020-03-31",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-01-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-07-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT04777851",
    "title": "Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7",
    "phase": "PHASE3",
    "imp": "Regorafenib in combination with pembrolizumab, Loco-regional therapy",
    "indications": "Carcinoma, Hepatocellular",
    "sample_size": "496",
    "enrollment_type": "E",
    "start_date_iso": "2023-10-11",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-02-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-02-28",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT02194842",
    "title": "Phase III Radium 223 mCRPC-PEACE III",
    "phase": "PHASE3",
    "imp": "Ra223, Enzalutamide",
    "indications": "Prostate Cancer",
    "sample_size": "446",
    "enrollment_type": "A",
    "start_date_iso": "2015-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-02-19",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-12",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT05457283",
    "title": "A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria",
    "phase": "PHASE3",
    "imp": "Finerenone (Kerendia, BAY94-8862)",
    "indications": "Chronic Kidney Disease, Proteinuria, Children",
    "sample_size": "100",
    "enrollment_type": "E",
    "start_date_iso": "2022-11-08",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-01-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-02-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT06944522",
    "title": "A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease",
    "phase": "PHASE3",
    "imp": "bemdaneprocel, Sham surgery",
    "indications": "Parkinsons Disease (PD)",
    "sample_size": "102",
    "enrollment_type": "E",
    "start_date_iso": "2025-06-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT05794906",
    "title": "A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies",
    "phase": "PHASE3",
    "imp": "Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT",
    "indications": "Biochemically Recurrent Prostate Cancer",
    "sample_size": "981",
    "enrollment_type": "A",
    "start_date_iso": "2023-04-03",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-03-29",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT06276465",
    "title": "Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging",
    "phase": "PHASE3",
    "imp": "Darolutamide 300 mg, Stereotactic body radiation therapy, Androgen deprivation therapy",
    "indications": "Prostatic Cancer, Castration-Resistant",
    "sample_size": "336",
    "enrollment_type": "E",
    "start_date_iso": "2024-10-07",
    "start_date_type": "A",
    "primary_completion_date_iso": "2029-10-15",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2032-10-07",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT06033950",
    "title": "A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists",
    "phase": "PHASE3",
    "imp": "Finerenone, Placebo",
    "indications": "Heart Failure",
    "sample_size": "2600",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT06736691",
    "title": "Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections",
    "phase": "PHASE3",
    "imp": "emodepside (BAY 44-4400), matching placebo of emodepside, Mebendazole, similar placebo to mebendazole",
    "indications": "Trichuris Trichiura; Infection, Hookworm Infection, Ascaris Lumbricoides Infection",
    "sample_size": "315",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-25",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-05",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-07",
    "completion_date_type": "E",
    "status": "ENROLLING_BY_INVITATION",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT06452277",
    "title": "A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",
    "phase": "PHASE3",
    "imp": "BAY2927088, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed",
    "indications": "Advanced Non-small Cell Lung Cancer, HER2 Mutation",
    "sample_size": "278",
    "enrollment_type": "E",
    "start_date_iso": "2024-08-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-10-28",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2029-06-27",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT05676203",
    "title": "A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients",
    "phase": "PHASE3",
    "imp": "Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel",
    "indications": "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
    "sample_size": "250",
    "enrollment_type": "A",
    "start_date_iso": "2023-05-16",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-07",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT06625970",
    "title": "Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse",
    "phase": "PHASE3",
    "imp": "Darolutamide, Stereotactic Body RadioTherapy (SBRT), ADT (Standard of Care), radiotherapy",
    "indications": "High Risk Prostate Carcinoma, Prostate Cancer",
    "sample_size": "700",
    "enrollment_type": "E",
    "start_date_iso": "2025-04-10",
    "start_date_type": "A",
    "primary_completion_date_iso": "2033-10",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2045-10",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT03970447",
    "title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma",
    "phase": "PHASE3",
    "imp": "Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390",
    "indications": "Glioblastoma",
    "sample_size": "1280",
    "enrollment_type": "E",
    "start_date_iso": "2019-07-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-06",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT06904274",
    "title": "Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months",
    "phase": "PHASE3",
    "imp": "BAY865028, Medroxyprogesterone acetate",
    "indications": "Endometrial Hyperplasia",
    "sample_size": "207",
    "enrollment_type": "E",
    "start_date_iso": "2025-11-24",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-05-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-05-03",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT06081894",
    "title": "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM",
    "phase": "PHASE3",
    "imp": "Aficamten, Placebo",
    "indications": "Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy",
    "sample_size": "500",
    "enrollment_type": "E",
    "start_date_iso": "2023-08-30",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-06",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT05619653",
    "title": "Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19",
    "phase": "PHASE3",
    "imp": "Prednisolone, Losartan",
    "indications": "COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle, Remodeling, Vascular, Left Ventricular Dysfunction, Exercise Intolerance, Vascular Inflammation, Microvascular Angina, Long COVID, Myocarditis, Pericarditis",
    "sample_size": "279",
    "enrollment_type": "A",
    "start_date_iso": "2022-12-12",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-08-08",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-31",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT06800248",
    "title": "Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections",
    "phase": "PHASE3",
    "imp": "emodepside (BAY 44-4400), Mebendazole 100 MG, similar placebo to mebendazole, matching placebo of emodepside",
    "indications": "Trichuris Trichiura; Infection, Hookworm Infection, Ascaris Lumbricoides Infection",
    "sample_size": "315",
    "enrollment_type": "E",
    "start_date_iso": "2026-04",
    "start_date_type": "E",
    "primary_completion_date_iso": "2026-09",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-12",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT06008197",
    "title": "A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients",
    "phase": "PHASE3",
    "imp": "Finerenone, Placebo",
    "indications": "Heart Failure, Acute Heart Failure",
    "sample_size": "5200",
    "enrollment_type": "E",
    "start_date_iso": "2024-01-17",
    "start_date_type": "A",
    "primary_completion_date_iso": "2026-04",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2026-04",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT06422507",
    "title": "A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema",
    "phase": "PHASE3",
    "imp": "8 mg aflibercept (BAY 86-5321) (High Dose), 2 mg aflibercept (EYLEA, BAY 86-5321), Sham",
    "indications": "Diabetic Macular Edema",
    "sample_size": "333",
    "enrollment_type": "A",
    "start_date_iso": "2024-05-29",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-03-22",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT05587296",
    "title": "A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer",
    "phase": "PHASE3",
    "imp": "Elinzanetant (BAY3427080), Placebo",
    "indications": "Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes",
    "sample_size": "474",
    "enrollment_type": "A",
    "start_date_iso": "2022-10-14",
    "start_date_type": "A",
    "primary_completion_date_iso": "2024-01-29",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2028-06-05",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT07129239",
    "title": "High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)",
    "phase": "PHASE3",
    "imp": "Maintenance",
    "indications": "Wet Age-related Macular Degeneration (wAMD)",
    "sample_size": "180",
    "enrollment_type": "E",
    "start_date_iso": "2025-08-20",
    "start_date_type": "E",
    "primary_completion_date_iso": "2027-02",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-02",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT07192952",
    "title": "A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction",
    "phase": "PHASE3",
    "imp": "Finerenone (Kerendia, BAY94-8862)",
    "indications": "Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)",
    "sample_size": "117",
    "enrollment_type": "E",
    "start_date_iso": "2026-04-01",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-12-30",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-30",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT05196035",
    "title": "A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria",
    "phase": "PHASE3",
    "imp": "Finerenone (Kerendia, BAY94-8862), Placebo",
    "indications": "Chronic Kidney Disease, Proteinuria",
    "sample_size": "219",
    "enrollment_type": "E",
    "start_date_iso": "2022-03-28",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-07-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-08-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT05047263",
    "title": "A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease",
    "phase": "PHASE3",
    "imp": "Finerenone (BAY94-8862), Placebo",
    "indications": "Non-diabetic Chronic Kidney Disease",
    "sample_size": "1584",
    "enrollment_type": "A",
    "start_date_iso": "2021-09-21",
    "start_date_type": "A",
    "primary_completion_date_iso": "2025-12-31",
    "primary_completion_date_type": "A",
    "completion_date_iso": "2026-02-09",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT07270367",
    "title": "Finerenone and Cardiac Remodeling",
    "phase": "PHASE3",
    "imp": "Finerenone, Placebo",
    "indications": "Heart Failure",
    "sample_size": "156",
    "enrollment_type": "E",
    "start_date_iso": "2025-12",
    "start_date_type": "E",
    "primary_completion_date_iso": "2030-12",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12",
    "completion_date_type": "E",
    "status": "NOT_YET_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT06282588",
    "title": "Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers",
    "phase": "PHASE3",
    "imp": "Darolutamide, Darolutamide matched placebo, Radiotherapy, Zoladex 3.6Mg Implant, Zoladex LA, Decapeptyl sustained release 22.5 mg, Decapeptyl sustained release 11.25 mg, Depo-Eligard 45 mg, Depo-Eligard 22.5 mg, Depo-Eligard 7.5 mg, Firmagon 120 MG Injection, Firmagon 80 MG Injection, Docetaxel",
    "indications": "Prostate Cancer",
    "sample_size": "493",
    "enrollment_type": "E",
    "start_date_iso": "2023-12-13",
    "start_date_type": "A",
    "primary_completion_date_iso": "2030-07-31",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2030-12-31",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": false,
    "nct_id": "NCT04464226",
    "title": "Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer",
    "phase": "PHASE3",
    "imp": "Darolutamide (Nubeqa, BAY1841788)",
    "indications": "Cancer",
    "sample_size": "402",
    "enrollment_type": "E",
    "start_date_iso": "2020-10-20",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-06-26",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2028-06-26",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT03574571",
    "title": "A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer",
    "phase": "PHASE3",
    "imp": "Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223",
    "indications": "Prostate Cancer",
    "sample_size": "732",
    "enrollment_type": "A",
    "start_date_iso": "2018-06-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2027-04-01",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2027-04-01",
    "completion_date_type": "E",
    "status": "ACTIVE_NOT_RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  },
  {
    "company": "",
    "actual_company": "Bayer",
    "is_collaborator": true,
    "nct_id": "NCT04916613",
    "title": "ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)",
    "phase": "PHASE3",
    "imp": "Darolutamide 300 mg, Placebo, Androgen deprivation therapy",
    "indications": "Prostate Cancer Metastatic",
    "sample_size": "300",
    "enrollment_type": "E",
    "start_date_iso": "2022-04-19",
    "start_date_type": "A",
    "primary_completion_date_iso": "2028-03",
    "primary_completion_date_type": "E",
    "completion_date_iso": "2037-09",
    "completion_date_type": "E",
    "status": "RECRUITING",
    "readout_summary": "",
    "readout_source": "",
    "source_url": ""
  }
]